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Abstract
The peptide endothelin (ET-1) was first described as an endothelium-derived potent
vasoconstrictor substance. However, cardiomyocytes can also synthesise ET-1 and
express ETa and ETb receptors. Previous studies in our laboratory have demonstrated
that healthy rat myocardium contains both ETA (80%) and ETb receptors (20%) and
that expression of the ETB subtype is increased in rats with chronic heart failure
(CHF) following coronary artery ligation (CAL). However, the significance of ETB
upregulation is unknown and functional studies investigating the relative roles of the
ETa and ETb receptors in normal or failing hearts have proved inconsistent.
The aims of this thesis were to investigate the endothelin system in failing and
nonfailing myocardium and to evaluate the role of ET receptor function in relation to
contractility in vivo and in vitro. In addition, transmural differences in gene
expression were explored in human failing myocardium to establish whether genes
associated with stiffness, hypertrophy and the ET system correlate to wall stress.
Rats underwent myocardial infarction (MI) and developed left ventricular (LV)
dysfunction at 15 weeks post-MI, as evidenced by an increase in LV end-diastolic
pressure (LVEDP, 3 ± 0.2mmHg to 12 ± 2mmHg, P<0.01) and an increase in
expression of atrial natriuretic peptide mRNA. A reduction in the basal contractile
response of papillary muscles from failing hearts was also consistent with
dysfunction. However, responses to ET-1 were inconsistent and prevented
conclusions about the role of individual receptors. Investigation of ET receptor
expression by RT-PCR failed to show a selective increase in ETb receptors and
prepro ET-1 mRNA remained unchanged at 15 weeks post-MI. Subsequently,
experiments were designed to investigate the influence of ET on myocardial
contractility using ET receptor antagonists in papillary muscles from control animals.
Results suggested that both ET receptors contribute to contractility in rat
myocardium, corresponding with the presence of both receptor subtypes, found using
RT-PCR. Furthermore, the data showed that expression of ET receptors in the heart
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undergo seasonal variation, which corresponds with the contribution of receptors to
regulation of contractility.
LV function was evaluated in vivo using a novel technique developed in our
laboratory. Echocardiography in conjunction with associated LV pressure data
demonstrated a reduced shortening fraction (SF, 18.7 ± 1.9% to 13.6 ± 1.3%,
P<0.05) and ejection fraction (EF, 31.1 ± 2.6% to 22.4 ± 1.2%, P<0.01) in rats 12
weeks post-MI indicating LV dysfunction, also evidenced by elevated LVEDP
(5.7+1.0mmHg to 15.6±1.5mmHg EO.OOl). Subsequently, the technique was used
on control animals following chronic (7 day) administration of Bosentan. a dual ET
receptor antagonist (lOOmg/kg/day). However, antagonist treatment failed to
influence haemodynamics, SF or EF, suggesting that unlike in vitro, the ET system
does not play a central role in regulating cardiac function in vivo.
In the human heart, wall stress is highest in the endocardial layer. Different types of
heart failure alter myocardial contractility and wall stress in different ways. Semi¬
quantitative RT-PCR identified that genes linked to hypertrophic remodelling were
consistently increased in the endo relative to epicardium. Interestingly, expression of
the ETa receptor and the cytoskeletal elastic protein, titin, in particular the N2B
isoform linked to increased myocardial stiffness showed 2 distinct patterns of
expression across the LV wall, depending on the type of heart failure. ETb
expression was uniform across the wall.
In conclusion, the ET system is expressed in the normal myocardium and both
receptors can regulate contractility in vitro, however the system is not essential for
normal heart function in vivo. The time course and severity of experimental heart
failure influences the expression of ET system in the rat, with results showing that
modification of ET system expression does not always accompany LV dysfunction.
In the failing human heart, proteins associated with wall stress and hypertrophy are
most abundant in the endocardium of the LV, while transmural distribution of the
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1.1 The cardiovascular system
Chapter 1 - Introduction
The cardiovascular system comprises the heart and two networks of blood vessels,
the systemic circulation and the pulmonary circulation, which convey oxygen and
nutrients to the tissues of the body and remove metabolic waste products such as
carbon dioxide and urea.
1.1.1 Anatomy of the heart
The heart consists of two intermittent muscular pumps, the right and left ventricles,
which are filled from reservoirs, the right and left atria. The heart wall is made up of
three layers, the endocardium, myocardium and epicardium, each with particular
structure and function (as reviewed by Stevens & Lowe, 1992). A delicate
connective-tissue membrane lined with endothelium comprises the innermost layer
of the endocardium. This forms a complete lining for the atrial and ventricular
cavities, it covers all the structures that project into the heart (valves, chordae
tendineae and papillary muscles) and is continuous with the lining of the major
vessels. Endothelial cells within the heart release a number of substances that
modulate myocardial contractile function. These agents include nitric oxide (NO),
endothelin-1 (ET-1), prostanoids, adenylpurines and other substances, which are
likely to be important mechanisms both physiologically and in pathological states (as
reviewed by Shah et al., 1996; Brutsaert, 2003). The middle layer of endocardium is
the thickest and consists of dense connective tissue along with elastic fibres that
alternate with layers of collagenic fibres, while the outer layer is composed of
collagen fibres that are arranged more irregularly and merge with collagen
surrounding adjacent cardiac muscle fibres. This layer has blood vessels and Purkinje
fibres and may also contain fat.
The myocardium is the thickest part of the wall and is responsible for contraction. It
is comprised of specialised cardiac muscle fibres that form an interconnecting
network (syncytium) separated by loose fibrocollagenous tissue termed the
endomysium. It also contains conducting cells and vascular and connective tissue.
The left and right atria have thin myocardial layers as they expel blood against
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minimal resistance. The right ventricle (RV) has a moderate muscle layer as it has to
push blood through the pulmonary valve and into the pulmonary tree. The thickest
myocardial layer is observed in the left ventricle (LV), as it has to pump blood
against the high resistance of the systemic circulation.
The epicardium is the third outermost layer of the heart, which varies over different
chambers. The superficial layer consists of ordinary connective tissue, which is
covered by mesothelium and contains some capillaries and nerves. Larger blood
vessels and more fat are contained in the deeper layer, which is continuous with the
endomysium of underlying myocardium. A mesothelial-lined fibro-elastic membrane
termed the pericardium also surrounds the heart and separates it from the rest of the
thoracic viscera. Between this and the epicardium is a cavity filled with fluid to
lubricate and allow the heart to contract with minimal friction.
The arterial supply of the heart is provided by the left and right coronary arteries,
which arise from the aorta, immediately above the aortic valve and lie on the surface
of the heart. Smaller branches then branch off from the surface to penetrate into the
myocardium. The right coronary artery supplies the right atrium (RA) and RV and
also serves both ventricles via the posterior intraventricular branch. The left coronary
artery is larger and divides into an anterior interventricular branch (left anterior
descending artery), which serves the LV, RV and the interventricular septum, and a
circumflex branch, which serves the left atria (LA) and LV lateral and inferior walls.
Valves between the atrium and ventricles, the atrioventricular valves (AV valves),
prevent backflow of blood to the atria during systole. The semilunar valves, between
the RV and the pulmonary artery or the LV and the aorta, prevent backflow into the
ventricles during diastole. Papillary muscles are attached to the cusps of the AV
valves by chordae tendineae and contract when the ventricular wall contracts.
However, they do not function to help the valves close but rather they pull the valves
towards the ventricles to prevent the cusps from being forced into the atrium and
turning inside out as the ventricular pressure rises. The chordae tendineae of each
papillary muscle are connected to the adjacent parts of two cusps to assist this
process (as reviewed by Guyton & Hall, 1996).
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The architecture and stiffness of the myocardium is preserved by a collagen network,
which is found in the extracellular space. Fibrillar collagens, mainly type I and III are
coexpressed in a constant ratio (Chapman et al., 1990). This is important to the
mechanical properties of tissue because it builds a scaffold to keep the different
cellular and noncellular compartments in order and groups the muscle fibres into
bundles. Muscle fibres are composed of cardiomyocytes that branch and attach to
adjacent cells end-to-end at specialised junctions termed intercalated discs. These
connections contain smaller specialised junctions, desmosomes and gap junctions.
Desmosomes hold the adjacent cells together, while communicating gap junctions
are regions of close apposition to adjacent cell membranes. The gap is spanned by
connexin proteins, which form a central pore, allowing the transmission of impulses
from cell to cell. The myocyte itself is packed with long contractile bundles of
myofibril-like units each composed of smaller units called sarcomeres.
The surface membrane of the bundled myofibril-like units is called the sarcolemma,
which is invaginated opposite the Z-line into a series of fine transverse tubules (T-
tubules), which run into the cell interior. These structures transmit the electrical
stimulus rapidly to the interior of the cell, inducing activation of numerous
myofibrils almost simultaneously. A separate tubular system, termed the
sarcoplasmic reticulum (SR) exists within the myocyte. It consists of a closed set of
anastomosing tubules coursing over the myofibrils and contains a store of Ca2+ ions.
The sarcomere is the basic contractile unit of striated muscle and contains many
different classes of proteins, assembled into a supramolecular structure with almost
crystaline order. They are defined as the material between two Z-lines and align
across the cell, giving the muscle its characteristic striated appearance. The
sarcomere is composed of two sliding, interdigitating filaments, a thick filament of
myosin and a thin filament composed chiefly of actin. Actin filaments are anchored
in the Z-line and protrude into the A band, between the myosin rods {Figure 1.1).
The myocardium develops active force by the cyclic attachment and detachment of
myosin crossbridges to actin filaments. The sarcomere shortens when activated by
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the binding of Ca2+ to troponin C, a component of the troponin complex. This
displaces tropomyosin, exposing a myosin-binding site and allows myosin to bind to
the thin actin filament. The force of contraction depends on the number of
2"b





Figure 1.1. Architecture of the myocyte. ATP, ATPase pump; Ica. inward Ca21
current; NCX, Na /Ca2 exchange; PLB, phospholamham; RyR, ryanodine receptor;
SR, sarcoplasmic reticulum; PEVK, region rich with P (proline), E (glutamate), V
(valine) andK (lysine). Modifiedfrom Bers (2002) and Gregorio et al. (1999).
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The third most abundant cytoskeletal protein is the giant molecule titin, which
contributes to the filament system in skeletal and cardiac muscle cells by connecting
the Z disc and the central M line of the sarcomere (Figure 1.1). Titin provides an
extensible scaffold for the contractile machinery and is crucial for myofibrillar
elasticity and integrity. In the A band region, titin filaments are composed of regular
domains that bind to other proteins of the thick filament (Labeit et al., 1992; Soteroiu
et al., 1993). The portion of titin that spans the I band segment is extensible and is
likely to account for the intrinsic elasticity of the myofibril and contribute to the
diastolic passive tension of striated muscle (see Chapter 6 for titin domain
arrangements). Previous studies of titin behaviour have used gelsolin to remove
cytoskeletal actin from cardiac myocytes (Granzier et ah, 1997) (see Chapter 6).
Gelsolin rapidly dissolves actin by severing, capping and nucleating growth and in
normal physiology plays an important role in the regulation of filament assembly (as
reviewed by Dos Remedios et al., 2003).
1.1.3 Excitation-contraction coupling
Spontaneous rhythmical contraction of the heart is generated and conducted by a
specialised system. Impulses originate in the sino-atrial (SA) node, a small strip of
pacemaker cells, located in the superior lateral wall of the RA. Any action potential
spreads immediately from the node to the atrial tissue and is subsequently conducted
to the AV node via internode pathways. A delay allows the atria to contract and
empty before ventricular contraction begins. Purkinje fibres then conduct the
impulses to the apex of the heart, dividing into smaller branches that course around
each ventricular chamber. Rapid transmission of action potentials by Purkinje fibres
produces synchronous contraction of the ventricles and therefore effective pumping.
When the cardiac action potential reaches the myocyte, depolarisation causes the
opening of fast sodium (Na+) channels as well as slow Ca2+ channels. The ubiquitous
2"bsecond messenger Ca is essential for cardiac electrical activity and is the direct
activator of the myofilaments. Ca2+ enters the cell during the action potential through
depolarisation-activated Ca2+ channels as inward Ca2+ current (7ca), two classes of
voltage-dependent Ca2+ channels (L- and T-type) are exhibited on the myocyte.
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Entry of Ca2+ triggers the release ofmore Ca2+, termed the Ca2+ spark (Cheng et al.,
1993), from intracellular stores via SR Ca2+ release channels or ryanodine receptors
(.Figure 1.1) and this is known as the Ca2+-induced Ca2+-release mechanism.
Concentration of free intracellular Ca2+ ([Ca2+]0 is raised by the combined Ca2+
• 2"b
influx and SR release, initiating contraction by allowing Ca to bind to the
myofdament protein troponin C (as reviewed by Bers, 2002). Contraction ends when
[Ca2+]i is reduced. Several routes achieve the removal of free cytosolic Ca2+, most is
moved into the SR by the SR Ca2+-ATPase pump, ready for the next contraction. The
Na+/Ca2+ exchanger removes some back across the cardiac membrane, while the
sarcolemmal Ca2+-ATPase pump and the mitochondrial Ca2+ uniporter remove a
2"bminimal amount (Bers et al., 1996). Normally the amount of Ca removed from the
cell during relaxation is the same as the amount that enters, otherwise the myocyte is
unable to maintain steady state contractions.
2"EThe mechanisms underlying both activation and termination of Ca release from the
SR are controversial, however, the Ca2+-induced Ca2+-release mechanism is the most
widely accepted. Several alternative mechanisms have been proposed as the main
contributor in triggering Ca2+ release, such as Ca2+ influx through the T-type 7ca
(7caj) or through the Na+/Ca2+ exchanger. However. 7ca via these mechanisms is
much less effective and slower than the flux through the L-type 7ca (7ca,L) (Sipido et
2~b
al., 1997, 1998). Ca release from smooth muscle SR and endoplasmic reticulum
can also be triggered by inositol (l,4,5)-triphosphate (IP3). High concentrations of
• 2+ • •
IP3 can induce Ca release in cardiac myocytes via IP3 receptors (Perez et al., 1997),
however, the rate and extent of Ca2+ release are much lower than that of the Ca2+-
induced Ca2+-release mechanism (Lipp et al., 2000).
1.1.4 Regulation of contractile force
The force of myocardial contractility is a variable, regulated quantity and can be
increased by two processes, (i) when influenced by an intrinsic mechanism regulated
by the degree of stretch of the myocytes during diastole or (ii) by nervous, hormonal
or chemical stimulation.
7
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This intrinsic ability of the myocardium to adapt to changing preloads is known as
the Frank-Starling mechanism. The degree of distension of the relaxed ventricle is
determined by diastolic filling pressure. The pressure distending the RV, RV end-
diastolic pressure (RVEDP), is almost equal to the central venous pressure (CVP)
and similarly, the pulmonary venous pressure governs LA pressure and hence LV
end-diastolic pressure (LVEDP). Initial fibre length at rest is proportional to the
energy of the subsequent contraction, partly because it influences the actin-myosin
overlap and to a greater extent because the sensitivity of the contractile machinery to
free Ca2+ is length dependent (Kentish & Wrzosek, 1998; Fukuda et al., 2001).
Therefore, raising the filling pressure and diastolic volume increases contractile
energy and stroke work. The most vital effect of the Frank-Starling mechanism is to
balance the output of the right and left ventricles over several beats. The importance
of which is observed when an imbalance between RV and LV outputs of a mere 1%,
if sustained, can raise pulmonary blood volume sufficiently to induce pulmonary
congestion and oedema.
In the intact circulation, venous return must equal cardiac output due to the closed
nature of the circulation, therefore, venous return is directly dependent on cardiac
output. In contrast, CVP is variable and can regulate stroke volume via the Frank-
Starling mechanism as previously discussed. CVP is set by several factors, these
include blood volume, gravity and peripheral venous tone. Dehydration or
haemorrhage reduces blood volume and lowers CVP, while gravity can redistribute
the blood to the lower limbs during long periods of standing (venous pooling).
Sympathetic nerves that induce venoconstriction innervate the veins of the skin,
kidney and splanchnic system. This controls the proportion of blood in the periphery
and thereby influences CVP. Conversely, venodilation as a result of
thermoregulation under hot conditions lowers CVP, reducing stroke volume.
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1.1.4.2 The autonomic nervous system
Both divisions of the autonomic nervous system innervate the heart. The sympathetic
division increases heart rate, the force of contraction and accelerates relaxation,
while the parasympathetic division, via the vagus nerve, evokes bradycardia.
Sympathetic fibres synapse with the electrical system and also directly innervate the
atria and ventricles. The nerve endings release noradrenaline, which binds to P i -
adrenoceptors on the cardiac membrane. These receptors are coupled to a signal
transduction pathway that activates the membrane bound enzyme adenylyl cyclase
(AC) via a G-protein (Gs). The subsequent increase in cyclic 3',5'-adenosine
monophosphate (cAMP) production activates protein kinase A (PKA), which
phosphorylates proteins involved with excitation-contraction coupling such as
2"b • •
phospholambam, L-type Ca channels, ryanodine receptors and troponin I. The
pacemaker cells are stimulated to increase the inward depolarising current (If),
consequently raising the depolarising rate and the heart rate, p-adrenoceptor
• 2+ •stimulation also induces positive inotropy as [Ca ]j is increased via the combination
of increased inward /ca and the accumulation of a greater store of SR Ca2+. The
activity of phospholambam is increased by PKA, this protein is responsible for
regulating the activity of the SR Ca2+-ATPase (SERCA) pump and accelerates
• 9+
relaxation by increasing re-uptake of Ca into the SR. Terminals of the vagus nerve
synapse mainly on the SA and AV nodes, to a lesser extent on the atria and even less
on the ventricles. The nerve endings release acetylcholine, which binds to muscarinic
(M2) receptors. These receptors are negatively coupled to AC, reducing cAMP
accumulation, slowing the firing rate of the SA node via the right vagus and
increasing the AV conduction delay via the left vagus to slow the heart.
1.1.4.3 Hormones, peptides and other factors
The endocardial endothelium plays an essential role in the heart with respect to
cardiac metabolism, growth, contractile performance and rhythmicity (as reviewed
by Shah et al., 1996; Brutsaert, 2003). Endothelial cells can synthesise and release a
variety of auto- and paracrine agents, such as NO, prostanoids, angiotensin II (Ang
II), ET-1 and other substances, which can directly modulate the subjacent myocytes
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(Discigil et al., 1995; Mebazaa et al., 1993a, 1993b; Dostal & Baker, 1999). These
agents are often synergistic with others to produce novel biological outcomes, which
would not necessarily be seen alone.
NO can be synthesised from L-arginine by three different nitric oxide synthase (NOS)
isozymes. Endothelial constitutive (ecNOS, NOSIII) and neuronal (nNOS, NOSI)
isoforms, are constitutively expressed in physiological conditions, while a third,
inducible isoform (iNOS, NOSH), is biosynthesised only after stimulation by various
stressors and cytokines. The ecNOS isoform is expressed in the coronary vascular
endothelium, the cardiac endothelium and to a lesser extent in cardiomyocytes (Seki
et al., 1996; Andries et al., 1998). Some studies have demonstrated that NO can
induce a biphasic response, where low levels produce positive inotropic effects and
high levels induce negative inotropic effects (Grocott-Mason et al., 1994; Cotton et
al., 2001). However, studies have most consistently reported that NO produces
isometric twitch relaxation in vitro and ventricular relaxation and enhanced diastolic
compliance in vivo. These effects are mainly attributed to the activation of
myocardial soluble guanylate cyclase to produce guanosine 3,5-cyclic
monophosphate (cGMP), thereby evoking relaxation of the underlying myocardium
(Paulus et al., 1994; Mohan et al., 1996; Flesch et al., 1997), but some are cGMP
independent. Cardiac responses to NO have been shown to be modified by other
factors, these include the interaction between NO and the Pi-adrenergic and
cholinergic pathways (Balligand, 1999; Gyurko et al., 2000) or the interaction with
the natriuretic peptides (Leskinen et al., 1995).
Several prostanoids are synthesised and released from cardiac endothelial cells in
response to various stimuli (Carter et al., 1992; Mebazaa et al., 1993a).
Cyclooxygenase (COX) plays a key role in regulating prostaglandin (PG) synthesis,
a constitutive (COX-1) isoform is expressed in all cardiac endothelial cells, while an
inducible (COX-2) isoform is expressed during inflammatory states. Contractile
responses to PGI2 or PGE2 have ranged from increased inotropy (Karazyn et al.,
1978; Katircioglu et al 1998) to no effect (Couttenye et al., 1985) and negative
inotropy (Schror et al., 1992). Studies have attributed the inconsistent responses to
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the interaction of PG with NO as there is continuous crosstalk between the NOS and
COX pathways (Gerritsen, 1996), therefore, the inotropic actions result from the
ratio between cAMP-cGMP.
Ang II is released via the activity of angiotensin converting enzyme (ACE) and also
via an ACE-independent pathway. Cardiac ACE is predominantly expressed in
endothelial cells but can also be found in cardiomyocytes and fibroblasts (Dostal &
Baker, 1999). The effects of Ang II on cardiac contractile performance are thought to
result from locally produced rather than circulating Ang II (Dzau, 1988). Ang II
• 2~b
generally exerts a positive inotropic effect partly by enhancing the Ca plateau
current and also by acting at sympathetic nerve endings to facilitate the release of
noradrenaline, to increase the rate of rise of the contractile phase and delay relaxation
(Baker & Singer, 1988; Meulemans et al., 1990). However, there have also been
inconsistent responses reported and these reflect the many interactions that modify
the cardiac synthesis, release and activity of Ang II. Studies have demonstrated
interactions with bradykinin, the NO and PGI2 pathways as well as ET-1 (Ritchie et
al., 1998a, 1998b; Kusaka et al., 2000). ET-1 is also synthesised and released in the
heart and its effects on cardiac contractility and venous tone are discussed in section
1.2.6.
In the heart, local extracellular electrolyte disturbances such as hyperkalaemia can
significantly alter cardiac function. In addition, other situations have negative
inotropic responses. Ischaemia is associated with hypoxia and intracellular acidosis,
both of which can depress contractility. Hypoxia results in an increased
concentration of inorganic phosphates, which interfere with Ca2+ binding and also
raises the intracellular H+ concentration. Acidosis reduces the sensitivity of the
2"b
myofibrils to Ca , thereby reducing the force of contraction. Endogenous agents
such as the circulating catecholamines, adrenaline and noradrenaline, can stimulate
cardiac (3-adrenoceptors, inducing inotropic and chronotropic responses (as discussed
above). Other factors that alter the contractile state of the heart include caffeine and
drugs like digoxin, which act on the SR membrane to increase the frequency of
opening of the Ca2+-release channels. In addition, caffeine inhibits
11
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phosphodiesterase, the enzyme that breaks down the second messenger cAMP,
thereby elevating cAMP and inducing actions similar to |31-adrenergic stimulation.
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1.2 The Endothelin system
1.2.1 Endothelin-1
The vascular endothelium is recognised as an important source of vasoactive factors.
In both health and disease, it modulates vascular tone through a variety of substances
that are locally synthesised and released. ET-1 is a potent vasoconstrictor peptide
produced by the vascular endothelial cells (Yanagisawa et al., 1988a). It is one of a
family of peptides which are characterised by their unique shape, each are comprised
of 21 amino acid residues, including two disulphide bonds linking cysteine amino
acids between residues 1 to 15 and 3 to 11 and six conserved amino acid residues at
the carboxy terminal (.Figure 1.2). Three isoforms of ET have been identified, of
which ET-1 is predominant in the mammalian cardiovascular system. Localisation of
the peptide suggests that ET-2 may possibly function as a mediator in the human
kidney (Karet & Davenport, 1996), while ET-3 may act as a mediator in the kidney,
gut and nervous system. Sarafotoxins (SRTXs), peptides isolated from the venom of
the Israeli burrowing asp, Actactaspis engaddensis (Kloog et al., 1988), share close
structural similarity to ET isopeptides. Both ETs and SRTXs act through common
receptors to evoke a multitude of effects. SRTX S6c (Figure 1.2) in particular, has
been used as a tool for characterising the actions of ET-1 at its receptors
(Sokolovsky, 1994).
1.2.2 Biosynthesis of ET-1
In the human genome, distinct genes encoding the precursors for ET-1, -2 and -3 are
found on chromosomes 6, 1 and 20 respectively (Bloch et al., 1989a, 1991, 1989b).
All three ETs are synthesised through a two-stage process from their respective
precursor peptides. In the case of human ET-1 (Figure 1.3), ET-1 mRNA is
translated in the nucleus to preproET-1, a 212 amino acid polypeptide and a short
terminal signal sequence (amino acids 1-17) is removed. The resulting propeptide is
then secreted into the cytoplasm where it is cleaved at two specific sites containing
pairs of dibasic amino acids by furin-like endopeptidases. In the first proteolytic step,
the polypeptide cleaves between Lys52-Arg53 and Arg90-Arg91, releasing an
intermediate 'big ET-1' which has 38 amino acids and is biologically inactive.
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Endothelin-3
Figure 1.2 The unique structure of the endothelin isopeptides and sarafotoxin S6c.
The fdled circles indicate that the amino acid differs from the ET-1 sequence.
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Figure 1.3. Biosynthesis of ET-1 and the signalling pathways involved in gene
regulation. Modifiedfrom Gray & Webb (1996).
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Subsequently, mature ET-1 is formed by cleavage at the c-terminal between Trp21-
Val22, catalysed by a specific endothelin converting enzyme (ECE) (Yanagisawa et
al., 1988b). Big ET-1 is several orders of magnitude less active than ET-1 (<10-fold)
and inhibition of ECE by the neutral metalloendopeptidase inhibitor
phosphoramidon, almost completely inhibits the pressor action of big ET-1,
indicating that conversion of big ET-1 to ET-1 is essential for biological activity
(Haynes & Webb, 1994).
Takahashi et al. (1993) were the first to purify and characterise ECE from rat lung.
Subsequently, cloning and expression of ECE-1 was demonstrated in rat lung
vascular endothelial cells (Shimada et al., 1994) and cultured human and bovine
heart endothelial cells (Schmidt et al., 1994), with ECE-1 being identified as a
membrane bound neutral metalloprotease. ECE-1 is a type II integral membrane
protein composed of 754 or of 758 amino acids, it has a neutral pH optimum and has
been shown to be localised on the cell surface as well as intracellularly in a variety of
cells including endothelial cells (Barnes et al., 1996). The enzyme has a short N-
terminal domain, a single transmembrane segment and a large C-terminal domain,
which contains the active site of the enzyme. Three ECE-1 isoforms have been
identified in the human (ECE-la, ECE-lb and ECE-lc), they are derived from a
single gene and differ only in a variation in their N-terminal region through the use
of alternative promoters. They cleave big ET-1 with similar efficiency but differ with
respect to their subcellular localisation (Schweizer et al., 1997). In addition, the
existence of a fourth human ECE-1 (ECE-Id) was demonstrated in cultured cells and
shown to have similar biochemical properties to the other isoforms (Valdenaire et al.,
1999). ECE-la is most strongly expressed at the cell surface, while ECE-lb is almost
exclusively intracellular. ECE-lc is the major isoform in most human tissues and is
moderately expressed on the plasma membrane while ECE-Id is localised
moderately on both the cell surface and intracellular structures (Schweizer et al.,
1997; Valdenaire et al., 1999).
ECE-2, a second ECE subtype was cloned by Emoto & Yanagisawa (1995). It is
homologous to ECE-1 but differs principally in sensitivity to phosphoramidon and in
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pH optimum, requiring acidic conditions (pH 5.5-5.7). ECE-2 cDNA is located in
diverse cell types but seems most abundantly expressed in neural tissues (Emoto &
Yanagisawa, 1995). Both show preference for big ET-1 over ET-2 and ET-3
however, targeted disruption of the ECE-1 gene in mice suggests that ECE-1 is the
predominant subtype responsible for the conversion of big ET-1 to ET-1
(Yanagisawa et al., 1998).
1.2.3 Regulation of the ET-1 gene
Regulation of endothelin synthesis is thought to occur at the level of transcription,
with de novo production and release occurring in response to stimulation.
Upregulation of ET-1 mRNA has been shown in a variety of cells in response to
vasoactive hormones, inflammatory mediators and physicochemical factors such as
shear stress and hypoxia (Table 1.1). These factors activate a protein kinase C (PKC)
/ phospholipase C (PLC) mediated increase of gene transcription (Lee et al., 1991).
In contrast, inhibition of ET-1 generation occurs via cGMP in response to nitric
oxide, natriuretic peptides and prostacyclin (Table 1.1). Promotor regions located at
the 5' gene flanking sequence of the ET precursor serve to control the rate of
transcription by mediating the effects of these diverse stimuli (Benatti et al., 1993).
Release of ET-1 from the endothelial cells of blood vessels or endocardial
endothelial cells of the heart, is predominantly abluminal, towards the underlying
vascular smooth muscle cells (SMCs) or cardiomyocytes. Local ET-1 concentration
within the vascular wall is >100-fold higher than that of plasma levels, stemming in
part from the fact that 80% of the ET-1 is secreted on the basal side of endothelial
cells (Wagner et al., 1992). As a consequence, big ET-1 and ET-1 are present in
plasma at low concentration (~lpM), while circulating concentrations of ET-2 and
ET-3 are even lower (Battistini et al., 1993). Therefore, ET peptides are generally
thought to act as autocrine and paracrine factors, rather than circulating hormones.
(Yoshimoto et al., 1991). Although ET-1 is identified within endothelial cells, it
remains unclear whether intracellularly stored peptide represents a pool available for
rapid release.
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Initial localisation studies reported that the processing of big ET-1 to mature ET-1
was attributed to the activity of a converting enzyme that was located on the plasma
membrane of human (Waxman et al., 1994), bovine (Corder et al., 1995) and rat
(Takahashi et al., 1995) cultured vascular endothelial cells, acting mainly in a post-
secretory manner. In contrast, other studies have suggested that ECE is either
primarily expressed or has predominant activity within intracellular compartments
(Gui et al., 1993; Xu et al., 1994). Localisation of intracellular ECE has been
demonstrated within the Golgi apparatus and discrete secretory vesicles, implicating
conversion of endogenous big ET-1 during its transit through the cell cytosol (Corder
& Barker, 1999). This is consistent with the localisation of both ET-like and ECE-
like immunoreactivity within storage granules, 'Weibel Palade bodies', in human
coronary artery endothelium (Russell et al., 1997, 1998). Together with functional
experiments showing rapid, stimulated release of ET-1 in vivo and in vitro (Fyhrquist
et al., 1990; Macarthur et al., 1994), these observations suggest that a regulated
pathway may also be important in the processing of big ET-1. Thus, two distinct
secretory pathways play a role in the secretion of ET-1: a constitutive pathway,
controlled at the level of protein synthesis, involving basal release of ET-1, and a
regulated pathway of release involving the stimulated mobilisation and degranulation
of endothelial cell-specific storage granules.
It has been observed that many endothelial cell stimulants such as thrombin
(Boulanger & Liischer, 1990) cause a delayed (i.e. hours), but not immediate (i.e.
minutes) elevation in the production of ET-1, which appears to depend upon an
increased synthesis of the peptide. In contrast, some stimuli, such as cold stress
(Fyhrquist et al., 1990) can cause an immediate increase in the circulating levels of
endothelin. Stretching of endothelial cells has also been shown to produce an
elevation in ET-1 production. Macarthur et al. (1994) demonstrated a rapid (<20
minutes) and a prolonged (>360 minutes) increase of ET-1 accumulation in bovine
aortic endothelial cells after stretching, indicating that both de novo synthesis and
release from intracellular stores is involved. Similarly, Elishikawa et al. (1995)
demonstrated a pressure induced ET-1 release from cultured human umbilical vein
endothelial cells (HUVEC), mediated partially through activation of PLC and PKC.
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Furthermore, Kuchan and Frangos (1993) observed that the level of shear stress
applied to the endothelial cells affected the ET-1 release. While exposure to a low
level of shear stress (1.8 dyne/cm2) resulted in a sustained increase in cumulative ET-
1 release via PKC activation, higher levels of stress (>6 dyne/cm2) progressively
inhibited PKC mediated ET-1 mRNA transcription in a dose dependent manner. As
endothelial cells are continuously exposed to blood flow and the resultant mechanical
forces, it implies an important role of ET-1 in the acute and chronic control of local
blood flow. In addition, mechanical stretching has been shown to stimulate the
secretion and production of ET-1 in cultured rat ventricular cardiomyocytes. This is
associated with an increase of ET-1 mRNA levels, as evidenced by Northern blot
analysis (Yamazaki et al., 1996).
Table 1.1. Factors influencing the gene transcription ofET-1
Factor Effect Cellular signal Reference
Angiotensin II Increase PLC/PKC Emori et al., 1991
Vasopressin Increase PLC/PKC Emori et al., 1991
Insulin Increase PLC/PKC Oliver et al., 1991
TGF-p Increase Kurihara et al., 1989
Cyclosporin Increase TGF-p Takeda et al., 1993
Hypoxia Increase Elton eta!., 1992
Shear stress (low) Increase PKC Kuchan & Frangos et al., 1993
Thrombin Increase PLC/PKC Emori et al., 1992
Oxidised LDL Increase PLC/PKC Boulanger et al., 1992
PGI2/PGE2 Decrease cGMP Prins et al., 1994
Nitric oxide Decrease Boulanger & Luscher 1990
Natriuretic peptides Decrease cGMP Kohno et al., 1992
Heparin Decrease NO/cGMP Yokokawa et al., 1993
Shear stress (high) Decrease NO/cGMP Kuchan & Frangos etal., 1993
PLC, phospolipase C; PKC, protein kinase C; TGF-{3. transforming growth factor-(3;
PGE, prostacyclin; PGE2, prostaglandin E2; cGMP, cyclic GMP; NO, nitric oxide.
1.2.4 Sites of ET-1 generation
The gene for ET-1 has been detected in a wide variety of tissues. It is predominantly
expressed in vascular endothelial cells, as initially demonstrated by Yanagisawa et
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al. (1988a), in both cultured endothelial cells and in porcine aortic intima in situ. ET-
1 is also released by human endothelial cells in culture (Clozel & Fischli, 1989) and
immunoreactive ET-1 has been detected in the endothelial layer of human blood
vessels of varying origin (Howard et al., 1992; Tokunaga et al., 1992). Cultured
vascular SMCs from human (Resink et al., 1990; Yu & Davenport, 1995), rat and
rabbit (Kanse et al., 1991) have also demonstrated mRNA expression of ET and
peptide production. Studies have identified mRNA expression and immunoreactive
ET-1 in endothelial cells from rat heart (Giaid et al., 1991) and cultured rat
cardiomyocytes (Suzuki et al., 1993; Ito et al., 1993). Previous studies in our own
laboratory have confirmed this, demonstrating expression of ET-1 mRNA and in situ
immunoreactive ET-1 localised in cardiomyocytes, myoendothelial cells and some
vascular endothelial cells of the rat heart (Sherry, 2000). In addition, cultured ovine
endocardial endothelial cells (Mebazaa et al., 1993b), cultured human right ventricle
endothelial cells (Plumpton et al., 1996) and porcine cardiomyocytes in culture
(Tonnessen et al., 1995) express ET-1 mRNA. Immunostaining for ET-1 was
localised in vascular and endocardial endothelial cells as well as cardiomyocytes of
explanted human hearts (Giaid et al., 1995), while in contrast, Davenport et al.
(1998) did not detect ET-1 in human cardiomyocytes, suggesting instead that in
humans, release of ET-1 from endocardial endothelial cells modulates myocardial
function in a paracrine manner.
Evidence suggests that cultured rat epicardial mesothelial cells are able to express,
synthesise and release ET-1 (Eid et al., 1994; Kuwahara & Kuwahara, 1998).
Additionally, high concentrations of the peptide have been reported in the pericardial
fluid of humans and dogs (Horkay et al., 1998; Szokodi et al., 1998). Furthermore,
strong immunoreactivity for ET-1 was observed in the endothelium of human
epicardial coronary arteries and veins (Opgaard et al., 1994), while both cultured
endothelial cells and SMCs from the coronary artery have also been shown to release
ET-1 (Ohlstein et al., 1998; Haug et al., 1998). In vitro studies have also
demonstrated that neonatal rat cardiac fibroblasts can synthesise ET-1 when
stimulated by other cardiac vasoactive factors (King et al., 1996; Gray et al., 1998).
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1.2.5 ET receptors
Not long after the discovery of ET-1, two high affinity receptor subtypes were
identified and cloned (Arai et al., 1990; Sakurai et al., 1990; Lin et al., 1991). These
specific binding sites for ET-1 were classified according to their relative affinities for
the ET isopeptides. The ETA receptor has subnanomolar affinities for the ET-1 and
ET-2 peptides and a 70-100 fold lower affinity for ET-3 (ET-l>ET-2»ET-3). The
ETb subtype has equal subnanomolar affinities for all three ET peptides and SRTX
S6c (ET-1=ET-2=ET-3=SRTX S6c) (Sakurai et al., 1990).
The human ETA receptor gene has 8 exons and 7 introns, is assigned to chromosome
4 and encodes for a 427 amino acid polypeptide (Hosada et al., 1992). The gene for
the human ETb subtype is assigned to chromosome 13, has 7 exons and 6 introns and
encodes a 442 amino acid polypeptide (Arai et al., 1993). Both predict classic
heptahelical G-protein coupled receptors. Sequence homology of 55-64% has been
found between the two, depending on the tissue studied (Arai et al., 1993). The
cytoplasmic loops of the receptors are highly conserved, but the N-terminal and other
extracellular domains differ in both length and amino acid sequence (Ogawa et al.,
1991; Elshourbagy et al., 1993). Specific regions along the sequences have been
identified as essential for receptor activity, as well as signalling domains located
within the c-terminal region (Sakamoto et al., 1993). Of the seven transmembrane
domains, I, II, III and VII are involved in ligand receptor binding, while IV, V and
VI domains determine isopeptide selectivity (Sakamoto et al., 1993). The third
cytoplasmic domain of the ETA receptor is very short (~30-50 residues) and is
implicated in coupling with the G-protein (Adachi et al., 1993).
Based on pharmacological studies, the ET receptors have been further classified.
Sudjarwo et al. (1994) proposed subclassification of the ETA receptor by its
susceptibility to BQ123, with a sensitive ETA1 and resistant ETA2 subtype. Two types
of ETb receptor were also proposed, ETBi and ETB2 were subclassified by their
existence on different effector cells (endothelial cells or SMCs) (Masaki et ah, 1994;
Douglas et al., 1994). A third putative ETc receptor with selective affinity for ET-3
was proposed in Xenopus laevis dermal melanophores (Karne et al., 1993), and later
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in rabbit saphenous vein (Douglas et al., 1995), but has not been detected in human
tissue. However, it is acknowledged that there is no genetic basis for the existence of
these proposed subtypes, as only ETa and ETb receptor genes have been identified.
The development of ET receptor agonists and antagonists (Table 1.2) has enabled the
selective study of the ET receptor subtypes in relation to the physiological and
pathophysiological function of ET-1 in the cardiovascular system. However, to date,
no selective ETa receptor agonist has been discovered. In addition, gene knockout
(KO) mice were developed to help characterise the function of the ET system
components. However, many of the phenotypes were lethal, indicating the
importance of the ET system in development. ET-1 and ETA receptor gene deficient
mice die shortly after birth due to respiratory failure and exhibit severe craniofacial
malformations, aortic and ventricular septal defects also exist in these mice (Kurihara
et al., 1994; Clouthier et al., 1998; Yanagisawa et al., 1998). Most ECE-1 KO mice
die earlier in utero but still exhibit craniofacial abnormalities (Yanagisawa et al.,
1998). Meanwhile, although ET-3 and ETB gene deficient mice are viable at birth,
they die 2-4 weeks after from intestinal dysfunction due to aganglionic megacolon,
resulting from the absence of the enteric neurons (Baynash et al., 1994; Hosada et
al., 1994). Interestingly, mutations of both ET-3 and ETB have also been reported in
patients of both sporadic and familial Hirschsprung's disease with or without
pigmentatory abnormalities (Puffenberger et al., 1994; Edery et al., 1996),
highlighting the importance of ET-3 and ETB mediated signalling in development of
enteric neurons and melanocytes in humans.
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Table 1.2. ET receptor agonists and antagonists
Category ETa ETb Reference
ET potency order ET-1>ET-2»ET-3 ET-1=ET-2=ET-3 Sakurai et al., 1990










Aramori et al., 1993






Stein et al., 1994




Bosentan (Ro 47-0203) (non peptide)
SB209670 (non peptide)
Kikuchi et al., 1994
Clozel et al., 1994
Ohlstein et al., 1994
1.2.6 ET receptor localisation, function and signalling
1.2.6.1 Vascular ET receptors
ETa and ETB receptors have different vascular distributions. In situ hybridisation and
Northern blotting techniques have revealed that in blood vessels, the ETA receptor is
predominately expressed in SMCs of bovine lung (Arai et al., 1990), bronchial
SMCs, renal arterioles, brain blood vessels and the aorta of the rat (Hori et al., 1992;
Sakurai et al., 1990; Maxwell et al., 1998) and human cerebral arteries, pulmonary
arteries and the aorta (Nilsson et al., 1997; Davenport et al., 1993). Meanwhile,
various techniques have demonstrated that ETB receptors exist predominantly on
endothelial cells but they are also detected on vascular SMCs of similar vessels
including hepatic tissue (Leivas et al., 1998), aorta and pulmonary arteries
(Davenport et al., 1993), human cerebral arteries (Nilsson et al., 1997) and glial cells
of many brain regions (Hori et al., 1992). However, in contrast, ETA is absent from
human endothelial cells (Hosada et al., 1991). The ratio of the two receptors on
SMCs varies depending on the vascular bed, with veins in general having lower ETA:
ETb ratios than arteries (Lipa et al., 1999).
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The role of endogenous ET-1 has been investigated in many animal and human
studies. Evidence shows that ET-1 has a role in maintenance of basal vascular tone
and blood pressure (Haynes & Webb et al., 1994). It has also been shown that both
receptors are involved in mediating the effects of ET-1 (Clozel et al., 1992) and the
rapid development of potent and selective ET receptor agonists and antagonists has
allowed the functional role ofET receptors to be more clearly defined (Table 1.2).
Intravenous bolus administration of ET-1 is known to cause a short-lived decrease
(up to a few minutes) in vascular resistance, followed by a marked pressor effect (> 1
hour) in both humans and animals (Yanagisawa et al., 1988a; Vierhapper et al.,
1990; Pemow et al., 1996). The initial increase in perfusion is caused via NO and
PGE release by ETb stimulated endothelial cells as studies have shown that ETb
antagonists (such as BQ788; Douglas et al., 1994) and inhibition of both PGI2 and
NO synthesis (Filep et al., 1993; Berti et al., 1993) abolish the dilator response both
in vivo and in vitro. Meanwhile, ETa receptors on SMCs primarily mediate the
vasoconstriction as infusion of selective ETA receptor antagonist, BQ123, leads to an
increase in local blood flow in human forearm vasculature studies (Haynes & Webb,
1994) and greatly attenuates the pressor response in rats (Bird et al., 1993). However,
BQ123 does not completely abolish the pressor response (McMurdo et al., 1993) and
ETb selective agonists have been shown to evoke constriction in vitro (Shetty et al.,
1993; Gray et al., 1994) and pressor responses in vivo (Cloze! et al., 1992).
Therefore, taken together, these observations are consistent with the view that
endothelial cell ETb receptors mediate the dilator response, SMC ETA receptors
predominately mediated the constrictor response and that ETb receptors are also
present on vascular SMCs to stimulate constriction (Figure 1.4).
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Figure 1.4. Endothelium derivedfactors that regulate vascular smooth muscle tone.
AA, arachidonic acid; ECE, endothelin converting enzyme; NO, nitric oxide; PGf,
prostacyclin. Modifiedfrom Gray & Webb, (1996).
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ET-1 induced vascular contraction is rapid and utilises various signalling
mechanisms. ET receptors on SMCs are G-protein-coupled, resulting in activation of
PLC, and generation of two second messengers, IP3 and 1,2-diacylglycerol (DAG)
(Griendling et al., 1989), which respectively stimulate Ca2+ release and protein
kinase C activation (Simpson & Ashley, 1989; Lonchampt et al., 1991). ETb
receptors on endothelial cells mediate relaxation of vascular SMCs via release ofNO
and PGE. The G-protein-coupled receptor mobilises Ca2+ via PLC (as described
above), generating a Ca2+/Calmodulin complex, which in turn activates NOS, the
enzyme which is central to NO biosynthesis. Diffusion ofNO occurs freely, enabling
it to leave the endothelial cell and cross over to the SMC, where depending on its
concentration, NO will induce an increase of cGMP (Ignarro, 1989). Elevated levels
of cGMP act on myosin light chain kinase, PKG, phosphodiesterases and ion
channels, resulting in reduced [Ca2+]j (Moncada & Higgs, 1991). A PKG-dependent
mediated reduction of myofilament responsiveness to Ca2+ also adds to the negative
contractile effect. Conversely, a positive contractile response is induced by an
increase of cAMP, induced by low level NO stimulation of a novel cGMP-
independent activation ofAC (Kojda et al., 1996).
Increased concentration of circulating ET-1 has been observed when mixed ETa/ETb
and selective ETB antagonists but not selective ETa antagonists are infused in rat,
rabbit and human (Fukuroda et al., 1994; Gratton et al., 1997; Strachan et al., 1999),
suggesting a role for ETB receptors in the clearance of ET-1. The lungs are the organ
containing the highest density of ETB receptors, with close to 50% of the
endothelium of the entire vascular tree. Considering the high blood volume in that
organ at any time, the pulmonary endothelium could act as a very efficient clearing
mechanism (Dupuis et al., 1996). Extraction of ET-1 follows binding to cell surface
receptors which are then internalised, allowing degradation to be carried out within
the cell (Gandhi et al., 1993). The ligand-receptor complex is thought to be
sequestered into lysosomes where the acidic environment promotes ligand
dissociation (Hirata et al., 1988). Other organs such as kidneys and liver are also
reportedly involved in the clearance of circulating ET-1 by ETB receptors (de Nucci
et al., 1988; Dupuis et al., 1999). Conversely, ETa receptors are not thought to be
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involved in clearance of plasma ET-1 as internalised ETA receptors are recycled back
to the cell surface (Bremnes et al., 2000).
1.2.6.2 ET receptors in the kidney
The ET system is known to play an important role in the regulation of vascular tone
and blood pressure. Studies have also indicated a role for ET-1 as a key natriuretic
hormone (as reviewed by Kotelevtsev & Webb, 2001). The kidney is uniquely
influenced by ETs and a wide variety of renal cell types express mRNA for the
receptors and the precursors of ET-1 and ECEs (Terada et al., 1992; Kohan, 1997).
The ET system controls renal blood flow, reabsorption of water and sodium and
acid-base balance (King et al., 1989; Bloom et al., 1993). ET-1 administration into
the renal artery of an anaesthetised rabbit results in reduced renal blood flow, cortical
perfusion, glomerular filtration rate, urinary flow and sodium excretion (Evans et al.,
1998). Systemic infusion of ET-1 in humans also causes renal vasoconstriction and
decreases renal sodium excretion (Sorensen et al., 1994). In contrast, administration
of big ET-1 into the femoral artery of rats produces a significant increase in sodium
and water excretion that cannot be blocked by BQ123, the ETA receptor antagonist.
This is due to the activation of ETB receptors deep in the medulla, causing natriuresis
and diuresis (Pollock & Opgenorth, 1994), indicating that ET-1 has different
functions in the renal tubule than in the vasculature. The role of ETs in sodium
excretion and acid-base status has been further explored in rats and mice genetically
lacking ETB receptors (Gariepy et al., 1998; Ohuchi et al., 1999). These animals
exhibit significant hypertension and data suggests that ETB likely acts within the
kidney, not in the vessel wall, to regulate pressure. In vivo, it is suggested that ETB
receptors in the collecting duct may tonically inhibit sodium reabsorption via luminal
epithelial sodium channels, the final regulator of sodium balance, as the sodium
channel blocker amiloride, restores normal mean arterial blood pressure (MAP) in
the salt-loaded ETB deficient animals (Gariepy et al., 2000).
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Autoradiography has been used to demonstrate binding of [ I] ET-1 to both ETA
and ETb receptors in human coronary arteries and veins. The ETA receptor subtype is
predominant in coronary artery SMCs (Bacon & Davenport, 1996), while, ETb
receptor binding is weak at the proximal regions but increases in density towards
distal regions of the vessel (Davenport et al., 1994). Meanwhile, ETb expression is
exclusively on the coronary endothelium (Davenport et al., 1993; Opgaard et al.,
1996). In addition, these studies indicated that ET-1 induced contractile response was
mediated only by ETA receptors, where as ETB receptors mediate relaxation. In
animal studies, quite a different receptor profile has been reported. Antagonist
studies have identified that contraction of pig coronary artery is mediated by both
receptors (Schoeffter & Randriantsoa, 1993) and the canine coronary circulation also
contains a significant population of ETe receptors that can mediate both vasodilation
and vasoconstriction (Teerlink et al. 1994).
In the myocardium, ETA and ETb receptors have a similar distribution, with mRNA
of both found on cardiomyocytes ofmany species, including rat (Sargent et al., 1994;
Sakai et al., 1996b), rabbit (Spiers et al., 1996) and human (Molenaar et al., 1993;
Davenport et al., 1993). Binding studies have demonstrated that both subtypes are
located in atrial and ventricular myocardium, although their distribution is not
uniform. Significant regional differences were shown in the human heart by
Molenaar et al. (1993), indicating ETA receptor density to be greatest in isolated right
atrial myocytes (91%), while in myocytes of the LV free wall, the ETA subtype
contributes approximately 57-67% of the total population. However, the ratio of the
receptors differs depending on the tissue and species, with the ETA receptor subtype
representing 90% of the endothelin receptors on rat right ventricular cardiomyocytes
(Sakai et al., 1996a; Fareh et al., 1996). In contrast, in situ studies in our own
laboratory have yielded a 80:20 distribution of ETA:ETB in LV (Sherry, 2000).
Both receptors are also found within the AV conducting system. Localisation using
autoradiography in the human heart has shown a higher proportion of ETB receptors
within the AV node, the penetrating and branching bundles of His, than in the
28
Chapter 1 - Introduction
surrounding atrial and ventricular myocardium (Molenaar et al., 1993). Fibroblasts
display an equal distribution of the receptor subtypes in rat (Fareh et al., 1996), but
not human (Modesti et al., 1999), where in situ hybridisation studies have
demonstrated that ETB receptor mRNA was almost exclusively expressed in
fibroblasts and endothelial cells of the human LV. In addition, functional ETB
receptors have also been identified on rat pericardial mesothelial cells (Kuwahara &
Kuwahara, 1998).
Like ET-1, expression of ET receptors is also influenced by various circulating
factors. Studies have shown that in cultured rat vascular SMCs, ETA is upregulated
by insulin and NO (Frank et al., 1993; Redmond et al., 1996). While expression of
ETb receptor mRNA was shown to be upregulated in cultured rat cardiomyocytes by
Ang II (Kanno et al., 1993) and in human HUVECs by cytokines and growth factors
(Smith et al., 1998). In addition, ET-1 itself has been shown to alter receptor number
(Hirata et al., 1988). Increasing evidence also shows that receptor expression is
modified in the diseased state (Batra et al., 1993; Sakai et al., 1996a; Gray et al.,
2000) (to be discussed later in section 1.3).
The role of the ET system in contractile function of the heart is still not clearly
defined. Clinical studies have shown that intracardiac infusion of the ETA selective
antagonist BQ123 in healthy volunteers causes a significant reduction in LV dP/dt, a
measurement of contractility, with no effect on relaxation and an absence of systemic
effects such as heart rate, aortic pressure or pulmonary artery pressure (MacCarthy et
al., 2000). In contrast, systemic infusion of the mixed antagonist TAK-044 in healthy
subjects increased cardiac index (Haynes et al., 1996). However, this was attributed
to the associated decrease in systemic vascular resistance, suggesting that a large part
of the effect is mediated in the resistance vessels. Meanwhile, systemic
administration of BQ788, the selective ETb receptor antagonist, caused a significant
increase in MAP, increased total peripheral vascular resistance and reduced heart
rate, cardiac index and renal blood flow (Strachan et al., 1999), due in part to
reduced clearance of ET-1 from the circulation. Furthermore the pressor effect
observed in anaesthetised dogs after bolus administration of ET-1 is associated with
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extreme peripheral vasoconstriction, a reduced cardiac output, bradycardia and
consequent activation of baroceptor reflexes (Given et al., 1989). Heart rate was not
influenced by ET-1 in anaesthetised rats but cardiac output was reduced due to the
decrease of stroke volume (Beyer et al., 1994). Consequently, it has proved difficult
to distinguish the functional characteristics of ET-1 in vivo due to direct and indirect
effects.
Difficulties in obtaining positive inotropic responses to ET-1 have also been
observed in studies using isolated hearts from rats (Neubauer et al., 1990), or rabbit
(Karawatowska & Wennmalm, 1990). This may be because pharmacological
interventions directly affect the closely linked coronary vasculature functions in vivo
(Beyer et al., 1994) and isolated heart preparations. In many species, ET-1 produces
potent and long-lasting constriction of coronary vessels (Clozel & Clozel, 1989;
Pernow et al., 1989), producing marked reductions in coronary blood flow and
causing associated myocardial ischaemia and even arrhythmias (Ercan et al., 1996).
ETa and ETb receptor antagonists have been shown to increase and decrease
coronary flow respectively in isolated perfused rat hearts indicating the presence of
both ET receptors on the coronary vasculature, suggesting an indirect effect of ET-1
on cardiac muscle through modulation of coronary artery tone (Wang et al., 1994). In
fact, although clinical studies have not observed coronary vasoconstriction, it has
been recognised in humans who are bitten by the Israeli burrowing asp Actactaspis
engaddensis, a source of SFTX S6c (Weiser et al., 1984).
Although in vivo and isolated heart studies have not proved successful in
demonstrating the positive inotropic effects in response to ET-1 administration, some
in vitro preparations of cardiac muscle have managed to show this effect.
Observations have shown that nanomolar concentrations of ET-1 can evoke positive
inotropic effects on isolated cardiac tissues such as guinea pig atria (Ishikawa et al.,
1988), rat atria and ventricular papillary muscle (Hu et al., 1988; Moravec et al.,
1989) and rabbit ventricular papillary muscle (Li et al., 1991; Kasai et al., 1994).
Studies using human atrial and ventricular myocardial strips (Moravec et al., 1989;
Meyer et al., 1996) have observed similar responses. In addition, both Davenport et
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al. (1989) and Moravec et al. (1989) have shown that ET-1 was less effective at
causing an increase of contractile force in human and rat ventricle compared to atrial
muscle. This difference is likely to be related to the fact that atrial muscle contains
more ET receptors than ventricular muscle. However, the identity of the receptor(s)
that mediate the response to exogenous ET-1 is unclear. Meanwhile, studies using
isolated cardiomyocytes from rabbit and humans have demonstrated positive ET-1
induced contraction (Kelso et al., 2000; Burrell et al., 2000) but suggest that only the
ETa receptors mediate the contractile effect via a PLC pathway.
In addition, separate studies have demonstrated anti- and pro-arrhythmic actions of
ET-1. James et al. (1994) demonstrated that in isolated ventricular cardiomyocytes,
ET-1 acting through ETa receptors inhibited the PKA-dependent chloride current to
protect the ventricle against arrhythmias. Meanwhile, ET-1 induced arrhythmic
contractions have been reported in human isolated atrial tissue, however, these
effects did not appear to be mediated by the ETa receptor (Burrell et al., 2000).
Paradoxically, high doses of BQ123, the selective ETa antagonist, have produced
arrhythmias while low doses of BQ123 were found to reduce the incidence in the rat
model of ischaemia (Garjana et al., 1995). Together, these studies indicate that ET-1
can affect the heart directly and indirectly and is involved in contractility and
rhythmicity.
In the heart, ET-1 induces positive inotropic effects by similar cellular mechanisms
to those mediating SMC contraction (Figure 1.5). Studies have shown that the
increased contractile force arises from an accumulation of IP3 and its associated rise
in [Ca2+]j in rat (Vigne et al., 1989; Kramer et al., 1991), rabbit (Takanashi & Endoh,
1992) and human cardiac tissue (Vogelsang et al., 1994). ET-1 induced DAG
9+
production together with Ca and phosphatidylserine activates PKC (Takanashi &
Endoh, 1991), which can activate targets such as the sodium/hydrogen exchanger
(Na+/H+X) (Meyer et al., 1996). This leads to an accumulation ofNa+, an increase of
intracellular pH, sensitising the contractile proteins and possibly increasing the
activity of the sodium/calcium exchanger (Na+/Ca2+X) to remove Na+ but further
2+
increasing [Ca ]j. In addition, PKC can activate other targets such as nuclear
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signalling mechanisms, activator protein (AP-1) and mitogen-activated protein
kinase (MAPK), suggesting possible effects on long-term regulation of cellular
function.
Vogelsang et al. (1994) demonstrated a second signal transduction pathway that
inhibits AC activity by a PKC-independent manner, reducing the accumulation of
cAMP in human right atrium. A similar mechanism has also been described in rat
(Hilal-Dandan et al., 1992) and feline cardiomyocytes (Jones, 1996). Furthermore,
multiple G-proteins may be involved in the inotropic response. Ladoux & Frelin
(1991) demonstrated that ET-1 -induced IP3 formation involves a PTX-insensitive G-
protein, whereas ET-1-induced inhibition of AC involves a PTX-sensitive G-protein
(Jones, 1996). It has also been suggested that ET-1 may increase inotropy by
enhancing Ca2+ responsiveness, with little or no increase in [Ca2+]j (Paik et al.,
1994). This myofilament sensitisation has been demonstrated to act via PKC and the
subsequent activation of the Na+/H+X (Meyer et al., 1996; Endoh et al., 1998).
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actions
Figure 1.5. The proposed mechanism for the ET-1 mediated increase in contractile
force. ATP, ATPase pump; SR, sarcoplasmic reticulum; RyR, ryanodine receptor;
PLB, phospholamham; IP3, inositol triphosphate; DAG, diacylglycerol; PKC,
protein kinase C; NCX, Na+/Ca2+ exchange; NHX, Na+/H+ exchange; Gs, G-protein;
PLC, phospholipase C.
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Two classes of voltage-dependent Ca2+ channels are exhibited on cardiac myocytes,
the L-type channel, which conveys the main depolarising current contributing to the
plateau-shape of the action potential and the T-type channel, which is negligible in
most ventricular myocytes (as reviewed by Bers, 2002). Channels carrying the 7Ca are
regulated by a number of second messengers and have been found to be modulated
by ET-1. Both stimulation (Lauer et al., 1992; Bkaily et al., 1995) and inhibition
(Ono et al., 1994) of the 7ca has been described in response to ET-1. Furthermore,
Kelso et al. (1998) demonstrated that the ETa receptor subtype was coupled to a
decrease in 7ca, whereas the ETb receptor was responsible for an increase in 7ca in
isolated rabbit ventricular cardiomyocytes. Additionally, Boixel et al. (2001) found
similar results in human atrial myocytes, suggesting an important mechanism in
• • • 2"h
protecting against arrhythmias and myocardial Ca overload. However, evidence has
2+ •shown that ETa receptor antagonists such as BQ123 reduced [Ca ]j rising in
neonatal atrial and ventricular cardiac cells (Touyz et al., 1996), meanwhile, ET-1
2"hhas also been shown to enhance Ca entry through T-type channels in cultured
neonatal rat ventricular myocytes (Furukawa et al., 1992), indicating that the
• 94-
mechanisms underlying the ET-1 receptor-induced [Ca ]i rise are not completely
understood.
Other actions in the heart include ET-1-induced hyperpolarisation and shortening of
action potential duration by inhibition of 7ca and stimulation of the K+ current (7K) in
isolated guinea pig myocytes (Ono et al., 1994). These effects are coupled to a PTX-
sensitive GTP-binding protein and the inhibition of cAMP accumulation, suggesting
that the endothelin system has chronotropic and inotropic effects in the heart.
The development of cardiac hypertrophy induced by haemodynamic overload is
likely to be triggered by mechanical stress and the involvement of growth factors. As
discussed before, stretch of endothelial cells results in a PKC mediated release of
ET-1 (see section 1.2.3) and similarly, an increased expression of ET-1 mRNA and
stimulated release of ET-1 is observed in response to mechanical stretch of cultured
cardiomyocytes (Yamazaki et al., 1996). The contribution of local ET-1 to
hypertrophy was demonstrated by an increase in ventricular ET-1 levels during
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pressure overload of rat cardiomyocytes, which display a positive correlation with
the degree of hypertrophy (Arai et al., 1990). In addition, it has been shown that ET-
1 stimulates hypertrophy as indicated by an increase in myocardial cell size, protein
synthesis, accumulation of contractile proteins and expression of immediate early
genes in cultured rat ventricular myocytes (Shubeita et al., 1990; Ito et al., 1991).
The importance of ET-1 stimulation as a paracrine mechanism for the in vivo
regulation of cardiac growth and hypertrophy was confirmed by Ito et al. (1994) in
rats with LV overload produced by aortic banding. The study also suggested that the
ETa receptors were involved in the mechanism of cardiac hypertrophy but only
during the first week of overload. Similarly, Yamazaki et al. (1996) demonstrated
that ET-1 induced activation of hypertrophic signals such as Raf-1 kinase (Raf-1)
and MAPK were mediated through the ETA receptor, followed by an increase in
protein synthesis in neonatal rat cardiomyocytes. The involvement of the ETb
receptor in mitogenesis has also been demonstrated. Aquilla et al. (1996) found it
was associated with the activation of three distinct MAPK signal transduction
pathways, the extracellular regulated protein kinase (ERK) 2, c-Jun N-terminal
kinase 1 (JNK), and p38 kinase. These mitogen-activated protein kinase isozymes are
thought to mediate very different biological outcomes and required residues in the c-
terminal for coupling the receptor to intracellular kinase pathways. Interestingly, in a
previous study in our laboratory, ETB receptors were increased in the hypertrophic
LV post MI in association with ERK and p-myosin heavy chain immunoreactivity
(McEwan et al., unpublished observations), indicating that the ET system has
remarkably diverse biological properties and actions.
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1.3 Heart failure
Chronic heart failure (CHF) is a major public health problem in the UK, affecting a
growing number of the population. It is associated with high morbidity and mortality
and is a major cause of recurrent hospitalisation. It is associated with activation of
compensatory neurohumoral reflexes, including renin-angiotensin-aldosterone
system (RAAS) and sympathetic nervous system activation that not only maintain
perfusion pressure but also increase peripheral vascular resistance, renal sodium
reabsorption and cardiac workload. This leads to a vicious cycle of declining cardiac
function and provides a rationale for the current mainstay of treatment, which are
directed at preventing sodium and water retention and antagonising the humoral
responses that cause peripheral vasoconstriction. The main causes of CHF are
ischaemic heart disease (IHD), hypertension, valvular disease and cardiomyopathies
such as hypertrophic, restrictive and dilated.
1.3.1 The aetiology of human heart failure
The most common cause of CHF is IHD, which usually follows an acute myocardial
infarction (MI), most commonly due to coronary atherosclerosis. LV systolic
dysfunction, such as low cardiac output, low ejection fraction and sometimes
hypotension, or diastolic dysfunction such as impaired LV filling, high LA pressure
and pulmonary oedema, or both, can cause cardiac failure after MI. Patients exhibit
exertional fatigue, breathlessness and often symptoms of fluid retention. Prognosis
can be predicted from the severity of symptoms, patients with LV ejection fraction
(EF) <30% suffer 15-40% mortality at 1 year, compared to less than 5% mortality for
those with EF >60%. The main modes of death are sudden arrhythmic death,
progressive pump failure and recurrent MI.
Dilated cardiomyopathy (DCM) is the most common cardiomyopathy, which causes
include idiopathic, familial (-25% of cases) and myocarditis. It is a heterogeneous
cardiac disease characterised by ventricular dilatation and systolic dysfunction.
Several genetic studies have recently revealed that mutations in genes for cardiac
sarcomere components lead to DCM (Olson et al., 1998; Itoh-Satoh et al., 2002;
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Gerull et al., 2002). Hypertrophic cardiomyopathy (HCM) is characterised by
myocardial hypertrophy in the absence of an identifiable cause such as hypertension
or aortic stenosis. The distribution of hypertrophy may be concentric, asymmetrical
or apical. Histologically, HCM is characterised by myofibrillar disarray and
myocardial fibrosis. It can be sporadic or hereditary, as a familial predisposition can
be identified in 50% of patients and inheritance is usually autosomal dominant. A
large number of gene defects have also been identified with HCM and usually affect
structural myocyte proteins such as P-myosin, myosin-binding proteins and the
troponin subunits. Different disease genes in HCM are associated with different
patterns of penetrance and different prognosis (Watkins et al., 1992; Moolman et al.,
1997).
Congenital heart disease is characterised by anatomical or structural abnormalities of
the heart chambers or great vessels, which may reflect particular deficiencies in
neural crest formation. Obstruction of the blood flow across valves or through the
great vessels produces a pressure gradient across the lesion, which can lead to the
development of hypertrophy or dilation.
Left ventricular hypertrophy (LVH) as an initially useful physiological adaptation to
conditions of increasing metabolic and haemodynamic overload is well recognised.
In this physiological hypertrophy, as seen in normal growth and increased regular
physical exercise, the normal cardiac ultrastructural architecture is preserved. In
contrast, pathophysiological hypertrophy is seen in diseased states or in the setting of
increased release of factors associated with abnormal cardiac physiology,
overexpression of proto-oncogenes and certain genetic mutations. Architectural
remodelling comprises of myocyte hypertrophy rather than hyperplasia to match
heart size to haemodynamic load. In addition to hypertension, the major aetiologies
of LVH include valvular heart disease, HCM, DCM and ventricular septal defects.
Among these, chronic severe valvular heart disease and HCM are most likely to
result in severe LVH. Thus in diseased states, the limits of LVH are determined
predominantly by the degree and duration of haemodynamic pressure and/or volume
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overload and any underlying genetic or hereditary susceptibility to cardiac
hypertrophy.
1.3.2 Current clinical treatments
Current clinical treatments are directed at correcting the inadequate contractility of
the failing heart by reducing workload of the ischaemic myocardium. Patients with
signs of fluid retention, including pulmonary oedema, peripheral oedema or elevated
jugular venous pressure are generally prescribed diuretics (such as frusemide or
bendrofluazide). Increased diuresis results in a reduced blood volume, which is
accompanied by an improvement in cardiac performance due to the reduced preload
and afterload. However, caution must be taken when using diuretics in combination
with other drugs, for example, potassium-sparing diuretics must be used with care
when combined with ACE inhibitors as serious renal dysfunction and life-threatening
hyperkalaemia may occur. Other side effects of diuretics can include activation of
neurohormonal systems, imbalance of electrolytes and hypotension.
ACE inhibitors (such as captopril or ramipril) block the conversion of angiotensin I
(Ang I) to Ang II and prevent the degradation of bradykinin by ACE. When added to
diuretic therapy, ACE inhibitors reduce the symptoms and signs of heart failure and
improve exercise capacity. A number of randomised controlled trials have shown
that ACE inhibitors improve ventricular function, improve survival in patients with
all grades of heart failure and reduce hospital admissions (as reviewed by Lonn &
McKelvie, 2000). In addition, ACE inhibition slows down the progressive
deterioration in cardiac status, which is seen in heart failure patients. Common
adverse effects associated with ACE inhibitors can include syncope, due to
hypoperfusion, hypotension, deterioration of renal function and hyperkalaemia.
However, careful initiation of treatment and regular monitoring helps to reduce these
problems. Ang II receptor antagonists have similar effects on haemodynamics,
neuroendocrine activity and exercise capacity to those of ACE inhibitors (Crozier et
al., 1995) and have been used in place of ACE inhibitors when side effects, such as
cough are encountered. Pitt et al. (1997) evaluated the effects of the ACE inhibitors
captopril, compared to Ang II receptor antagonist losartan (in addition to diuretic and
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digoxin therapy) and reported a significantly lower mortality in the losartan group.
However, losartan was not superior to captopril in respect of symptomatic status or
hospitalisation rates for worsening heart failure. Aldosterone antagonists such as
spironolactone have also been shown to have a beneficial effect on both mortality
and morbidity in heart failure and a substudy has shown that these effects are at least
partly linked to a reduction in cardiac fibrosis (as reviewed by Delcayre &
Swynghedauw, 2002).
Positive inotropes such as digoxin improve the symptoms and signs of heart failure,
the quality of life and the exercise tolerance of patients with mild, moderate, or
severe heart failure. In addition, digoxin increases the delivery of sodium to the distal
tubules, leading to the suppression of renin secretion from the kidneys and activates
the parasympathetic nervous system to increase vagal tone (as reviewed by Dec,
2003). However, the major pharmacokinetic drawback of digoxin is its narrow dose-
response relationship and it is administered at a fixed dose (0.125-0.25 mg daily in
the majority of patients) to avoid toxicity.
Beta adrenoceptor antagonists (beta-blockers; such as carvedilol or metoprolol)
decrease the three major determinants of myocardial oxygen demand, heart rate,
contractility and systolic wall tension, allowing improvement in LV function.
Originally, P-adrenoceptor antagonists were used to treat angina and hypertension,
however, clinical trial evidence suggested that patients with clinically stable, mild to
moderately symptomatic heart failure caused by LV systolic dysfunction may benefit
from treatment (Packer et al., 1996; CIBIS-II Investigators, 1999; Swedberg et al.,
1999). However, major side effects such as hypotension, fluid retention and
bradyarrhythmias are often related to the use of P-adrenoceptor antagonists. In
addition, conventional doses can cause worsening of heart failure, therefore, small
doses are started cautiously and carefully observed. Controversy still surrounds the
management of heart failure and despite all of the recent advances in medical and
other therapies, there is still room for improvement.
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Animal models of heart failure have provided a useful starting point for the
investigation of cardiac diseases and have aided in the development of therapeutic
drugs (as reviewed by Hasenfuss, 1998a). The most widely used model in
cardiovascular research is LV coronary artery occlusion (CAL), as described by
Pfeffer et al. (1979), which results in MI. The popularity of this model stems from
the fact that it is the only animal model of heart failure to closely mimic IHD in
humans (as reviewed by Arnolda et al., 1999). Rats, which survive the acute phase
of MI, develop progressive LV and RV hypertrophy and remodelling. Failure is
associated with LV dilatation, reduced systolic function and increased filling
pressures. Altered haemodynamics and neurohumoral activation, similar to those
seen in patients with CHF are also observed. Another technique, aortic banding,
creates haemodynamic overload which leads to the development of LV hypertrophy
(Ito et al., 1994). This model is also associated with an elevation in activity of the
renin-angiotensin system. In addition, CHF induced by rapid ventricular pacing
displays characteristic reductions in cardiac output and mean arterial pressure,
increased pulmonary capillary wedge pressure and increased levels of plasma
norepinephrine, aldosterone and the hypertrophic marker atrial natriuretic peptide
(Ohnishi et al., 1998). Models of hypertrophic cardiomyopathy have been developed
experimentally to study the functional aspects of myocardial hypertrophy and more
recently molecular biology techniques have engineered more refined animal models
of hypertrophic cardiomyopathy (Tardiff et al., 1998; Yang et al., 1998). However, it
is accepted that no animal model can completely mimic human heart failure.
1.3.4 Heart failure and the endothelin system
1.3.4.1 Elevated levels of ET-1 in human heart failure
Plasma levels of the ET-1 precursor, big ET-1 are increased in patients with CHF,
indicating an increase of ET-1 synthesis. These levels are found to correlate with the
degree of haemodynamic and functional impairment (Pacher et al., 1993; Wei et al.,
1994). Plasma concentrations of mature ET-1 peptide are also elevated in more
40
Chapter 1 - Introduction
severe cases, when renal failure and pulmonary congestion are associated with
reduced clearance of ET-1. A two-threefold increase of plasma ET-1 concentration
has been reported in patients with CE1F compared to healthy individuals (McMurray
et al., 1992) and such levels are capable of producing systemic vasoconstriction and
reduction of the cardiac index (Cowburn et al., 1998). However, the clearest
indication that ET-1 is a mediator, rather than a marker of CHF comes from ET-
receptor antagonist studies (see section 1.3.4.3 below).
The expression and distribution of the ET-1 system has been studied in human heart
failure. Endothelial cells of ventricular tissue from patients with IHD or DCM have
previously been shown to express ET-1 mRNA and immunoreactive ET-1 (Plumpton
et al., 1996). In addition, expression of ET-1 immunoreactivity and ppET-1 mRNA
have been localised to vascular and endocardial endothelial cells, as well as
cardiomyocytes from explanted hearts of patients with end-stage heart failure (Giaid
et al., 1995). The most intense staining for ET-1 has been identified in myofibrils,
which are located in areas of granulation tissue surrounding the infarcted area.
Furthermore, in addition to increased ET-1 mRNA, a recent study reported the
upregulation of ECE-1 mRNA in failing human myocardium, supporting the increase
in ET-1 synthesis (Morawietz et al., 2002). However, a contrasting study
demonstrated that immunoreactive ET-1 displayed similar intensities in both healthy
and CHF ventricular myocardium (Wei et al., 1994).
1.3.4.2 Altered expression of ET receptors in human heart failure
ET signalling is activated in failing human hearts and may contribute to progressive
myocardial dysfunction and remodelling. However, the behaviour of ET receptor
subtypes in failing human hearts is not well understood. Both receptor genes are
expressed in the failing myocardium, with the ETA receptor the dominant subtype but
no clear pattern has emerged for altered expression levels relating to aetiology.
Ponicke et al. (1998) demonstrated elevated ETA receptor density in the LV of
human end-stage failing myocardium. Similarly, ETA upregulation in the LV
myocardium of hearts in end-stage failure due to DCM compared to non-failing was
demonstrated by Pieske et al. (1999), while ETB receptor expression remained
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unchanged. In contrast, Zolk et al. (1999) reported a significant decrease of ETB
receptor mRNA in DCM samples compared to non-failing and no significant change
in expression of the ETA receptor, or ET-1 mRNA. Knowledge of ET receptor
density in heart failure is of importance as the actions of ET-1 during the progression
ofCHF may depend on the cardiac ratio.
1.3.4.3 Endothelin antagonists and human heart failure
CHF is clearly one of the most important pathologies that could potentially benefit
from treatment with ET receptor antagonists (Duchman et al., 2000). Clinical studies
have shown that short-term therapy with the dual ETA/ETB receptor antagonist
bosentan improves systemic and pulmonary haemodynamics substantially in
conventionally treated patients with symptomatic severe CHF (Kiowski et al., 1995;
Sutsch et al., 1998). In addition, selective ETA receptor blockade has also been
reported to induce favourable effects in patients with CHF (Cowburn et al., 1998).
These studies have established that ET-1 exerts measurable haemodynamic effects in
heart failure. However, whether selective ETA receptor antagonists are as efficient as
mixed antagonists in CHF remains to be determined, as they have not been compared
directly in the same study. It is suggested that theoretically, selective ETA receptor
antagonists may offer advantages over mixed ETA/ETB receptor antagonists. ETB
receptors are known to evoke vasodilatation and are involved in clearance of ET-1.
Therefore, blockade of the ETB receptors may exacerbate the already reduced
pulmonary clearance of ET-1, which may contribute to the elevated circulating ET-1
levels in CHF (Dupuis et al., 1998).
1.3.4.4 The endothelin system in experimental models of heart failure
Elevated circulating levels of plasma ET-1 and bigET-1 concentration have been
reported in some experimental models of heart failure and like in the human,
correlate positively with disease severity during the progression from MI to CHF.
Previous studies have demonstrated that ET-1 mRNA levels are significantly
elevated in the LV CHF rats (Yorikane et al., 1993; Sakai et al., 1996b), peaking 1
week after MI and declining thereafter (0ie et al., 1997; Tonnessen et al., 1997).
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Studies in our laboratory, using a model of less severe heart failure did not find ET-1
mRNA to be changed at 12 weeks post MI (Sherry, 2000), suggesting that
upregulation of ET-1 expression may be time dependent or related to disease
severity.
Upregulation of ET receptor density has also been reported in the LV ofMI induced
CE1F rats. Tonnessen et al. (1997) demonstrated that both ETA and ETB receptor
subtypes tended to be upregulated in the LV 1 week following MI. In addition,
similar studies have also demonstrated elevated levels of both receptors 3 weeks
(Sakai et al., 1996a; Kobayashi et al., 1999), 4 (Picard et al., 1998) and 12 weeks
(Sakai et al. 1996b) after CAL surgery. Meanwhile, in our laboratory, a selective
upregulation of ETB receptor mRNA was expressed in the failing LV of rats during
the 5-12 weeks following CAL surgery (Sherry, 2000), possibly attributed to the
model exhibiting less severe heart failure. As discussed before, the abundance and/or
sensitivity of the ET receptors may play an important role in the actions of ET-1
during the progression of heart failure. However, to date the function of the receptor
subtypes in failing and non-failing myocardium is not clear. It is likely that
upregulation of endothelin pathways is beneficial in providing short-term inotropic
support for the failing myocardium in which P-adrenergic responsiveness is
frequently attenuated. However, as heart failure progresses, ET system activation
becomes a maladaptive response, as identified from the results of ET antagonists,
which indicate the symptomatic benefits ofET blockade.
Long-term treatment of CHF rats with the mixed ETa/ETb receptor antagonist
bosentan (Fraccarollo et al., 1997; Mulder et al., 1997; 0ie et al., 1998) or selective
ETa receptor antagonist BQ123 (Ito et al., 1994; Sakai et al., 1996a, 1996b), has
previously been reported to improve the survival of rats post MI by improving
cardiac haemodynamic function and limiting LV dilatation. Both receptors are
reportedly involved with the hypertrophic response to ET-1 in experimental heart
failure (Mullan et al., 1997). However, if cardiac ET receptors are upregulated to
provide inotropic support to the failing myocardium, the beneficial effects of ET
receptor antagonists must be due to the blockade of the systemic effects of ET-1
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action. To date, the contribution of ET receptor subtypes to cardiac contraction in the
failing myocardium has not clearly been defined. Therefore investigation would
provide a better understanding of the influences affecting cardiac function in health
and disease and identify whether cardiac ET receptors play a central role.
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ET-1 is considered to be involved in the development and progression of heart failure
as levels of the endothelium-derived vasoconstrictor-inotropic peptide are increased
in heart failure and correlate to prognosis (Rubanyi & Polokoff, 1994; Love &
McMurray, 1996). Upregulation of ET-1 system components has been demonstrated
in both heart failure patients (Pieske et al., 1999; Zolk et al., 1999) and experimental
animal models of heart failure (Kobayashi et al., 1999), with selective upregulation
of the ETb receptor having been previously demonstrated in our laboratory (Sherry,
2000). However, a distinct lack of clarity exists regarding the contribution of the
receptor subtype(s) in the regulation of cardiac contractility in health and disease
states.
The main aims of this thesis were to investigate the function of the ET receptor
subtypes in relation to cardiac contractility in the CAL rat in vivo and in vitro and to
identify whether upregulation of the ETb receptor contributes to the contractile
behaviour of failing myocardium in vitro. In addition, selective or dual ETA/ETB
receptor blockade of endogenous ET-1 was investigated in the normal rat
myocardium with the aim to better define the receptor subtype(s) responsible for
mediating the inotropic response to ET-1. Echocardiography was used to compare
the LV contractility of sham-operated rats with CAL rats in vivo. Additionally,
control animals following acute or 1-week chronic administration of the dual
ETa/ETb receptor antagonist bosentan were compared with placebo treated animals
to further investigate the contribution of endogenous ET-1 to cardiac contractile
behaviour. Finally, transmural expression of ET system components, cytoskeletal
proteins and genes associated with hypertrophy were explored in human failing LV





Chapter 2 - Methods
This chapter describes the experimental techniques used in one or more of the
subsequent chapters in this thesis. All experiments using animals were carried out in
accordance with the Animals (Scientific Procedures) Act 1986.
Informed consent was obtained from patients to allow storage and use of human
myocardial tissue as part of medical research. Samples were acquired between
October 1997 and February 1998 from patients undergoing transplant surgery.
2.1 Rat coronary artery ligation model of CHF
2.1.1 Introduction
In cardiovascular research, animal models provide a useful tool for the investigation
of cardiovascular diseases and have aided in the development of therapeutic drugs.
The characteristics required by an ideal model are i) to provide an adequate likeness
to human disease, ii) allow studies in chronic, stable disease, iii) produce symptoms
which are predictable and controllable, iv) to be relatively inexpensive and satisfy
technical and animal welfare considerations and v) allow the measurement of
relevant functional parameters (Doggrell & Brown, 1998). A variety of techniques
are currently available for the induction of experimental heart failure in a range of
species (reviewed by Doggrell & Brown, 1998; Hasenfuss, 1998a). However, it is
acknowledged that the complex pattern of human heart failure cannot be entirely
mimicked by any one animal model.
Myocardial infarction (MI) following coronary artery ligation (CAL) in rats is the
most common rat model of heart failure (HF). Selye et al., (1960) were the first to
describe the CAL technique in the rat and subsequently, Pfeffer et al. characterised
the model in 1979 (Pfeffer et al., 1979). Left ventricular (LV) MI occurs as a
consequence of complete occlusion of the left coronary artery and as a result, LV
function is impaired. LV dilatation, increased filling pressures and reduced systolic
function are associated with the progression of LV dysfunction (Litwin et al., 1994)
as well as changes in neurohormonal activation, similar to those seen in patients with
CHF (Hodsman et al., 1988).
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Several limitations exist with all HF models regarding the differences in myocardial
function compared to the human heart. Indeed, since CAL surgery is carried out on
essentially healthy coronary arteries and myocardium, it is accepted that the rat
model is not entirely analogous to the pathogenesis of coronary artery disease or
infarction in humans (Pfeffer et al., 1979). A high initial mortality rate and variable
size of infarct present further problems for the CAL model. However, despite the
disadvantages, the rat CAL model of CHF has proven to be useful in evaluating
particular aspects of failure, has clinical relevance and has predicted results of
pathophysiological and pharmacological studies in man. It is for this and the
aforementioned reasons that the chronic infarcted rat heart was used as a model in
this thesis.
2.1.2 Induction ofmyocardial infarction
MI was produced in male Wistar rats (200-250g, Charles River, France) by occlusion
of the left anterior descending coronary artery according to the method described by
Selye et al. (1960) and modified by Pfeffer et al. (1979). The animals were
anaesthetised with sodium pentobarbital (60 mg-kg" , i.p., Sagatal, Rhone Merieux
Ltd., Essex, U.K.). Prior to surgery, the left side of the chest was shaved and
sterilised using 70% alcohol. The animals were placed on a thermostatically
controlled heat mat (37°C) and intubated with a plastic cannula (1.65mm diameter,
5FG, Portex Ltd., Kent, U.K) using a guide wire. Mechanical ventilation with
oxygen enriched room air was provided by use of a small rodent ventilator (Harvard
Apparatus Ltd., Kent, U.K.) at a rate of 60 cycles per minute and a tidal volume of
lml/lOOg body weight.
An incision (~2 cm) was made into the left side of the chest, parallel to the direction
of the ribs. The underlying muscles were carefully separated and held in position
with metal clips to expose the ribs. A left thoracotomy was performed between ribs 4
and 5, with care being taken not to damage the lungs while making the incision. The
left lung was then gently pushed down and away from the heart using a triangular
piece of synthetic surgical sponge (Fine Science Tools, InterFocus Ltd., Suffolk,
England). A hole was made in the pericardium using a blunt pair of scissors and the
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heart was gently and rapidly manipulated out of the thoracic cavity by applying
pressure to the right hemithorax. A 5-0 silk suture (10mm round bodied. Ethicon
Ltd., Edinburgh, U.K.) was passed around the proximal part of the left anterior
descending coronary artery, below the left atrial appendage. The heart was then
swiftly returned into the thorax. The animal was allowed 10 minutes to recover from
the exteriorisation before the suture was tied. Sham-operated animals were subjected
to the same protocol, except that the snare was not tied. Animals were randomly
assigned to groups. The sponge used to collapse the lung was removed and a plastic
cannula (0.75mm diameter, 3FG, Portex Ltd.) connected to a 2.5ml syringe was
placed in the thorax before closure with a 3-0 silk suture (16mm round bodied,
Ethicon Ltd.). Before tying the last suture, the chest was gently squeezed to expel air
from the thoracic cavity. The overlying muscles were returned to their original
position. Any remaining air within the thorax was removed by way of the cannula
and syringe, allowing the rat to resume spontaneous respiration. The cannula was
removed and the skin was sutured using a 3-0 mersilene suture (25mm round bodied
suture, Ethicon Ltd.). The animal was maintained on the ventilator for a further 15
minutes and then moved to a recovery box, placed on a heated blanket (37°C), where
it was positioned near a 100% oxygen source. When the rat showed signs of
recovery, the tracheal cannula was removed. Once the animals had fully recovered
from the anaesthesia they were given buprenorphine hydrochloride (0.05mg-kg"',
Vetergesic, Redcut & Coleman, U.K.) subcutaneously and returned to their cages.
Analgesia was also administered the following morning. All rats were housed in
climate-controlled conditions with a 12-hr light-dark cycle and free access to normal
rat chow and drinking water. CAL surgery was performed by Dr. Gillian Gray.
2.1.3 In vivo characterisation
CAL was used to generate animals for two heart failure studies. Group 1 animals
were used 15 weeks post surgery to investigate the activation of the ET system, while
group 2 were used 12 weeks after surgery to explore the left ventricular pressure-
dimension relationship of the failing rat heart.
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2.1.3.1 Fifteen week ET system activation study
2.1.3.1.1 Haemodynamic measurements
Fifteen weeks after surgery, CAL (>2=10) or sham-operated (n=\ 0) rats were
weighed, anaesthetised with sodium pentobarbital (60 mg-kg"1, i.p. Sagatal) and
placed on a thermostatically controlled heating mat (37°C) to maintain body
temperature. The neck area was shaved and an incision was made from the mandible
to the sternal notch. The right carotid artery was located, isolated and cannulated
with a fluid filled (heparin, Multiparin, CP Pharmaceuticals, Wrexham, U.K. diluted
to 100 U-mf1 in saline) plastic catheter (0.75mm diameter, 3FG, Portex, Ttd.)
attached to a pressure transducer. After an initial stabilisation period (5 minutes),
arterial blood pressure was measured. The catheter was then carefully inserted via the
carotid artery into the left ventricle (LV) to continually record LV pressure. Data was
recorded on an Apple Mac computer via a MacLab (version 3.4/e) data analysis
system (AD Instruments, blastings, U.K.). A representative trace of arterial blood
pressure and TV pressure measured from a CAL rat is shown in Figure 2.1. From
Figure 2.1 it can be seen that as the catheter was advanced into the LV, an increase
in the pressure pulse was obtained. Mean arterial pressure (MAP), LV systolic
(LVSP) and end-diastolic pressure (LVEDP) values were measured by calculating
the average pressure readings from no less than 10 pressure spikes along the
respective traces. Measurements of heart rate (FIR), the maximal rate of rise and
maximal rate of decline of LV pressure (dP/dtmax / d/Vd/min) were also obtained.
Ligated rats with LVEDPs > 1OmmHg were considered to have LV dysfunction.
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Figure 2.1. A sample trace of arterial blood pressure measured from within the
carotid artery (CA) and left ventricular (LV) pressure measuredfrom a CAL rat.
2.1.3.1.2 Tissue harvesting
Following exsanguination, the heart was removed and briefly placed in Tyrode's
solution (room T°C: see section 2.4 for composition) where it was permitted to beat
four or five times to expel the blood. It was then transferred into an ice-cold
cardioplegic solution (Tyrode's solution containing 30mM 2,3-butanedione-
monoxime, BDM), causing the heart to cease contractile activity and kept on ice
while the other organs were removed, rinsed in Tyrode's, blotted and weighed. Using
a stereomicroscope (Leica MZ75, Leica, Solms, Germany), the atria and large vessels
were removed and the heart was weighed. The right ventricle (RV) was then opened
along the septum to expose the papillary muscles, which were carefully dissected out
for functional studies (see Section 2.2). Throughout the dissection period, the heart
remained immersed in ice-cold Tyrode's-BDM solution. The use of BDM during
dissection has been shown to protect the myocardium from cutting injury and its
effects are fully reversible after washout (Mulieri et al. 1989). BDM is a quick-
acting, reversible inhibitor of cardiac contractility. It exerts a direct inhibitory effect
on cross-bridge interactions and decreases the sensitivity of the contractile proteins to
2_j_Ca thereby reducing contractures (Mulieri et al. 1989).
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Tissue samples (approximately lOOmg) of the RV free wall, LV free wall and the
interventricular septum were taken, snap frozen in liquid nitrogen and stored at -
70°C for subsequent gene expression studies (see section 2.3). In the case of CAL
hearts, the infarcted area (scar tissue) was excised from the non-infarcted LV,
carefully avoiding contamination of viable myocardial tissue with necrotic tissue.
2.1.3.1.3 Assessment of infarct size
Due to the dissection of the heart for the removal of papillary muscles, an alternative
method for analysing infarct size was employed. The area of infarcted ventricle was
placed under a CCD video camera module (Kontron Elektron Images, Carl Zeiss
vision GmbH) and the images were viewed on a computer. The area of the infarct
was measured using Image Analysis software (Carl Zeiss KS 300 version 3.0).
2.1.3.2 Twelve week Pressure-Dimension study
2.1.3.2.1 Haemodynamic and echocardiographic measurements
Twelve weeks following CAL (n= 12) or sham-operation (n=6), rats were weighed
and anaesthetised in a chamber with 4% halothane (Halothane-vet, Merial Animal
Health Ltd., U.K.) vaporised in a mixture of O2 (2 Frnin" ) and N2O (0.4 1-min"1) to
achieve unconsciousness. The animal was then transferred to a thermostatically
controlled heat mat (Harvard Apparatus Ltd.) and body temperature was monitored
by a rectal probe and maintained at 37 ± 0.5°C. Anaesthesia was delivered via a nasal
cone (reduced to 3% halothane in gas mixture) and the neck, chest and left groin
areas were shaved. Once fully unconscious, the left femoral vein was located,
isolated and cannulated with a fluid filled (heparin, Multiparin, CP Pharmaceuticals,
diluted to 100 U-mf1 in saline) plastic cannula (0.75mm diameter, 3FG, Portex Ltd.)
for the infusion of drugs. Subsequently, the right carotid artery was isolated and
cannulated with a high-fidelity micromanometer-tipped catheter (SPR-407, size 2F,
Millar Instruments Inc., Houston, TX, U.S.A.) connected to a control unit (TCB-500,
Millar Instruments Inc.). Halothane anaesthesia was reduced to a level that
maintained unconsciousness (usually 1.5%) and after a stabilisation period.
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measurements of arterial pressure and HR were recorded. The Millar catheter was
then carefully advanced through the aorta into the LV to record LV pressure. All
measurements (as before, see section 2.1.3.1.1) were recorded on a laptop computer
using a Powerlab system. The Millar control unit was connected to a data acquisition
system which consisted of a Powerlab (Powerlab /8sp, AD Instruments), which in
turn was connected to a DELL laptop computer (model PP01X, Inspiron 8000) with
CHART v4.1 software (AD Instruments).
An incision was made down the midline of the thorax and the skin on the left side
was carefully pulled back by blunt dissection to expose the underlying pectoral
muscles. Initial investigation showed that better images were obtained this way as
scar tissue obscured the image in some animals. The rat was then placed in the left
lateral position and the chest smothered with acoustic gel (Clear Image medical
ultrasound couplant, Diagnostic Sonar Ltd., Livingston, U.K).
Transthoracic echocardiography was performed using DIASUS Ultrasound
Equipment (Dynamic Imaging, Livingston, U.K.) to assess the position of the
catheter and to set the depth and focal length of the scan. Care was taken to avoid
excessive pressure on the thorax. Using a 128-element probe (10-22MHz) with
DIASUS P5.26 software (Dynamic Imaging), the depth was set at 30mm with 1
focus line. On this setting the image was acquired over 0.775 seconds. To obtain an
echo image and a synchronised LV pressure recording, a trigger was attached from
the ultrasound unit to the Powerlab and the CHART software set to capture catheter
data only during this triggered 0.775s fixed period. A representative scan of two-
dimensional long and short-axis b-mode images of LV dimensions are shown in
Figure 2.2. From Figure 2.2 it can be seen that the anterior and posterior LV wall
boundaries are well defined. The Millar catheter can also be seen in the aorta, with
the tip in the LV {Figure 2.2a). The corresponding catheter data (4-5 cardiac cycles;
see Figure 2.3) was inspected to avoid recording ectopic beats. Several image and
pressure sets were captured during the different afterload states.
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Two-dimensional long-axis b-mode images of the LV were obtained and captured at
baseline conditions before administration of any experimental drugs. The echo
images were played back to ensure good quality before saving. Subsequently, short
axis b-mode images were obtained at the level of the papillary muscles.
Figure 2.2. Two-dimensional images of (a) long-axis and (b) short-axis b-mode
transthoracic echocardiographic scans. LV, left ventricle; LA, left atrium; A, aorta.
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The venous cannula was connected to an infusion pump (Treonic 1P4H Syringe
pump, Vickers Medical, Stirling, U.K.) via a three-way tap. Sodium nitroprusside
(SNP, Sigma, 25 pg-mf1 dissolved in saline), a nitric oxide donor drug, was infused
to induce a desired systolic pressure drop of 20-30mmHg less than baseline (usually
between 1-5 pg-kg^-min"1). Images were captured at 2-3 minute intervals to obtain
a range of pressure changes (usually lOmmHg increments). Short-axis b-mode
images were also recorded. Heparinised saline (100 U-mf1) was then used to flush
the catheter and a recovery period of 20 minutes was allowed, starting at the end of
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Figure 2.3. A pressure-transducer reading from within the left ventricle, acquired
over 0.775 seconds to correspond with an echocardiographic scan.
(iii) Phenylephrine infusions
Following the recovery period, the ai-adrenergic receptor agonist phenylephrine
(PE, Sigma, 0.2 mg-mf1 dissolved in saline) was infused to induce a desired increase
in systolic pressure of 20-30 mmHg greater than baseline (usually between 13 - 40
pg-kg^-min"1). Images of both long and short axis were taken in b-mode.
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Organs were removed and rinsed in Tyrode's-BDM solution (see section 2.4 for
composition), prior to being blotted and weighed. The CAL hearts were sectioned
apex-base through the infarcted region. Half was placed in 10% formalin and the
remaining tissue divided into LV, RV and septum. Myocardial samples and the
kidneys were snap frozen in liquid nitrogen and stored at -70°C for future molecular
analysis.
2.1.3.2.3 Histological analysis
As a result of chronic left coronary artery occlusion, a collagen rich scar developed
in the infarcted zone of the LV. Using van Gieson's stain for collagen (see section
2.4), infarct size in relation to the LV free wall was measured. Hearts were cut along
the apex-base axis and placed in 10% formalin. After 24 hrs samples were taken out
and immersed in 70% alcohol. Subsequently, 24 hrs later they were transferred into
50% alcohol before being processed and embedded in paraffin wax. Briefly, the
samples were dehydrated by immersion in ascending alcohol concentrations and then
into xylene. The xylene was then replaced with paraffin wax under vacuum
conditions. The resulting blocks were sliced in 3pm sections and mounted on TESPA
(3-Aminopropyltriethoxy-saline, Sigma) coated microscope slides (see section 2.4).
After drying in an incubator (37°C) overnight, sections were de-waxed in xylene (10
minutes), sequentially taken through descending alcohol concentrations (100, 90 and
70%, 2 minutes each) and washed in water. Subsequently, the sections were dipped
in Celestine Blue nuclear stain (Sigma) for 4 minutes. After rinsing with water, slides
were treated with van Gieson's collagen stain for 3-5 minutes and rinsed briefly with
water. The sections were then dehydrated by going through an ascending alcohol
series (70, 90 and 100%, 3 minutes each) to xylene (10 minutes). Finally the slides
were taken individually, dried and mounted with DPX medium (BDH Laboratory
Supplies, Dorset, U.K) and coverslips.
Using a method previously described by Mulder et at. (1997), the infarct size was
measured. Briefly, the stained sections were placed under a CCD video camera
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module (Carl Zeiss Vision) and the images were viewed on a computer. The
epicardial and endocardial circumferences of the infarcted tissue and of the LV free
wall were determined with Image analysis software (Carl Zeiss Vision, KS 300,
version 3.0). Infarct size was calculated as (endocardial + epicardial circumference of
the infarcted LV tissue) / (endocardial + epicardial circumference of the free LV
wall) and expressed as a percentage.
2.2 Pharmacological studies of isolated rat right ventricular papillary
muscles
2.2.1 Introduction
In vitro studies, such as isolated cardiac muscle preparations have proven to be a
powerful and reliable tool in the evaluation of functional changes in contractile
parameters both in human and in animal, normal and failing myocardium. For
experimental purposes, papillary muscle preparations are simple to dissect and
mount, require little specialised apparatus and will contract in a reliable manner in
response to a stimulus. Although isometric contraction is not physiological, it is
roughly analogous to isovolumetric contraction in vivo and provides a state for
normalisation. Papillary muscles are convenient for the purpose as their fibres run a
fairly straight course. Consequently, the technique was employed in this thesis to
investigate the effects of drugs and other interventions on cardiac muscle. However,
it is acknowledged that isolated preparations of heart muscle have some
disadvantages due to i) cessation of its circulation, ii) one end of the preparation
being crushed, iii) a reduction in the range of hormonal and autonomic transmitters
which reach it and iv) being immersed in a solution that is only an approximation of
normal extracellular fluid (for review, see Allen, 1983). On balance, it is a suitable
preparation for measurements of contractile behaviour and has a small enough cross
section for adequate oxygenation.
2.2.2 Preparation of rat right ventricular papillarymuscles
The heart (from section 2.1.3.1) was pinned out on a silicon-coated (Sylgard 184
silicone elastomer, Dow Corning Corporation) dissecting dish containing ice-cold
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cardioplegic Tyrode's-BDM solution. The right ventricle (RV) was opened under a
dissecting microscope and suitable papillary muscles were isolated by first dividing
the chordae tendineae at the tip of the muscle, then freeing the muscle base along
with a small amount of surrounding myocardium from the ventricular wall. As far as
possible, only long, thin, uniformally cylindrical muscles were used. The muscular
end of the papillary was fixed to a muscle holder with a spring clip and the tendinous
end was tied with a 4-0 surgical silk (Davis and Geek, Hampshire, U.K.) and
connected to an isometric force transducer (Fort 10, World Precision Instruments
Inc., U.S.A.) via a stationary hook. All dissection and manipulation was carried out
in ice-cold Tyrode's-BDM. The preparation was vertically mounted in a 7ml organ
chamber (World Precision Instruments Inc., U.S.A.), superfused with carbogen-
bubbled (95% O2: 5% CO2) cardioplegic solution (37°C) and allowed to stabilise for
20 minutes (see Figure 2.4). The passive length-tension relationship was then
investigated by progressively stretching the muscle via a micromanipulator, 0.1mm
increments / minute. Once achieving Zmax (passive), the tension was released and the
cardioplegic solution was replaced with Tyrode's solution (same composition but
without BDM, 2 rinses). The preparation was then stimulated by 2ms square wave
pulses at 3Hz, at a voltage 20% above threshold and left to equilibrate for 30
minutes. Following stabilisation, the active-length tension relationship was evaluated
by progressively stretching the muscle until an additional stretch did not produce an
increase in the developed force; this length was taken as Lmax (active). The
pharmacological protocols applied subsequent to stabilisation are described in the
relevant sections ofChapter 3 and Chapter 4.
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Figure 2.4. Apparatus for stimulating and recording tension from vertically mounted,
isolated papillary muscles, tt, tension transducer; mm, micromanipulator; mc,
muscle chamber; gi, gas inlet; so, solution outlet. Illustration modified from (Allen,
1982).
2.2.3 Calculations & data normalisation
The following contractile parameters were analysed: developed tension (active
"y #
tension produced by the muscle when stimulated, mN/mm ), time to peak tension
(TPT, time from the beginning of the contraction to peak tension in ms), and time to
50% relaxation (RT50, time from peak tension to 50% of relaxation in ms) (see
Figure 2.5).
Cross-sectional area (CSA) was determined as a ratio of blotted muscle weight (W)
to length (ML) by assuming a density of 1.06 gem"3 (CSA=W/ML x 1.06, Hill,
1931).
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Figure 2.5. Illustration of a single contractile twitch indicating the contractile
parameters measured. Developed tension, peak active tension; TPT, time to peak
tension; RT5q, time to 50% relaxation; RT, resting tension.
2.2.4 Investigation of collagen content in papillary muscles from CAL
and sham-operated rats
Following the functional investigation, papillary muscles were fixed in formalin and
processed as described above (see Section 2.1.3.2.3). Histological sections (3pm
thick) were prepared and stained by van Gieson's method for collagen as previously
described. Slides were viewed under a microscope (Axioskop, Zeiss, Leica,
Germany) attached to a digital camera (ProgRes 3012, Kontron Elektronik). An
independent observer (Mr. Mark Patrizio), unaware of surgical outcome, assessed the
sections by assigning a score (1-4, where 1 is negligible and 4 is abundant) to the
collagen content of each papillary.
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2.3 Semi-Quantitative Reverse Transcriptase Polymerase Chain
Reaction
2.3.1 Introduction
Reverse transcription polymerase chain reaction (RT-PCR) is the most sensitive
method for the detection of low-abundance mRNA, often obtained from limited
tissue samples. It allows reproducible quantification of gene expression and has the
ability to identify altered patterns of gene expression in different sample populations.
Several RT-PCR strategies are available for the quantification of mRNA such as,
quantitative and semi-quantitative methods. Quantitative procedures include non¬
competitive, or more commonly, competitive RT-PCR techniques, which depend on
spiking the RNA samples before the RT step with known amounts of RT-PCR-
amplifiable competitors. This section describes the development of a semi¬
quantitative RT-PCR approach involving an external control, the ubiquitously
expressed housekeeping gene glyceraldehyde-3-phosphate (GAPDH) and a serial
dilution method for verification. The approach was used to quantify (i) the ET
system in failing and nonfailing rat myocardium and (ii) transmural expression of
cytoskeletal proteins, the ET system and a hypertrophic marker in human failing
myocardium from explanted hearts.
All RT-PCR methods assume equal reaction efficiencies, therefore, if reactions are
kept within the exponential range a linear relationship will exist between the amount
of input template and the amount of amplification product.
2.3.2 General laboratory practice
All work was performed using RNase-free techniques to protect samples from
RNases present in the environment. Gloves were worn at all times and work surfaces
and equipment were regularly cleaned with RnaseZap (Ambion). All solutions were
made using a 0.1% solution of the RNase inhibitor diethyl pyrocarbonate (DEPC) in
distilled water followed by autoclaving (see section 2.4). At all times during
processing, samples were kept on ice to slow any degradation.
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(i) Rat tissue
Total mRNA was isolated from rat myocardium using a modified version of the acid
guanidinium thiocyanate-phenol-chloroform method previously described by
Chomczynski & Sacchi (1987). Each sample (~50mg) was removed from the freezer
and immersed in 1ml of denaturing solution (solution D, see Solutions section 2.4)
where it was minced on ice and homogenised at room temperature. An equal volume
of water-saturated phenol (Fisher Scientific, Loughborough, U.K.) was then added,
followed by 50p.l of 2M sodium acetate (pH 4). The homogenate was mixed
thoroughly by inversion, followed by the addition of lOOp.1 of chloroform-isoamyl
alcohol (25:1). This final suspension was shaken vigorously for 15 seconds and left
on ice for 15 minutes. Subsequently, the samples were centrifuged at 10,000g
(Biofuge A centrifuge rotor) for 15 minutes at 4°C and the upper aqueous phase,
containing the RNA, was pipetted off into a fresh tube. Care was taken not to disturb
the interphase and phenol phase where DNA and protein subsist. An equal volume of
isopropanol (500-600|al) was added to the lysate and the contents were mixed by
inversion before being placed at -20°C for at least 1 hour. Following RNA
precipitation, the samples were centrifuged (10.OOOg) at 4°C for 10 minutes, the
supernatant was removed and the resulting pellet washed twice in 1ml of 75%
ethanol. The pellets were then dried at room temperature, dissolved in 30pl of DEPC
FFO and stored at -20°C.
All hazardous waste reagents (phenol, guanidinium thiocyanate solutions etc.) were
disposed of according to University policy ofwaste management.
(ii) Human tissue
Sample tissue was acquired from explanted hearts of patients undergoing transplant
surgery at the Scottish Cardiac Transplant unit, Glasgow. LV epicardial and
endocardial sections were dissected out, snap frozen in liquid nitrogen and stored at -
70°C.
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Total mRNA was isolated from frozen human myocardial samples with the use of
QIAGEN RNeasy® midipreps (QIAGEN Ltd, Crawley, U.K), as outlined by the
manufacturer. Briefly, 60-80mg of tissue was disrupted and homogenized in 2ml of
QIAGEN lysis buffer RLT, a reagent containing P-mercaptoethanol and a highly
denaturing guanidine isothiocyanate salt. A digestion step was incorporated by
adding 4mls of double-distilled water along with 65pl proteinase K solution (>600
mAU/ml, QIAGEN) and incubated at 55°C for 20 min. The homogenate was then
centrifuged for 5 min at 4000g (Model J-6B centrifuge, Beckman Coulter U.K. Ltd.
High Wycombe, U.K.) between 20-25°C and the supernatant transferred into a fresh
tube. 0.5 volumes of ethanol was added and mixed well by pipetting. Subsequently
the lysate was passed through a QIAGEN RNeasy spin column (silica-gel-based
membrane) in 3ml aliquots, aided by centrifugation (same conditions as before). All
flow-through was discarded and 4ml of buffer RW1 (a reagent containing guanidine
isothiocyanate) was added to the column. Following a centrifugation step (see
conditions above), 2.5ml of RPE (ethanol) buffer was applied to wash the bound
RNA and spun for 2 min at 4000g (20-25°C). Subsequently, another 2.5ml of RPE
buffer was added to the spin column and centrifuged for 5 min (conditions as above)
to dry the RNeasy membrane. RNA was recaptured from the spin-column membrane
into a fresh tube by incubating with 100pi RNase-free water for one minute before
spinning at 4000g for 3 min, 20-25°C. To increased the yield, the elute was passed
through the membrane a second time and respun. Samples were then stored at -20°C
until use.
2.3.4 RNA integrity and quantification
2.3.4.1 Agarose gel electrophoresis
Agarose gel electrophoresis was used to check the integrity of the RNA yield. An
agarose gel (0.8%; LE Agarose, Seakem, BMA, Rockland, U.S.A.) was made with
tris-boric acid (TBE) buffer (see Solutions section 2.4) and (0.04%) ethidium
bromide (500pg/pl, Sigma, Dorset U.K.). The gel was placed in an electrophoresis
tank (Sub-cell, Model 96, Bio-Rad Laboratories Ltd, Hemel Hempstead, U.K.) and
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immersed in TBE buffer. Wells were loaded with 3 pi of sample and 4pi of
bromophenol blue loading solution (Promega, Southampton, U.K.). Subsequently,
the gel was run (100V) until the loading dye had migrated two thirds of the way
down the gel. The RNA was visualised in an ultraviolet transilluminator (Ultra-violet
Products Ltd., Cambridge, U.K.) attached to a video display unit (SONY
Corporation, Japan). Good quality RNA samples showed clearly defined bands
corresponding to 28S, 18S and 5S ribosomal RNA. Examples of good quality RNA




Figure 2.6. An image of an electrophoresed agarose gel representative of good
quality RNA demonstrating clearly defined bands at S28, SI8 and S5.
2.3.4.2 RNA quantification
The concentration and purity of total RNA was determined by measuring the
absorbance at 260nM (A260) and the ratio of A260/A280 respectively in a
spectrophotometer (Bio-Rad SmartSpec 3000, Bio-Rad, U.K.). The absorbance was
zeroed using DEPC H20. RNA samples were diluted 100 fold with DEPC H20 and
placed in a quartz cuvette (200pl, UV transparent cuvette, Bio-Rad, U.K.). The
spectrophotometer simultaneously measured at wavelengths of 260 and 280nM, and
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calculated the concentration and the ratio of A260/A280. Values of total RNA yield
(fig-Ill"1) were obtained by adjusting for the dilution factor. A ratio of A260/A280 in the
range of 1.8 to 2.1 was taken as an indication of pure RNA. For spectrophotometers
that do not calculate the value, an absorbance of 1 unit at 260nM corresponds to
40pg of RNA per ml (A260 = 1 = 40|ig-ml"').
Where RNA concentration was below O^pg-pl"1, an ethanol precipitation step was
carried out. The RNA was precipitated by adding 2.5 volumes of absolute ethanol
(stored in freezer) and 0.1 volume of 3M sodium acetate (pH5.2). Samples were
placed at -20°C for a minimum of 20 minutes before centrifugation at 12000g for 15
minutes at 4°C (Biofuge A centrifuge). The supernatant was carefully removed and
200jal of 70% ethanol was added. Subsequently, samples were centrifuged at 12000g
for 10 minutes at 4°C. The supernatant was then removed and the RNA pellets left to
air-dry. Pellets were then resuspended in 20pl or 60pl DEPC H2O (rat and human
respectively) and the concentration reanalysed using the spectrophotometer (BIO-
RAD SmartSpec 3000, Bio-Rad, U.K).
2.3.5 RT-PCR
2.3.5.1 Synthesis of first strand cDNA
Total RNA (2pg) was primed with lOOpM oligo-dTi5 and reverse-transcribed in the
presence of 200U Moloney-murine leukemia virus reverse transcriptase (M-MLV
reverse transcriptase; Promega), 0.5mM dNTPs and first strand buffer (final
concentration; 50mM Tris-HCL, pH 8.3 at 37°C; 75mM KC1; 3mM MgC^) in 20jul.
The incubation was performed in a PCR thermocycler (Primus 25/96 Thermocycler,
MWG-Biotech, Milton Keynes, U.K for rat and PTC-200 Peltier thermal cycler, MJ
Research Inc., Waterown, U.S.A. for human) at 37°C for 45 minutes, then at 95°C
for 5 minutes to denature the reverse transcriptase. Oligo-dTi5 was purchased from
MWG-Biotech, all other reagents were purchased from Promega.
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2.3.5.2 Primer design
Primers were designed to span introns to avoid false positive results arising from
amplification of contaminating genomic DNA.
(i) Rat tissue
Gene-specific primers were designed for ppET-1, ETa, ETb and ANP using
Genejockey II software (Biosoft, Cambridge, U.K.) and were synthesised by MWG-
Biotech according to previously published oligonucleotide sequences. The primer
sequences and their sizes are summarised in Table 2.1. For semi-quantitative
analysis, the constitutively expressed enzyme GAPDH served as an external control
in the calculation of the densitometric results.
(ii) Human tissue
Published cDNA sequences for human GAPDH, BNP, ppET-1, ETa, ETb, gelsolin
and titin were obtained and primers were designed using Genejockey II software.
Isoform specific primers (N2A and N2B) were designed within the unique conserve
sequences for each isoform (Freiburg et al., 2000). All primer sequences and their
respective product sizes are shown in Table 2.1.
2.3.5.3 Primer optimisation
Optimal PCR conditions were determined methodically for each primer pair.
Annealing temperature was estimated from the GC content and tested over a range
(2°C increments), while the effect of MgCf concentration on reaction efficiency was
investigated between 1.75 - 2.50mM. The desired annealing temperature and MgCl2
concentration were those which produced the greatest amount of desired product
with the least amount of extranous product (see Figure 2. 7). Subsequently, PCR was
performed to the point of plateau. The reaction was paused every 2 cycles (after 16)
and a (5%) sample removed. Products were visualised on a 1% agarose gel and a
cycle number was chosen within the exponential range of amplification to provide a
linear relationship between the amount of input template and the amount of
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amplification products for each primer pair (see Figure 2.8). For rat and human
primer profiles, see Table 2.1).
L L
1.75mM 2.00mM 2,25mM 2.50mM blank ""
Figure 2.7. A representative scan ofan electrophoresed agarose gel, demonstrating
optimisation ofhuman GAPDHprimers. Optimum yield ofdesiredproduct observed
at an annealing temperature of57 X! and a [Mg2+] of1.75mM. L, 50 base pair DNA
ladder. Temperature range 56.9, 59.0, 61.6, 64.7, 67.2, 69.2°C increments for each
concentration ofMg2+.
(a)
18 20 22 24 26 28 30 32 34
(b)
18 20 22 24 26 28 30 32 34
Cycle number
Figure 2.8. Agarose gel (a) and associated graph (b) ofPCR cycle number: product
relationship. L, 50 base pair DNA ladder.
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2.3.5.4 PCR
(i) Rat tissue
Ten microlitres of the cDNA from the RT reaction was used for PCR amplification.
Each PCR reaction (50pl) contained 2.5U Taq DNA polymerase (Promega), 200pM
dNTPs (Promega), lOOpM specific primers for gene of interest (MWG-Biotech), lOx
PCR reaction buffer (final concentration, lOmM Tris-HCl, pH 9.0, at 25°C, 50mM
KC1 and 0.1% Triton, Promega) and MgCl2 (Promega) at a concentration specific to
each primer (see Table 2.1). The samples were transferred directly from ice into the
thermocycler (MWG-Biotech) and the DNA was denatured for 4 minutes at 94°C.
Subsequently, n cycles (see Table 2.1) of amplification were performed, denaturation
(1 min at 94°C), annealing (1 min at a temperature specific to each primer, see Table
2.1) and elongation (2 mins at 72°C). After the last cycle the 72°C elongation step
was extended to 10 mins. Negative control tubes (no cDNA) with DEPC H20 were
included to ensure the reactions were not contaminated.
(ii) Human tissue
Five microlitres for human cDNA was used in a 25jli1 total reaction volume PCR and
amplified in a PTC-200 Peltier thermal cycler (MJ Research Inc.). The PCR mixture
was made up as before and samples were amplified under the conditions in Table
2.1.
2.3.5.5 Verification
Verification of the alterations in mRNA levels in LV epi- and endocardial samples
from end-stage heart failure patients was carried out. A two-fold serial dilution of
each cDNA sample was made and used as template for PCRs that were carried out on
each primer pair.
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2.3.6 Determination of the absolute alterations ofmRNA
2.3.6.1 Agarose gel electrophoresis and densitometry
The PCR products were separated on an agarose gel (1%; Seakem) and stained with
ethidium bromide (0.04%). A 100 base-pair stepladder (Promega) was used for
products to be identified by their size. The expression of the PCR product was
quantified by densitometry (FLA2000, Fujifilm, Fuji Photo Film Co., Ltd, Tokyo,
Japan; AIDA 2D Densitometry software 2.11, raytest Isotopenmessgeraete GmbH,
Straubenhardt, Germany). Changes in transcription of the genes investigated were
determined by comparison of gene-of-interest/GAPDH ratios in rat LV, RV and
septum and between human epicardial and endocardial samples and dilution curves
were plotted to confirm the changes of expression.
2.3.6.2 Sequencing
The specificity of the amplified sequences was confirmed by DNA sequencing. The
PCR product was cut from the agarose gel and purified using a GFX purification kit
(Amersham Pharmacia Biotech UK Limited, Buckinghamshire, U.K.). Briefly, the
DNA of interest was specifically bound to a glass fibre matrix using a chaotropic
agent that denatures protein and dissolves agarose gel. The column was centrifuged
briefly following incubation at 60°C to allow the agarose to dissolve completely.
The fibre matrix containing the DNA was then rinsed with wash buffer (Tris-EDTA
buffer with absolute ethanol to a final concentration of 80%) and spun briefly at full
speed (30 seconds; 16,000g) before the purified DNA was reclaimed from the fibre
matrix with 30pl double distilled autoclaved H2O. The DNA was precipitated as
previously described for RNA (see section 2.3.4.2) and recovered (dry) samples were
sent to MWG-Biotech for sequencing.
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Table 2. l.PCR primer sequences andprofiles for rat and human genes
Sequence GeneBank Product Annealing Number [MgCI2]
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2.4 Solutions, drugs and chemicals
Salts were purchased from Sigma-Aldrich Company Ltd., Dorset, U.K., unless
otherwise stated.
Saline
0.9w/v sodium chloride solution.
Heparin
Heparin Sulphate 5000 Uml"1, Multiparin, CP Pharmaceuticals, Wrexham, U.K.
diluted to 100 U-mf1 in saline.
Tyrode's
Tyrode's solution (pH 7.4) contained (mM): 118.0 NaCl, 5.0 KC1, 1.0 MgS04.7H20,
20.0 NaHC03, 1.0 NaH2P04, 2.0 CaCl2 and 10.0 glucose.
A xlO stock was prepared without CaCl2 or glucose and stored in the fridge. On
experimental day, the stock was diluted and CaCl2 and glucose were added fresh.
Tyrode's/BDM
The cardioplegic solution contained Tyrode's and 30.0mM, 2,3-butanedione-
monoxime (BDM) this was also freshly prepared each day.
Tespa Coating
Slides were immersed for 10 seconds in each of the following:
1. 10% Hydrochloric Acid in 70% ethanol
2. Sterile water
3. 100 Acetone
The slides were air dried and then placed for 10 seconds in each of the following:
4. 2% Aminopropylethoxysilane (TESPA) in Acetone
5. 100% Acetone
6. 100% Acetone
Slides were air dried again and were stored for one month in an air tight container.
Van Gieson's stain for collagen
Saturated aqueous picric acid lOOmls
1% acid fuchsin lOmls
DEPC H20
5 drops of diethyl pyrocarbonate (DEPC) were added to 500mls of distilled H20. The
bottle was shaken vigorously for 30 seconds and left to stand for 20 minutes. The
solution was then shaken again and left for 1 hour before being autoclaved.
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Solution D
Solution D (pH 7.0) contained 4M guanidinium thiocyanate, 25mM sodium citrate
(pH 7) and 0.5% sarcosyl. 360pl P-mercaptoethanol was added/ 50ml of solution.
This solution was kept in a dark bottle at room temperature for a month.
TBE
TBE contained 0.45M Tris base, 0.445M Boric acid and 0.5M EDTA (pH 8.0) made
up to 1L with sterile water.
Ro 47-0203/029
Bosentan (Ro 47-0203/029)
Dr. Martine Clozel (Actelion Pharmaceuticals Ltd., Basel, Switzerland), generously
supplied Bosentan (Ro 47-0203/029).
Chronic bosentan administration
A 5% gum arabic solution was prepared and stirred for 1 hour before being filtered.
Bosentan was then added (100mg/4ml) and a polytron was used (30 sec) to make a
microsuspension. This was administered to the rat via gastric gavage (lOOmg-kg"1).
Acute bosentan administration
Bosentan (30 mg-kg"1) was dissolved in 5% DMSO and infused intravenously.
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Comparison of the expression and function of
the endothelin system in failing and non-failing
rat myocardium
Chapter 3 - Results
3.1 Introduction
Endothelin-1 (ET-1) is a powerful mediator of vasoconstriction, however, its exact
role as a regulator of myocardial contractile function is unclear. Direct positive
inotropic effects of ET-1 have been demonstrated in some preparations but responses
are complex and tend to vary depending on the preparation used, experimental
conditions and the species involved. Various studies provide evidence that ET-1
exerts positive inotropic responses in isolated cardiomyocytes (Kelly et al., 1990;
Kramer et al., 1991) and isolated cardiac tissue preparations from animals (Li et al.,
1991) and humans (Meyer et al., 1996). Controversially, positive inotropic responses
have not been detected in isolated whole heart preparations from rats (Neubauer et
al., 1990), rabbits (Karwatowska-Prokopczuk & Wennmalm, 1990) or in vivo studies
(Yang et al., 1991; Beyer et al., 1994), possibly due to ischaemia resulting from
coronary vasoconstriction.
The cellular basis for the actions of ET-1 on myocardial tissue is highly complex and
still not fully understood. Studies have shown that both ET receptors can couple to at
least two distinct signal transduction pathways leading to adenylyl cyclase inhibition
and formation of inositol-1,4,5-triphosphate (IP3) and 1,2-diacyl glycerol (DAG), via
stimulation of phospholipase C (PLC) (Vogelsang et al., 1994). Activation induces a
rise in cytosolic Ca2+ and sensitises cardiac myofilaments to intracellular calcium
(Kramer et al., 1991), thus increasing the force of contraction. However, it is still
unclear as to which receptor(s) is responsible for modulation of myocardial
contractility. Many factors are responsible for stimulating synthesis and release of
ET-1 including stretch stimulated release of ET-1. Previous studies have shown that
cultured endothelial cells (Kuchan & Frangos, 1993; Macarthur et al., 1994) and
cardiomyocytes (van Wamel et al., 2001) release ET-1 upon mechanical stretch.
In an attempt to maintain cardiac output and peripheral perfusion, many
compensatory mechanisms are activated in response to myocardial infarction (MI).
Cardiac upregulation of prepro ET-1 (ppET-1) mRNA has been reported and a
significant elevation of plasma ET-1 and big ET-1 concentration is also observed,
correlating positively with disease severity during progression from MI to chronic
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heart failure (CHF) (T0nnessen et al., 1997). However, ET receptor mRNA levels do
not diminish following MI, as is the case with adrenergic receptors in response to
increased catecholamine levels. Cardiac upregulation of both ETA and ETB receptors
has been demonstrated in the rat model of experimental heart failure at 3 (Sakai et
al., 1996a), 4 (Picard et al., 1998) and 12 weeks (Sakai et al., 1996b) post MI.
However, studies in our laboratory, using a model of less severe heart failure, have
shown that ETB receptor mRNA is selectively increased in the LV during the period
from 5-12 weeks post coronary artery ligation (CAL) (Sherry, 2000; Smith et al.,
2000), suggesting that disease severity is important in regulation of the ET system.
Administration of ET receptor antagonists has been shown to exert favourable
haemodynamic effects, improve cardiac function and prevent ventricular remodelling
in the rat model of CHF (Teerlink et al., 1994; Sakai et al., 1996a, 1996b). This
highlights the importance of the ET system during experimental HF and suggests that
increased expression of ET-1 and ET receptors in the failing ventricle may contribute
to cardiac remodelling. In addition, raised levels of endogenous ET-1 may directly
influence cardiac contractility in pathological conditions or contribute to the Frank-
Starling response by increasing peripheral resistance.
The aims of this study were to evaluate the effects of exogenous ET-1 on cardiac
contractility in the rat CHF model by comparing the contractile behaviour of
papillary muscles from sham and CAL rats and to determine whether increased ETB
receptor expression influenced the response. In addition, the relative changes in the
density of ETA and ETB receptor subtypes were established.
3.2 Methods
Initial procedures for the induction and characterisation ofMI and the preparation of
papillary muscles were carried out as described in Chapter 2. After complete
mechanical stabilisation (section 2.2.2), a cumulative concentration-response curve
to isoprenaline (10~9-10~6 M) was established. Following washout and return to a
steady state, the concentration of ET-1 in the organ bath was increased in a
cumulative manner in steps of 0.5 log units (10~n to 10~7 M). When steady contractile
75
Chapter 3 - Results
force had been achieved, ET-1 was added to yield the next higher concentration.
Finally, after subsequent wash out and stabilisation, the preparation was challenged
with CaCl2(2xlO~3 - l.l"2 M). Papillary muscles were removed and measured, blotted
and weighed, fixed in formalin and processed for the evaluation of collagen content
(as described in section 2.2.4). All forces were normalised by cross-sectional area
(CSA) of the papillary muscle. Morphological changes in heart (HW) and body
weight (BW) were recorded (Table 3.1). The area of the infarct was measured using
Image Analysis software (Carl Zeiss Vision) as described in section 2.1.3.1.3.
Subsequently, expression of the ET system and atrial natriuretic peptide (ANP), a
marker of cardiac hypertrophy, were investigated in the LV, septum and RV tissue
samples from sham-operated and CAL animals using semi-quantitative RT-PCR as
described in section 2.3.
Comparison between groups was performed by unpaired Student's t-test or analysis
of variance followed by Bonferroni's multiple comparisons test where appropriate. A
P value <0.05 was considered significant. Correlation analysis was used to examine
the interaction between the parameters measured. The Pearson correlation coefficient
(r) was calculated for each simple linear regression to determine the closeness of the
straight line to the points.
3.3 Results
3.3.1 Effects of coronary artery ligation on mortality
Twenty-seven rats underwent CAL for the induction of CHF. Deaths occurring
during or immediately following surgery were 22% of the whole group. Most of
these were attributed to post-infarct arrhythmias, a common problem associated with
CAL surgery in the rat. Only one CAL animal died in the 24hr period after surgery.
No early or late deaths of sham-operated animals occurred. Infarct sizes of the free
LV wall measured 12.35 ± 2.75mm2 (n=5).
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At 15 weeks post-ligation, cardiac haemodynamic parameters were recorded in vivo
under general anaesthetic using a fluid filled intraventricular catheter placed via the
right carotid artery. CAL animals with LVEDPs > lOmmHg were considered to have
significant LV dysfunction (LVD), a significant decrease in dP/drmax was also
observed but no significant difference was obtained in HR, MAP or d/7drmjn between
groups (Table 3.1). No significant difference was observed in BW between sham and
CAL animals but the HW: BW ratio was significantly increased, despite the free wall
of the infarcted area being very thin and consisting of connective tissue (Figure 3.1).
3.3.3 Baseline responses of isolated papillary muscles
(i) Passive length-tension relationship
In the presence of 2,3-butanedione-monoxime (BDM) to inhibit cardiac contraction,
the passive length/tension relationship of rat right ventricular papillary muscle was
investigated. As expected, passive stretch produced an increase in tension in
papillary muscles of both groups. A greater rate of rise in tension was observed in the
CAL group (Figure 3.2). Simple linear regression of the data, performed on a semi¬
log plot, indicated a significant difference in the length-tension relationship between
groups (PcO.OOOl). CAL resulted in an increased slope of the straight line (Figure
3.2). The y-intercept was also increased and the condition of linearity was met (sham,
r = 0.985; CAL, r = 0.973).
(ii) Active length-tension relationship
Typical changes in developed tension after muscle stretch were observed in
electrically stimulated papillary muscles. It can be seen in Figure 3.3 that twitch
tension increased as the muscle was progressively stretched. Peak developed tension
at Lmax under baseline conditions was considerably greater in papillary muscles from
sham animals (Figure 3.4). There was the tendency towards an increased resting
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tension in the CAL group at Lmax (sham, 4.59 ± 1.07mN/mm2; CAL 9.22 ±
3.67mN/mm2), although the difference was not statistically significant (P=0.25).
Baseline twitch timing parameters were not significantly altered between groups,
time to peak tension (TPT); 53.17 ± 1.51 ms compared with 50.83 ± 2.22 ms and
time from peak to 50% relaxation (RT50); 41.17 ± 1.95 ms compared with 40.17 ±
1.35 ms for sham and CAL respectively.
3.3.4 Effects of J3i agonist isoprenaline
In isolated rat papillary muscles, isoprenaline produced concentration-dependent
increases in peak isometric tension and a reduction in TPT and RT50, consistent with
stimulation of (3-adrenoceptors. Although the data were not statistically different, the
pattern of responses for a range of contractile indices suggests a reduced inotropic
response to isoprenaline in papillary muscles from CAL animals compared to sham
animals (Figure 3.5).
3.3.5 Effects of ET-1 on contractile behaviour
Contractile responses to ET-1 were slow in onset, long lasting and extremely
variable. In both groups ET-1 produced both positive and negative inotropic effects.
It can be seen in Figure 3.6a that negative responses occurred at lower
concentrations while more positive effects were elicited at higher concentrations (10"
O *7
-10" M) in papillary muscles from sham animals. However, due to inconsistent
responses, no significant difference was observed when the data were averaged. The
biphasic pattern that emerged in the sham group was not as obvious in the CAL
group, where the relaxation phase was less profound (Figure 3.6b). Linear regression
analysis was used to investigate the relationship between the resting tension at Lmax
and peak response to exogenous ET-1. CAL responses produced a negative slope,
indicating that a larger resting tension at Lmax, achieved by a greater degree of stretch,
tended to be associated with a reduced response to exogenous ET-1. However, the
condition of linearity was not met (r = 0.212). Cumulative addition of ET-1 caused
no modification of the timing parameters of contraction, TPT or RT50 (Figure 3.7).
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Table 3.1. Haemodynamic and morphological characteristics ofsham-operated and
CAL animals indicating L V dysfunction.
Sham (n=6) CAL (n=6)
Body Weight (g) 430 ± 12 442 ± 15
Heart: Body Weight ratio (gkg"1) 2.35 + 0.09 2.81 ±0.15*
Lung: Body Weight ratio (g kg"1) 3.25 ± 0.09 3.23 ±0.11
HR (bpm) 344 + 13 332 ± 13
MAP (mmHg) 95.4 ±4.6 99.1 ±8.9
LVEDP (mmHg) 3.3 ±0.2 12.2 ± 1.8**
dP/dtmax (mmHgms1) 2606±134 2045 ± 71**
dP/dtmin (mmHgms"1) -2679±170 -2294 ± 99
CSA (mm2) 0.40 ± 0.02 0.47 ± 0.03
Values are means ± SEM, *P<0.05, **P<0.01 compared to sham. HR, heart rate;
MAP, mean arterial pressure; LVEDP, left ventricular end-diastolic pressure;
dP/dtmax, maximal rate of pressure rise; dP/dtmin, maximal rate of pressure decline;
CSA, cross sectional area ofpapillary muscle.
Figure 3.1. Cross section of a CAL heart cut apex to base through the infarcted
region.
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Figure 3.2. The passive length-tension relationship ofpapillary muscles from sham
(n—6) and CAL animals (n=6, *P<0.01) plottedfrom (a) basic meaned data and (b)
the same data expressed on a semi-log plot, indicating linear regression analysis.
The gradient ofthe lines and the correlation coefficient values (r) are also displayed.
80











I 1 1 1—I—I—I 1—I—I—J- 1 1 1 r— -i 1 1 r~
40 45 50 55
Time (minutes)
60
Figure 3.3. Sample trace ofactive twitch tension from rat right ventricular papillary
muscle, progressively stretched in 0.1mm increments / minute until maximum
isometric twitch tension was achieved (Lmax).
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Figure 3.4. Peak developed tension achieved at Lmax bypapillary muscles from sham
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Figure 3.5. Increasing concentration of isoprenaline and its effects on (a) change in
twitch tension, (b) time to peak tension and (c) time from peak to 50% relaxation of
isometrically contractingpapillary muscles (n=6 in each group).
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Figure 3.6. The influence of increasing ET-1 concentration on contractile behaviour
of rat right papillary muscles from (a) individual sham, (b) individual CAL and (c)
mean data offailing and nonfailing hearts (n=6 in each group).
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Figure 3.7. Influence ofET-1 concentration on contractile parameters (a) TFT and
(b) RTso of isometrically contracting papillary muscles from sham and CAL animals
(n=6 in each group).
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3.3.6 Influence of extracellular Ca2+ concentration
Addition of extracellular Ca2+ produced typical positive inotropic responses in
stimulated papillary muscles. However, in the CAL group, a decreased
responsiveness to Ca2+ was observed, the maximum developed tension was reduced
and peak inotropic effect was evoked with llmM compared to 9mM in the sham
group (Figure 3.8). The positive inotropic effects of Ca2+ were not associated with
changes in the contractile timing parameters in the sham group (Figure 3.9),
however, although the data was not statistically significant, there was the tendency
towards an increase of TPT and RT50 values in the CAL group.
3.3.7 Investigation of collagen content in papillary muscles from sham
and CAL animals
Sections of rat right ventricular papillary muscle from sham and CAL animals were
stained with van Gieson's histological stain and assessed for collagen content.
Normal myocardium stained yellow, while collagen appeared pink. The nuclei were
counterstained with haematoxylin (dark blue). A significant increase in collagen
content was observed in the CAL papillary muscles compared to sham (Figure 3.10).
Linear regression analysis was used to determine whether there was an association
between the resting tension at Lmax and the collagen content of papillary muscles. The
slope and the y-intercept of the CAL group were greater than those for the sham
group (sham, y = 0.006x + 0.799; CAL, y = 0.01 Ox 1.715), however, the condition of
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Figure 3.8. The positive inotropic responses to extracellular Ca2+ concentrations in
rat papillary muscle from failing and nonfailing hearts (a) developed tension in
response to increasing Ca2 concentration and (b) peak inotropic effect evoked by
9mM and 1 ImMCaCh respectively (n=6 in each group, *P<0.05).
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Figure 3.9. Effects of increasing extracellular Ca2+ concentrations on (a) TPT and
(b) RTso in papillary muscles from sham and CAL animals (n=6 in each group).
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Figure 3.10. Images of right ventricular papillary muscle from rats having
undergone (a) sham-op surgery or (b) CAL for the induction ofCHF. van Gieson 's
stain highlights collagen in pink and normal myocardium in yellow with nuclei
counterstained dark blue with haematoxylin (x40 and x200 magnification), (c)
histogram ofcollagen score (n=6 in each group, *P<0.05).
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3.3.8 Comparison of the ET system and ANP mRNA expression in
failing and non-failing rat heart
Expression of ANP, the ETA and ETB receptors and ppET-1 mRNA levels were
examined in the LV, septum and RV of sham-operated and CAL rats 15 weeks post
MI (Figure 3.11). LV ANP/GAPDH mRNA expression was significantly elevated
(1.4-fold) and correlated with collagen levels in the failing hearts (r = 0.628). A 1.6-
fold increase of ANP mRNA was also detected in the septum of failing hearts,
however, no change was measured in the RV. Densitometric analysis revealed that
the ETa mRNA was more abundant in myocardial tissues of sham animals compared
to CAL, however, the differences were not statistically significant. In contrast, there
was a tendency towards upregulation of ETB receptor mRNA in the LV of the failing
hearts but again, the differences were not statistically significant. No difference was
observed in the level of ppET-1/ GAPDH mRNA expression in the LV, septum or
RV from failing hearts.
Densitometric analysis of serial dilution data showed that GAPDH mRNA was not
significantly different between sham and CAL rat hearts 15 weeks post MI. In
contrast, ANP mRNA was elevated in each CAL tissue, confirming the semi
quantitative observations.
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Figure 3.11. Comparison of the relative intensities ofANP, ETa, ETb and ppET-1 /
GAPDH mRNA levels from the (a) left ventricle, (b) septum and (c) right ventricle of
failing and nonfailing rat hearts (n=6 in each group, *P<0.05).
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3.4 Discussion
The purpose of this study was to evaluate the role of cardiac ET receptors in the
regulation of myocardial contractility in failing and nonfailing rat myocardium by
examining the contractile behaviour of papillary muscles from sham and CAL rats
and to establish whether a change in receptor density influenced the inotropic
response in HF.
3.4.1 The effects of CAL
The deterioration of cardiac haemodynamic parameters observed in the chronically
infarcted rat heart has previously been described (Pfeffer et al., 1979). Characteristic
elevation of LVEDP and reduced myocardial contractility (dP/dtmax) indicates that
CAL rats had developed LVD. This is supported by the presence of cardiac
hypertrophy, as evidenced by an increase in HW: BW, elevated interstitial collagen
and elevated expression of LV ANP levels in CAL animals.
3.4.2 Passive and active length-tension relations
Mechanical stretch produced a more rapid rise of tension in passive papillary from
CAL animals than sham-operated animals and the degree of stretch required to
achieve Lmax in the passive CAL papillary was less than that for sham-operated rats.
These findings suggest a reduction of the myocardial elastic accommodation of CAL
papillary muscles compared to the papillary from sham-operated. Correlation
analysis confirmed that the length-tension relationship differed between the groups
as the slope of the relationship was greater for the CAL papillary. The y-intercept
was also greater for the CAL group, indicating an increased stiffness of the CAL
myocardium compared to sham. Basal isometric contractile behaviour of CAL
papillary was also altered. Peak developed tension was significantly reduced in the
CAL group and was associated with an elevated resting tension, indicating
myocardial dysfunction. Previous studies have observed a prolongation of TPT and
RT50 in failing myocardium, most likely due to Ca2+ handling (Sandmann et al.,
1999). In contrast, baseline TPT and RT50 values in this study were not significantly
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altered, however, the associated dP/drmax and dP/dtmin of these animals was reduced,
indicating LV dysfunction. Lowered contractility and elevated stiffness of the
myocardium of infarcted animals can partly be attributed to an increased content of
non-contractile material in the extracellular matrix, as evidenced here by an
increased collagen content. Several studies have shown that the progressive
development of cardiac fibrosis is accompanied by the accumulation of collagen type
I and III (Weber et al., 1988). This results in elevated stiffness of the noninfarcted
hypertrophied myocardium and may be responsible in part for the deterioration of
peak developed tension of the papillary muscle in the chronic state of MI induced
heart failure. A possible relationship was demonstrated between the resting tension at
Lmax and the collagen content for the CAL group, where papillary muscles with high
collagen content were associated with a high resting tension at Lmax. However, the
condition of linearity was not quite met. Increasing sample size may improve the
statistical significance of the result.
3.4.3 Effects of^-adrenoceptor stimulation
Isoprenaline stimulation causes positive inotropic effects and a hastening of
contraction and relaxation that are associated with cyclic AMP-dependent protein
kinase phosphorylation of contractile proteins. Stimulation of the G-protein coupled
[3-adrenoceptor activates adenylyl cyclase which in turn activates PKA via cAMP to
increase [Ca2+]j during the plateau phase, this then enhances the intracellular calcium
stores over the course of several beats. (3-adrenoceptor activation also interacts with
the pacemaker current channels to increase their open-state probability, thus
increasing the depolarising rate and quickening contraction. In addition, the second
messenger pathway increases the activity of phospholambam, the protein associated
with the network sarcoplasmic reticulum (SR) that is responsible for regulating the
activity of the SR Ca2+-ATPase (SERCA) pump, to accelerate the re-uptake of Ca2+
by the SR and shorten the period of relaxation. A tendency for a reduction in the
positive inotropic response to isoprenaline in the CAL group is consistent with the
previously described down regulation and desensitisation of (3-adrenoceptors in heart
failure (Bristow et al., 1993).
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Previous studies using multicellular preparations have described the positive
inotropic actions of ET-1 occurring in a simple concentration-dependent manner in
animal (Li et al., 1991; Kasai et al., 1994) and human myocardial preparations
(Meyer et al., 1996; Pieske et al., 1999). In contrast, consistent responses to direct
ET-1 application were not achieved in this study, instead, a biphasic tendency was
observed in the sham group. At low concentrations of exogenous ET-1 a decrease of
tension was observed. This was possibly due to relaxation induced by endothelial cell
ETb receptor stimulated release of nitric oxide (NO). At higher ET-1 concentrations
a positive inotropic response was predominant, mediated by ETA and possibly ETB
receptors expressed on cardiomyocytes. However, in the present study, responses
from sham papillary muscles were variable and although the results appeared
biphasic, the changes were not statistically significant.
In a recent study using a similar protocol Qi et al. (2001) reported similar biphasic
responses to ET-1 in normal rat papillary muscles and attributed them to receptor
distribution. However, in contrast to the current study, Qi et al. (2001) observed less
variation of responses in the control group. There are several potential explanations
for the differences between the Qi et al. (2001) study and the current study. Bathing
[Ca2+] and the bath temperature were both higher in the current study (2mM and
37°C compared to 0.7mM and 29°C respectively) and sample size was greater in the
Qi et al. (2001) study. In addition, a previous study established that removal of the
endothelial layer by brief immersion in the detergent Triton did not alter the level of
tension induced by ET-1 but shifted the dose-response curve to the left, decreasing
the threshold at which ET-1 has myocardial effects (Li et al., 1991). These results
indicate that endocardial endothelial ETB receptors may modify the ET-1 induced
twitch configuration characteristics via stimulation and release of NO. Variability in
endocardial endothelial integrity could therefore account for some of the variability
observed in papillary muscles from sham-operated animals the present study.
In the current study, exogenous ET-1 had no significant influence on the contractile
state of papillary muscles from CAL animals. Although a slight biphasic response
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was observed, responses were not significantly altered by increasing ET-1
concentration and were not as exaggerated as the biphasic response of sham-operated
papillary muscles. The lack of consistent relaxation at lower concentrations of
exogenous ET-1 again indicated the loss of an endothelial-mediated mechanism in
CAL papillary muscles. Potential loss of the ETB mediated release of NO may have
resulted from variable endocardial endothelial integrity due to mechanical transfer, or
could have resulted from the endothelial dysfunction that occurs in heart failure.
Similarly, Qi et al. (2001) reported that low concentrations of exogenous ET-1 had
no effect on papillary muscles from infarcted hearts. However, in contrast to the
current study, responses to higher ET-1 concentrations in the CAL group were
significantly increased compared to the sham-operated group of papillary muscles
(Qi et al., 2001). The differences between the current study and the Qi et al. (2001)
study are most likely attributed to the larger sample size used and the condition that
was employed, where only papillary from hearts with infarcts of a specified size
range (30-45%) were used (Qi et al., 2001).
3.4.5 Stretch and ET-1
ET-1 is synthesised in endocardial endothelial cells and in cardiomyocytes. Another
possible explanation for the inconsistent results in the present study could be that
endogenous ET-1 was released upon stretch (Kuchan & Frangos, 1993; Macarthur et
al., 1994; van Wamel et al., 2001). Release of ET-1 through an autocrine-paracrine
mechanism would have increased the local concentration and led to receptor
occupation at the level of the myocyte. Once bound, the peptide was capable of
causing stimulation for over 40 minutes and masking the effects of additional
binding by exogenous ET-1. A possible relationship between the resting tension at
Lmax and the peak response to exogenous ET-1 was demonstrated by linear regression
analysis. CAL responses produced a negative correlation slope, where high resting
tension was associated with a reduced response to exogenous ET-1, however, the
condition of linearity was not met. The degree of stretch required to achieve peak
isometric tension was greater for CAL papillary muscles compared to sham-operated
muscles and resulted in an increased resting tension. Therefore, the degree of
mechanical stretch may have influenced the amount of endogenous ET-1 released
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and this would have influenced the availability of free receptors not bound by
endogenous ET-1. However, no significant difference in response to exogenous ET-1
was observed between sham-operated and CAL papillary muscles. Using a larger
sample size and imposing a condition, which would exclude rats with infarcts under
a specified size, as many studies do, would provide a more accurate correlation.
However, papillary muscles would still have to be stretched to normalise forces,
therefore, the use of mixed or selective antagonists would be required to exclude the
influence of endogenous ET-1.
3.4.6 The intracellular mechanisms of ET-1 action
ET-l produced positive inotropic effects at higher concentrations in most papillary
muscles but was less consistent at producing a response at lower concentrations. The
positive effects were induced by a rise in [Ca2+]i via complex intracellular pathways.
The mechanisms underlying ET-l receptor-induced [Ca2+]i rise are not completely
understood, however, patch-clamp studies have shown ET-1 to be involved in
activating voltage operated and voltage independent Ca2+ channels in cultured cells
(Inoue et al., 1990; Miwa et al., 1999). In a recent study, Hong (2002) demonstrated
that ET-1 stimulates two phases of [Ca2+]i increase in cultured myocardial ventricular
cells, the first results from the entry of external Ca2+ via L-type channels while the
secondary phase induced by ET-1 is a result of both external Ca2+ influx and internal
Ca2+ release from Ca2+ stores.
ET-1 is capable of influencing other ionic currents. In a previous study the
effectiveness of ET-1 to stimulate Na+/H+ exchanger activity was impaired in rat
cardiac hypertrophy, resulting in reduced functional effects of ET-1 (Ito et al., 1997).
This was partly due to the failure to develop intracellular alkalinisation, required to
sensitise the contractile proteins. Furthermore, as previously described, the L-type
Ca2+ current (/rni.) is the main depolarising current contributing to the plateau-shape
2+of the cardiac action potential and governs release of Ca from the sarcoplasmic
reticulum (SR) (Cleemann & Morad, 1991). IcaL has been found to be stimulated by
ET-1 (Lauer et al., 1992; Bkaily et al., 1995) and is downregulated in heart failure
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(Boixel et al., 2001). Conversely some studies have shown that the ETa receptor
subtype is coupled to a decrease in 7Ca via L-type Ca2+ channel inhibition, possibly to
protect against ventricular arrhythmias and myocardial Ca2+ overload (Ono et al.,
1994; Kelso et al., 1998). Therefore, this suggests that alterations of the subcellular
mechanisms that mediate the functional responses of ET-1, may contribute to reduce
the inotropic effect in diseased myocardium and counterbalance any potentiated
effect induced by an increased ETA or ETB receptor density. In the present study, the
presence of LVD did not modify the inotropic response to ET-1. However, Qi et al.
(2001) and others have reported potentiated contractile responses to ET-1 in isolated
tissues from failing hearts. The difference in the two studies could be attributed to the
severity of experimental heart failure or the time course of the experiment. In the Qi
et al. (2001) study, animals exhibited moderate to severe HF as indicated by a more
elevated LVEDP, reduced d77drmax and moderate to large infarct sizes, all parameters
more pronounced than the present study. In addition, the animals were younger and
were used at 4 weeks post MI compared to 15 weeks in this study. Furthermore, it is
likely that receptor distribution and other factors change with time and over the
course of CHF development.
Consistent with other studies, ET-1 had no effect on twitch configuration
characteristics, unlike isoprenaline, consistent with the influence of ET being
mediated via a different mechanism. (3-adrenoceptor stimulation activates the
pacemaker current (/Na) via cAMP to increase the depolarisation rate and decrease
the TPT, however, there is no evidence to suggest that ET-1 modulates the 7na
(Bkaily et al., 1995). In addition, isoprenaline stimulation shortens RT50 by
increasing re-uptake of Ca2+ into SR stores by activating the SERCA pump via
phospholambam whereas ET-1 does not.
3.4.7 The influence of exogenous Ca2+ concentration
In normal myocardium, an increase of extracellular Ca2+ produced typical
concentration-dependent responses in isometric twitch tension. Ca2+ enters the
2+
myocyte through voltage-gated dihydropyridine-sensitive sarcolemmal Ca" channels
during depolarisation, this local pool is sufficient to activate adjacent ryanodine
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receptors to release Ca2+ from the SR. This punctate increase of Ca2+ is termed Ca2+
spark, according to its visualisation by confocal microscopy (Cheng et al., 1993) and
cytosolic increase of [Ca2+] causes activation of the contractile proteins. During
relaxation Ca2+ is then removed from the cytosol into the SR by the SERCA pump
and across the sarcolemma, mainly by the Na+/Ca2+ exchanger (Barry & Bridge,
1993). A gradual increase of SR loading occurs, resulting in an elevated quantity
available for the next contraction. The maximum amplitude of isometric force in
sham papillary was obtained at 9mM Ca2+. In contrast, isometric twitch tension was
reduced in the failing papillary and required llmM extracellular Ca2+ to reach a
maximum. Furthermore, the present study showed that TPT and RT50 values tended
to increase after addition of extracellular Ca2+. The change in sensitivity to Ca2+ in
the CHF group indicates an alteration in intracellular Ca2+ handling which is
associated with disturbed contractile function. Indeed, it has been shown that the
pharmacology of the 7ca is altered in heart failure and hypertrophy. The density of L-
type Ca2+ channels has been shown to decrease in moderate to severe stages of CHF
in rats, as evaluated by antagonist binding studies (Dixon et al., 1990;
Gopalakrishnan et al., 1991). Furthermore, patch-clamp studies of isolated rat CHF
myocytes have demonstrated that Iq3l showed both a significantly reduced peak
amplitude and a slower inactivation compared with myocytes from sham-operated
animals (Aimond et al., 1999; Boixel et al., 2001). Additionally, mRNA and protein
levels of the SERCA pump, which is crucial for Ca2+ accumulation within the SR,
were found to decrease continuously with increasing severity in the rat model of
CHF (Zarain-Herzberg et al., 1996). Therefore, the results from the current study are
consistent with the reports that failing myocardium is associated with altered Ca2+
handling via changes in the density and function of several Ca2+ regulatory proteins
(for review see Hasenfuss, 1998b).
3.4.8 Expression of ET-system and ANP mRNA
Previous studies in our laboratory using in situ hybridisation have demonstrated a
localised increase of the ETb receptor subtype in the LV surrounding the infarcted
region (Sherry, 2000; Smith et al., 2000). In the current study, ETb receptor mRNA
expression was greater but not significantly increased in the failing LV tissue,
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suggesting that ETb receptor expression may exhibit a marked increase in the tissue
nearest the scar but this is not necessarily reflected throughout the LV myocardium.
Another possibility is that ETB mRNA is increased in cardiomyocytes while ETB
receptor mRNA in endocardial endothelial cells has decreased, therefore
counterbalancing the result. No significant change in the expression pattern for the
ETa receptor was observed in CAL animals, contrasting with previous studies (Sakai
et al., 1996b; Tpnnessen et al., 1997; Picard et al., 1998). Plasma ET-1 and big ET-1
levels were not measured in this study, as previous investigations in our laboratory
have consistently shown no change in concentration in CAL animals (Sherry, 2000).
In the current study, ppET-1 mRNA expression remained unchanged, in agreement
with our previous findings but again in contrast with the other published data (Sakai
et al., 1996b; Tpnnessen et al., 1997; Picard et al., 1998). The discrepancy between
this study and the other reports is most likely due to the severity of LVD resulting
from CAL.
In conclusion, it has been demonstrated that the papillary muscle technique is a
suitable preparation for the evaluation of contractile function in heart failure.
However, investigation of the contribution of the ET-system to cardiac contraction
following CAL was restricted most likely due to the influence of stretch-released
endogenous ET-1. Furthermore, no clear pattern emerged to define the role of the
ETb receptor in the regulation of cardiac contraction in the infarcted heart.
Additionally, results indicated that the severity of experimental heart failure
influenced the contractile responses to ET-1, suggesting that a more accurate
assessment would require imposing a condition of inclusion on the basis of infarct
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4.1 Introduction
In the normal rat heart, both ETa and ETb receptors are diffusely distributed
throughout the atrial and ventricular myocardium. In our laboratory, previous in situ
studies have revealed an 80:20 distribution of ETA:ETB receptors in the normal left
ventricle (LV) (Sherry, 2000), while other studies have reported 85:15 (Touyz et al.,
1996) or a 90:10 distribution of ETA:ETB receptors (Fareh et al., 1996; Sakai et al.,
1996a) in normal rat LV. The positive inotropic effects of ET-1 have consistently
been observed in atrial and ventricular tissue preparations from many species,
including humans (Davenport et al., 1989; Moravec et al., 1989; Meyer et al., 1996).
However, there is a distinct lack of clarity regarding the contribution of the ETB
receptor subtype in the regulation of cardiac contractility. Some antagonist studies
have suggested that the predominant ETA receptor subtype is solely responsible for
mediating the positive responses of ET-1 in the heart (Meyer et al., 1996; Ponicke et
al., 1998), while others have demonstrated that both receptor subtypes are involved
(Kasaieta/., 1994; Beyer et al., 1996).
In the previous chapter (Chapter 3), in vitro contractile responses to direct
application of agonist failed to provide consistent results. The influence of ET
receptor subtypes on contraction was complex and endogenous ET-1, potentially
released by stretch, may have confused the responses in papillary muscles from
sham-operated as well as CAL animals. Therefore, a study was designed to assess
contractility in papillary muscles from control animals using an antagonist approach,
to identify the contribution of endogenous ET-1 to normal contraction.
The aims of this chapter were to develop a protocol that may be used to better define
the role of receptors in heart failure. The role of ETA and ETB receptors in the
regulation of normal contractility were investigated by determining the influence of
endogenous ET-1, using the ETA receptor selective antagonist, BQ123, the ETB
receptor selective antagonist, BQ788, or a combination of both.
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4.2 Methods
Male Wistar rats (390-590g, Charles River) were weighed and anaesthetised with
sodium pentobarbital (60mgkg"', i.p. Sagatal). The hearts were rapidly excised and
placed in Tyrode's solution to expel blood from the ventricles prior to immersion in
ice-cold cardioplegic solution. After removing the atria and large vessels, the heart
was weighed. The right ventricle (RV) was dissected open and the papillary muscles
were carefully dissected out and vertically mounted in carbogen bubbled 2,3-
butanedione-monoxime (BDM)-Tyrode's solution (pH 7.4, 37°C) as described before
in section 2.2.2. Papillary muscles were incubated with one of four different bath
conditions; 1, vehicle, bovine serum albumin (BSA 0.1%); 2, BQ123 (106 M); 3,
BQ788 (10"6M); 4, BQ123/BQ788, randomised by a Latin square method.
After an initial incubation period of 20 minutes, the passive length/tension
relationship was investigated. The preparation was then returned to slack and the
bath solution replaced with Tyrode's solution. Treatments were re-administered and
the preparation was stimulated (3Hz, 20% above threshold voltage). The papillary
was left to equilibrate (20 minutes) before the active length/tension relationship was
investigated to Lmax. Two separate functional studies were carried out using the
antagonist conditions described above.
4.2.1 Functional study 1 - January/February
After a period of stabilisation, a cumulative concentration-response curve for
isoprenaline (10"9-10"6M) was performed. Following washout, replacement of
treatment and stabilisation, the muscle was challenged with a single 10"8M dose of
■j
ET-1. Finally, after a subsequent washout, CaCl2 was added cumulatively (2x10""-
10 2 M). All forces were normalised by cross sectional area (CSA) of the papillary
muscle. Subsequently, due to encouraging observations in study 1, a second study
was designed to (i) increase sample size and (ii) look at the interaction of ET-1 and
Ca2+ in more detail.
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The protocol for this study was the same as described above for study 1, with an
2+ 3 2
additional Ca concentration-response curve (2x10" - 10" M) after isoprenaline
stimulation and before the application of ET-1. All forces were normalised by CSA
of the papillary muscle.
4.2.3 Molecular study
Tissue samples (approximately lOOmg) of the RV free wall, LV free wall and the
septum were taken from both functional studies, snap frozen in liquid nitrogen and
stored at -70°C for subsequent analysis of gene expression. Semi-quantitative RT-
PCR was performed as described in section 2.3 using 2|lg of mRNA to investigate
the atrial natriuretic peptide (ANP), ETA, ETB and ppET-l/GAPDH mRNA ratios.
All samples were processed under the same conditions concurrently and PCR
products of a gene were evaluated densitometrically on the same agarose gel.
Comparison between groups was performed by a one-way or two-way analysis of
variance where appropriate, followed by Bonferroni's multiple comparisons test. A P
value <0.05 was considered significant.
4.3 Results
4.3.1 Basal responses
Papillary muscles stretched under passive conditions produced typical length/tension
relationship curves. No significant difference was observed between treatment
groups of each study (results not shown). No significant difference in CSA was
reported between groups. January/February study: vehicle, 0.33 ± 0.04mm2; BQ123,
0.44 ± 0.07mm2; BQ788, 0.49 ± 0.11mm2 and mixed, 0.50 ± 0.10, n=8, P=0.43;
July/August study: vehicle, 0.34 ± 0.05mm2; BQ123, 0.33 ± 0.03mm2; BQ788, 0.30
± 0.03mm2 and mixed, 0.35 ± 0.05mm2, n=9, P=0.82.
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As expected, progressive stretch of electrically stimulated papillary muscles
produced characteristic increases in developed tension. The peak isometric tension
achieved at Lmax was significantly different between the vehicle and mixed antagonist
groups from study 1, while no significant difference was observed between groups
from study 2 (Figure 4.1). No significant difference in resting tension was reported
between groups of either study. Antagonist treatment had no significant effect on
baseline time to peak tension (TPT) or time from peak to 50% relaxation (RT50)
values in either study (Table 4.1).
4.3.2 Influence of isoprenaline in the presence of endothelin
antagonists
The positive inotropic effects of (3-adrenergic stimulation were demonstrated in
papillary muscles of all treatment types and were associated with the hastening of
timing parameters (TPT and RT50) (results no shown). In study 1, the antagonist
treatments had no significant influence on the response to isoprenaline, although
there was a tendency toward reduced responsiveness in the presence of the mixed
antagonist compared to vehicle (Figure 4.2a). In contrast, in study 2 no difference
was observed against the vehicle group but there was a significant difference
between antagonist groups (Figure 4.2b). Responses to isoprenaline in the presence
of the ETb selective antagonist, BQ788, were significantly reduced at higher
concentrations (10"7-10"6M) compared to the ETA selective antagonist and mixed
groups. Antagonist treatment had no significant effect on the shortening of
contractile parameters in response to isoprenaline stimulation (results not shown).
4.3.3 Contractile responses to exogenous ET-1 in papillary muscles pre-
incubated with ET antagonists
Papillary muscles in the vehicle group of study 1 produced positive inotropic
responses to exogenous ET-1. Although papillary muscles treated with ETa/b
antagonist tended towards reduced responses, there was no significant difference
between these groups due to the wide variation of responses (Figure 4.3a). The
effects of ET-1 in study 2 were again varied and no difference was found between
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groups (Figure 4.3b). No change was observed in contractile timing parameters (TPT
or RT5o), consistent with previous studies of normal myocardium.
Table 4.1. TPT and RT50 values of electrically stimulated right ventricular papillary
muscles preincubated with ET antagonists in Study 1 and Study 2.
Study 1 (n=8) Study 2 (n=9)
TPT (ms)
_ RT5q (ms) TPT (ms) RT50 (ms)
Vehicle 57.7 ± 1.3 44.2 ± 2.6 50.2 ± 1.6 40.1 ± 2.4
BQ123 53.0+ 1.7 40.2 ±1.9 52.2 ±1.9 41.8 ±1.7
BQ788 54.8 ±3.2 46.8 ± 2.5 51.5 ± 1.3 40.2 ±1.6
Mixed 50.3 ±2.7 41.5 ±0.9 51.9 ± 1.2
_ 40.7 ± 1.2
Values are means ± SEM. Study 1, January/February; Study 2, July/August; TPT,
time to peak tension; RT50, time from peak to 50% relaxation.
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Study 1 January/February
Vehicle BQ123 BQ788 Mixed
Vehicle BQ123 BQ788 Mixed
Figure 4.1. Comparison ofpeak developed tension at Lmax achieved by papillary
muscles from normal animals after pre-incubation with ET antagonists (a) Study 1,
January/February (n=8, *P<0.05), (b) Study 2, July/August (n=9).
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Study 1 January/February
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Figure 4.2. Positive inotropic responses to isoprenaline in papillary muscles pre-
incubated with ET antagonists (a) Study 1 (n=S'), (b) Study 2 (n=9, *P<0.()I BQ788
compared to mixed, fP<0.05 BQ788 compared to BQ123).
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(a) Study 1 January/February
6-i
Vehicle BQ123 BQ788 Mixed
Study 2 July/August
Vehicle BQ123 BQ788 Mixed
Figure 4.3. Change in twitch tension ofpapillary muscles in response to exogenous
ET-1 (10~8M) in the presence ofET antagonists (a) Study 1 (n—8), (b) Study 2 (n=9).
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4.3.4 Effects of extracellular Ca2+ on contractile behaviour
An increase of extracellular Ca2+ concentration produced positive inotropic effects
and no alteration of contractile timing parameters. Results from study 1 showed that
responses to increasing bathing [Ca2+] were significantly reduced in the antagonist
groups compared to the vehicle group. In addition, peak response to extracellular
Ca2+ was achieved at 6mM for the vehicle group and 7mM for the antagonist groups
(.Figure 4.4a). Responses in study 2 were not modified by the presence of ET
antagonists (Figure 4.4b), while maximum developed tension was achieved in all
groups with 7mM Ca2+. No difference in TPT or RT50 was observed from either
study (results not shown). In study 2, no difference in contractile response to Ca2+
was observed when evaluated before or after the administration of ET-1 (results not
shown).
4.3.5 Seasonal comparison of the ET system and ANP mRNA
expression in cardiac tissues from control animals
Due to the variation of contractile responses between the two studies, GAPDH, ANP,
the ETa and ETB receptors and ppET-1 mRNA expression levels were examined in
the LV, septum and RV of hearts from study 1 and 2 (Figure 4.5). The two sets of
functional experiments were conducted 6 months apart, study 1 in January/February
and study 2 in July/August. ANP/GAPDH mRNA expression was significantly
elevated in septum and RV tissue samples from study 2 compared to study 1
(P<0.05). The ratio of ANP/GAPDH mRNA also tended to be elevated in the LV
sample of study 2, however, the result was not significant. The expression ratio of
ETa/GAPDH mRNA was significantly greater in all myocardial samples from study
2, while, ETb/GAPDH mRNA was also increased, showing statistical difference in
the septum and the RV myocardial tissues. In addition ppET-1 was significantly
elevated in the septum and RV of study 2 compared with study 1. No change in
GAPDH mRNA expression was observed between groups as evidenced by
densitometric intensities ofGAPDH bands.
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Figure 4.4. The influence ofextracellular Ca2+ on twitch tension ofpapillary muscles
pre-incubated with ETantagonists in (a) Study 1 (n—5, *P<0.01, **P<0.001, vehicle
versus BQ123; fP<0.05, ffP<0.01, vehicle versus BQ788 and mixed) and (b) Study
2 (n=8).
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Figure 4.5. Comparison of the relative intensities ofANP, ETa, ETb and ppET-1
mRNA/ GAPDH mRNA levels from the (a) left ventricle (LV), (b) septum and (c)
right ventricle (RV) of normal rat hearts used in Study I (Jan/Feb) and Study 2
(July/Aug) (n=5, *P<0.05, **P<0.01).
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4.4 Discussion
The purpose of this investigation was to develop an effective protocol to evaluate the
functional influence of ET receptors on cardiac contractility in normal rat
myocardium and to determine the role of endogenous ET-1 using selective ET
receptor antagonists. The expression of the ET system was also investigated.
As discussed in the previous chapter (Chapter 3, section 3.4.5), release of
endogenous ET-1 from endothelial cells and cardiomyocytes can be induced by
mechanical stretch (Kuchan & Frangos, 1993; Macarthur et al., 1994; van Wamel et
al., 2001) and may have contributed to the inconsistent results observed when using
agonist. Therefore, ET antagonists were included in the current protocol to block the
influence of stretch released endogenous ET. Myocardial ET receptors are coupled
via G-proteins to PLC-IP3 and -DAG intracellular cascades that induce ET-1
stimulated release of Ca2+ from intracellular stores, increase the inward Ca2+ current
(7Ca) through L-type channels and increase myofilament sensitivity. Therefore,
blockade of ET receptors should result in a reduction of the background inotropic
influence provided by endogenous ET-1 via reduced intracellular Ca2+ concentration
([Ca2+]i).
Baseline results from study 1 suggest that ET receptors are involved in regulating
basal contractile force as a significant reduction in peak active tension was observed
in the mixed antagonist group compared to the vehicle group. This observation also
suggests that endogenous ET-1 was released within the myocardium, perhaps by
stretch, consistent with other studies (Alvarez et al., 1999; van Wamel et al., 2001).
However, selective receptor blockade was not sufficient to produce a significant
reduction in isometric tension. ETA blockade was expected to reduce the response
more than ETB blockade due to the predominance of ETA receptors (80%) (Sherry,
2000) in rat myocardium. The fact that neither selective antagonist reduced
contraction alone suggests the possibility of receptor crosstalk, where one receptor
compensates when the other receptor is blocked, as previously demonstrated in
vascular tissue (Mickley et al., 1997).
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The positive inotropic responses to isoprenaline in study 1 were not significantly
altered by the bath presence of ET antagonists. However, a slight reduction of
responses in the mixed group suggests an interaction between [^-adrenergic receptors
and ET receptors in the normal rat heart.
In study 1, the positive inotropic response to exogenous ET-1 was not significantly
reduced by the presence of ET antagonists. Incubation with selective ET receptor
antagonists was not effective, only the mixed antagonist group tended towards a
reduced inotropic response compared to the vehicle group. However, large variations
in responses to exogenous ET-1 were observed, possibly due to receptor occupation
by endogenous ET-1 or to failure of the antagonists to exert their actions.
Responses to increasing concentration of extracellular Ca2+ in study 1 suggest that
both receptors, activated by endogenous ET-1, are involved in mediating positive
inotropism. Papillary muscles in the vehicle group produced a greater change in
twitch tension, compared to those achieved by the antagonist groups. This is
consistent with reports that ET receptors alter the force of contraction by influencing
Ca2+ handling (Touyz et al., 1996; Kelso et al., 1998; Pieske et al., 1999; Boixel et
al., 2001; Hong, 2002). However, an alternative explanation could be that the
antagonist had a direct negative inotropic effect, which could explain the reduction in
the response to Ca2+ without involving endogenous release of endothelin.
As discussed before, ET-1 does not influence the pacemaker current or the rate of
Ca2+ re-uptake by intracellular stores (Chapter 3, section 3.4.6), therefore as
expected, bath treatments had no effect on baseline contractile timing parameters
TPT or RT50. Isoprenaline induced a concentration-dependent decrease in TPT and
RT50, consistent with (3-adrenoceptor stimulation that were not altered by the
presence of ET antagonists. Similarly, ET antagonists had no effect on TPT and RT50
values in response to exogenous ET-1 or extracellular Ca2+.
Therefore, in summary, contractile behaviour of papillary muscles from control
animals in study 1 suggested that both ET receptors are involved in regulating
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positive inotropy. However, as these differences were not all significant, a second
study was undertaken to increase the sample size.
In contrast to study 1, data from study 2 demonstrated that baseline responses were
not affected in the presence of ET antagonists. Furthermore, responses to exogenous
ET-1 or increasing [Ca2+]i were not modified by any treatment. However, a
significant difference was reported between antagonist groups in response to
isoprenaline, suggesting a major disparity between the two studies, which could not
be fully explained by competitive antagonism or the complexity of receptor
interaction. In addition, inactivity of the receptor antagonists was also ruled out as
other in vitro experiments in our laboratory were achieving appropriate responses
using the same batch of drug. An alternative explanation may be that the drugs were
perhaps unable to penetrate the tissue, as suggested be the lack of modulation of
responses to ET-1 by any antagonist or combination.
Animals of study 1 and study 2 were age matched and weight matched yet different
contractile results were reported. One obvious difference between the two studies
was the time point, study 1 was carried out 6 months prior to study 2
(January/February and July/August respectively). Therefore, semi-quantitative RT-
PCR was carried out on the tissues from each study to establish if there was a
molecular basis for the functional differences.
ANP and ET system mRNA expression was significantly elevated in myocardial
samples from study 2 compared to study 1, despite the tissues being processed
concurrently, with the same starting quantity of total RNA. Changes in mRNA levels
do not necessarily reflect a change in protein level. However, in correlation with the
contractile changes, it is possible that the seasonal variation in ET system mRNA
expression was translated into protein. An increase in ET receptor level would have
increased competitive antagonism between endogenous ET-1, BQ123 and BQ788.
ppET-1 was also elevated in myocardial samples (and perhaps translated into mature
ET-1), therefore, stretch of papillary muscles in the preparatory stages may have
released more endogenous ET-1 to compete with antagonist for receptor binding
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sites. It is not fully understood how or why laboratory animals would undergo a
seasonal variation of the ET system as they are housed in climate-controlled
conditions with a 12 hour light-dark cycle. However, it is not altogether unlikely, as
other genes are known to vary in expression periodically (Kastrup & Christensen,
1984). Disparity between other factors many also have contributed to the differences
between groups. It may be that conditions during carriage to the animal house were
different, or that the stress levels experienced by the animals differed, possibly due to
the animal handler or other activity in the animal house at the time. An observation
that was noted was that the body weight of study group 2 increased more rapidly
while in the animal house awaiting use, however, this was not considered significant
at the time and was not investigated.
Therefore, in conclusion, data from this study suggests that ET receptors are possibly
involved in regulating the contractile responses to ET-1 in isolated cardiac tissues,
consistent with previous reports (Kasai et al., 1994; Beyer et al., 1996; Qi et al.,
2001). In addition, positive inotropic responses have also been shown to be mediated
by both receptors in healthy human atrial and ventricular myocardial strips (Opgaard
et al., 2000). Binding studies have confirmed the 80:20 distribution of ETa:ETb
receptors in rat ventricular myocardium (Qi et al., 2001). In contrast, studies using
isolated cardiomyocytes maintain that ETA receptors are solely responsible for
mediating the positive inotropic responses of ET-1 mainly through stimulation of
Ca2+ channels (Kelso et al., 2000). Others suggest that ET-1 exerts the positive
inotropic effect mainly through the activation of the ETA receptor-mediated Na+/H+
exchanger (Takeuchi et al., 2001). Seasonal variation of the ET system has not
previously been reported and it is not understood why it would undergo change. To
confirm these findings, functional and molecular investigations would have to be
repeated at one or both of the time points as well as performing binding studies on
myocardial samples. However, there was not enough time available to investigate
this phenomenon further during the period of this study. In addition, the use of
antagonists in this study has also exposed the complexity of ET receptor interactions,
with the possible indication of ET receptor crosstalk.
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Assessment of the LV end-systolic pressure-
dimension relationship by transthoracic 2-
dimensional echocardiography in rats
Chapter 5 - Results
5.1 Introduction
Characterisation of the basic mechanical properties of ventricular contractility has
typically been investigated at the myocardial level due to the complexity of assessing
the instantaneous pressure and volume of the intact ventricle. Regulation of cardiac
performance can be influenced by a variety of factors including heart rate, end-
diastolic volume, arterial blood pressure and inotropic background, therefore
evaluation of ventricular performance in vivo ideally requires load insensitive
measures of both systolic and diastolic properties.
The Frank-Starling mechanism describes the intrinsic ability of the heart to increase
contractile force in response to elevated end-diastolic volume. Using this principle,
studies in the '70s, using isolated canine hearts found that end-systolic values from
the pressure-volume relations, taken at isochronic points of heartbeats occurring
under different conditions had a linear relationship. The inclination of this straight
line was termed the end-systolic pressure-volume relationship (ESPVR) and
provided a good representation of ventricular contractility (Suga et al., 1973; Sagawa
et al., 1977). ESPVR is now regarded as an index of contractility and has been
validated as a fundamental description of systolic cardiac mechanics (Mahler et al.,
1975; Maughan et al., 1984).
Obstruction of the inferior vena cava by balloon catheter (Chen et al., 1997),
occlusion of the inferior vena cava (Sato et al., 1998; Nemoto et al., 2002) and aortic
banding (Bregagnollo et al., 2000) are experimental methods of adjusting the preload
or afterload respectively in humans and animal models. However, the desired
pressure changes can be achieved more accurately using vasoactive drugs and can
generate a family of curves that go in both directions from baseline. Altering venous
distribution with infusions of sodium nitroprusside (SNP) and phenylephrine (PE)
has previously been demonstrated in mice to provide a linear ESPVR (Williams et
al., 1998). Administration of SNP, a direct endothelium-dependent vasodilator,
reduces peripheral resistance, which reduces the afterload and shifts the pressure-
volume loop (PV loop) down and to the left via the Frank-Starling mechanism. SNP
is reported not to affect cardiac contractility (Crystal & Gurevicius, 1996). In
116
Chapter 5 - Results
contrast, PE elicits vasoconstriction via oci adrenoceptors, increasing the afterload to
shift the PV loop up and to the right, however, the effects of PE on myocardial
contractility remain ambiguous (Kronenberg et al., 1989; Strang & Moss, 1995).
Technological advancements such as the conductance catheter (Sato et al., 1998),
have provided a more accurate measurement of combined pressure and volume
values, while two-dimensional transthoracic echocardiography allows a less invasive,
repeatable assessment of LV dimension and volume. This requires dedicated and
expensive equipment. Small animal high frequency echocardiographic probes are
now available and are employed routinely to evaluate cardiac geometry and function
of rats and mice in vivo (Litwin et al., 1994; Williams et al., 1998). Relatively
inexpensive high fidelity pressure catheters are also available (Millar Instruments)
and combining these techniques allows the assessment of the ESPVR. The
assessment of ventricular contractility in vivo by this method has not previously been
reported in the coronary artery ligated rat.
In Chapter 4, myocardial responses to endothelin-1 (ET-1) and endothelin
antagonists failed to provide indication of a role for the ETA and ETb receptors in the
heart. In this study, by assessing cardiac contractility in vivo, following chronic
administration of the mixed ETa/b receptor antagonist bosentan, the role of
endogenous ET-1 may become clearer.
The aims of this chapter were to assess cardiac contractility in vivo by investigating
the end-diastolic pressure-dimension relationship of sham-operated and coronary
artery ligated rats using an echocardiographic approach. In normal animals,
following chronic treatment with the dual ETa/b receptor antagonist bosentan,
possible contribution of endogenous endothelin to cardiac contractility was
investigated.
5.2 Methods
Two-dimensional transthoracic echocardiography in conjunction with simultaneous
LV pressure data from a Millar catheter was used to construct pressure-dimension
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loops for the investigation of LV contractile function of (i) coronary artery ligated
(CAL) compared to sham-operated rats and (ii) rats chronically treated with the
ETa/b receptor antagonist bosentan compared to placebo.
5.2.1 The experimental groups
To evaluate the cardiac performance of failing and nonfailing animals, forty male
Wistar rats were chosen at random to undergo CAL or sham-operated surgery as
previously described in section 2.1.2. Subsequently, 12 weeks following surgery, the
animals were weighed, anaesthetised and instrumented for haemodynamic and
echocardiographic analysis (as described in section 2.1.3.2).
To investigate the influence of endogenous ET-1 on cardiac contractility, a group of
healthy male Wistar rats (450-550g, Charles River, U.K.) were randomly assigned to
either drug (dual ETa/b receptor antagonist bosentan, 100 mg-kg '-day"1, n=6) or
placebo group (n=6). Bosentan (25 mg-mf1, Acetlion Pharmaceuticals Ltd.,
Switzerland) was freshly prepared daily as a microsuspension in 5% gum arabic
(Sigma, see section 2.4) and administered by gastric gavage once daily for 7 days.
The bosentan dose (100 mg-kg^'-day"1) was chosen as the maximally effective dose
on the basis of in vivo pharmacological studies by Clozel et al., (1994). After a week
of treatment, animals were weighed, anaesthetised and haemodynamic and
echocardiographic studies were performed as described before in section 2.1.3.2.1.
Additionally, at the end of the PE infusion and a 20 minute stabilisation period, a
bolus of bosentan (30 mg-kg"1) was infused into the femoral vein of the placebo
animals to assess the acute effects of dual ETa/b blockade. The haemodynamic
effects were observed and echocardiographic images were captured 30 minutes after
acute bosentan administration.
Halothane was used for anaesthesia as an initial investigation showed that it
controlled and maintained the level of anaesthesia more adequately than Sagatal
(sodium pentobarbital). Initial studies also obtained the concentration and infusion
rates of SNP and PE, which achieved the desired change of pressure.
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5.2.2 Haemodynamic and echocardiographic data analysis
Haemodynamic parameters such as heart rate (HR), mean arterial pressure (MAP),
LV end-systolic (LVSP) and end-diastolic pressures (LVEDP), maximal rate of
pressure rise (dP/dtmax) or decline (dP/dtimn) were measured from the CHART data.
Echocardiographic images were acquired digitally (Diasus, Dynamic Imaging) using
a 10-22MHz probe. Files were transferred to a laptop computer (DELL, Inspiron
8000) and analysed in conjunction with the associated pressure data using Image
Analyser software (version 1.1, ©David Anderson, Dynamic Imaging).
Two-dimensional long-axis echocardiographic images were viewed simultaneously
with pressure data from the micromanometer. LV internal dimension values were
obtained by manually tracing around the LV borders for at least three cardiac cycles,
using Image Analyser software. LV pressure and internal dimension data was then
exported to a spreadsheet. Initial investigation showed that the waveforms were
slightly out of synchronicity (Figure 5.1). This was more obvious for cycles acquired
later in the acquisition period. Therefore LV internal dimension and pressure values
were averaged from the first cardiac cycle of at least three consecutive data sets of
similar pressure, captured under each condition. The mean values were represented
graphically by pressure-dimension loops (PD loops) using GraphPad Prism software
(Version 3.02, GraphPad Software, Inc.). In the human, LV pressure measurements
are typically combined with LV volume measurements to generate a pressure-
volume loop (PV loop). LV area can be converted to LV volume by combining the
value with the ventricular long-axis (area-length method, V=A2-8.0 / (3.0-7U-L); where
V, volume; A2, area; L, ventricular long-axis; St. John Sutton et al., 1996). However,
due to the geometric assumption of the derivative and border distortions in some
echo images, it was considered to be adding unnecessary error to the results and
therefore, PD, rather than PV loops were derived.
End-systole was defined as the smallest LV internal dimension (ESD) and end-
diastole defined as the onset portion of the upstroke of the PD loop, the largest LV
internal dimension (EDD). In each animal, the LV end-systolic pressure (ESP) and
ESD values were taken (the top left-hand corner of the PD loop) as co-ordinates (x,y)
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for each condition (baseline, SNP, PE). Simple linear regression was used to fit a line
through these points. The angular coefficient obtained, defined the value of the end-
systolic pressure-dimension relation (ESPDR) for each animal.
LV systolic (LVSD) and diastolic (LVDD) diameters and ESD and EDD were
measured at baseline with the aid of the Image Analyser software. LV fractional
shortening (SF) was calculated from the equation: (LVDD - LVSD)/LVDD x 100
and LV ejection fraction (EF) from: (EDD - ESD)/EDD x 100.
Drug infusion of SNP or PE to achieve a desired pressure change was kept to a
minimum volume by using concentrated solutions, low infusion rates and short
duration of infusions, however, some volume loading still occurred as a
consequence. To establish whether cardiac volume loading had a significant effect on
LV compliance, the inclination of the diastolic portion of each PD loop was assessed
and compared to the baseline value in each group.
Comparison between groups was performed by unpaired Student's t-test or one-way
analysis of variance followed by Bonferroni's multiple comparison test where
appropriate. A P value <0.05 was considered significant. Correlation analysis was
used to investigate the interaction between the parameters measured. The Pearson
correlation coefficient (r) was calculated for each simple linear regression, to
determine the closeness of the straight line to the points.
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Figure 5.1 Examples ofsuperimposed left ventricular pressure and dimension values
from (a) sham-operated and (b) CAL rats, illustrating the progressive loss of
synchronicity.
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5.3 Results
The results from the two studies, CAL versus sham and bosentan versus placebo are
reported separately in this section.
5.3.1 Effects of 12 week chronic CAL
5.3.1.1 Effects of CAL on mortality
Forty rats underwent CAL for the induction of CHF. Deaths occurring during or
immediately following surgery were 50% of the whole group, due mainly to
ischaemic arrhythmias. Only one CAL animal died in the 24hr period after surgery.
No early or late deaths of sham-operated animals occurred.
5.3.1.2 Baseline haemodynamic and echocardiographic measurements
At 12 weeks post-ligation, cardiac haemodynamic parameters were recorded in vivo
under general anaesthetic using a Millar catheter placed via the right carotid artery.
CAL animals with LVEDPs > lOmmHg were considered to have LV dysfunction
(LVD), a significant decrease in dPldtmaxIP and dP/dtmin/P was also observed,
however, no significant difference was obtained in HR, MAP, dP/drmax or dP/drmjn
between groups (Table 5.1). LV EF and SF were both significantly reduced in the
CAL group compared to the sham group (Table 5.1). In Figure 5.1 it can be seen that
the LV dimensions were greater in the infarcted rat compared to the sham-operated
rat. This individual CAL rat had a huge transmural infarct (68% of the free LV wall),
a large heart: body weight ratio (3.86 g-kg"1) and large internal dimensions (see
Figure 5.1, compare LV area of sham and CAL). However, not all CAL animals had
such substantial infarcts (31.9 ± 9.3%, n=5) or heart: body weight ratio (sham, 2.77 ±
0.13 g-kg"1, n=5; CAL, 3.02 ± 0.22 g-kg"1, n=6) and this was also reflected in the
averaged LV internal diastolic dimensions (Table 5.1).
There was no significant correlation between LVEDP, EF or SF in each group.
Although LVEDP values tended to be inversely associated the EF in the CAL group,
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where higher LVEDPs were associated with lower EF values, the condition of
linearity was not met (r = 0.15). A stronger correlation was observed between EF and
SF, where the greater the EF, the greater the associated SF but again, linearity was
not achieved for the relationship (sham, r = 0.54: CAE, r = 0.76). Additionally, a
trend was observed between EF and dP/dtmax where a greater dP/dfmax was associated
with a greater EF, however, correlation analysis was not significant (sham, r = 0.60:
CAL, r = 0.67).
5.3.1.3 The end-systolic pressure-dimension relationship of sham-
operated or CAL rats
All rats showed the expected shifts of PD loops for SNP or PE infusions. Figure 5.2
illustrates the PD loops obtained from individual animals under the different
afterload conditions. For each animal, simple linear regression was used to analyse
the end-systolic points of baseline, SNP and PE conditions to determine the ESPDR.
Obtaining the ESPDR index assumes the existence of linearity between the end-
systolic points used for determining each of the straight lines. In this study the
Pearson correlation coefficient values (r) ranged from 0.95 to 0.99 for sham and 0.90
to 0.99 for CAL respectively, indicating that the condition of linearity was met in
most cases (Table 5.2). Statistical analysis showed that ESPDR values were
significantly decreased in the CAL group compared to the sham group and that the y-
intercept had also significantly shifted, indicating a significant reduction in
contractility (Table 5.2). No significant association was identified between ESPDR,
LVEDP, EF or SF values.
Linear regression analysis was used to determine whether volume loading had an
effect on the SNP or PE PD loops. The slope of the diastolic portion of the SNP or
PE PD loops were not significantly different from the baseline loop in either the
sham or CAL group (sham: baseline, 0.46 ± 0.08 mmHg/mm2; SNP, 0.32 ± 0.07
mmHg/mm2; PE, 0.79 ± 0.04 mmHg/mm2; CAL: baseline, 0.48 ± 0.06 mmHg/mm2;
SNP, 0.19 ± 0.08 mmHg/mm2; PE, 0.74 ±0.16 mmHg/mm2), in the majority of
cases, the condition of linearity was met. Figure 5.3 illustrates this effect in an
individual sham and individual CAL animal.
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Table 5.1. Baseline haemodynamic and echocardiographic characteristics of sham-
operated and CAL animals indicating LV dysfunction.
Sham (n=5) CAL (n=8)
BodyWeight (g) 518 ±3.3 520 ± 27.6
Heart: body weight ratio (g-kg1) 2.77 + 0.13 3.02 ±0.22
HR (bpm) 316.4 ±6.4 321 ±11.4
MAP (mmHg) 78.9 ± 1.8 78.2 ±7.1
LVEDP (mmHg) 5.7 ±1.0 15.5 ± 1.5***
dP/dfmax (mmHg-ms"1) 3550.7 ± 182.8 3595.2 ±203.2
dP/dfmax/P 62.2 ±2.1 54.6 ± 1.88*
dP/dfmin (mmHg-ms"1) -4251.1 ±420.4 -3828.6 ±245.4
dP/dfmin/P -71.1 ±3.8 -55.7 ±2.8**
LV diastolic dimension (mm2) 80.3 ±8.6 82.93 ±4.8
LV Ejection Fraction (%) 31.1 ±2.6 22.4 ± 1.2**
LV Shortening Fraction (%) 18.7± 1.9 13.6 ± 1.3*
Values are means ± SEM, *P<0.05, **P<0.01, ***P<0.001 compared to sham. HR,
heart rate; MAP, mean arterial pressure; LVEDP, left ventricular end-diastolic
pressure; d/J/dfmax, maximal rate of LV pressure rise; dP/dfmjn, maximal rate of LV
pressure decline.
Table 5.2. Values of left ventricular end-systolic pressure-dimension relation
(ESPDR) obtained from sham and CAL rats. The y-intercept and the correlation
coefficients (r) of the straight lines determining the ESPDR are included.









6.01 -397.0 0.99 0.78 49.1 0.99
6.39 -221.1 0.95 3.18 -19.8 0.94
5.06 -135.4 0.99 2.17 -127.7 0.99
8.90 -371.5 0.99 1.73 -15.7 0.90
Mean 6.59 -281.25 - 1.96** -28.5* -
SEM 0.82 62.2 _ 0.50 36.6 -
*P<0.05, **P<0.01 compared to sham.
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Figure 5.2. Examples ofpressure-dimension loops from individual experiments (a)
sham-operated or (b) CAL rats under baseline conditions and during the infusion of
sodium nitroprusside (SNP, bottom left loop) or phenylephrine (PE, top right loop).
The end-systolic pressure-dimension relationship (ESPDR) is also indicatedfor each
animal.
125
Chapter 5 - Results
Figure 5.3. Examples of the diastolic phase of the pressure-dimension loops from (a)
sham and (b) CAL rats to illustrate that infusion volumes do not significantly alter
the diastolic slope compared to baseline. Linear correlation analysis of the diastolic
portion ofeach PD loop is represented, where: Dl, baseline; D2, SNP; D3, PE.
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5.3.2 Effects of chronic administration of bosentan
5.3.2.1 Baseline haemodynamic and echocardiographic measurements
Haemodynamic parameters were not significantly altered in response to 1 week
chronic treatment with the dual ETa/b receptor antagonist bosentan in normal animals
(Table 5.3). No change was observed in the basal HR, MAP, LVEDP or differential
functions of the pressure waveform. LV EF and SF were not significantly different
between groups (Table 5.3). Pressure and dimension averages were calculated as
before from at least three first cardiac cycles of multiple data sets captured under
each preload condition. No significant difference was observed in LV internal
diastolic dimensions between groups (Table 5.3).
5.3.2.2 End-systolic pressure-dimension relationship of placebo or
bosentan treated rats
Infusions of SNP and PE produced the expected shifts of the PD loop in each animal,
however, no significant change occurred in the ESPDR as a result of chronic
bosentan administration (Figure 5.4). The angular coefficient and the y-intercept
values for each group were not significantly altered (Table 5.4). The condition of
linearity was met in the majority of cases and the correlation coefficient values (r)
ranged from 0.78 to 0.99 for the placebo group and 0.95 to 0.99 for the bosentan
treated animals (Table 5.4). In addition, it was observed that the ESPDR values for
healthy animals treated with placebo or bosentan differed significantly from the
sham-operated group of the previous study (sham 6.59 ± 0.82mmHg/mm ; placebo,
2.93 ± 0.29 mmHg/mm2, P<0.01 compared to sham; bosentan, 2.88 ±
0.19mmHg/mm2, P<0.001 compared to sham).
The diastolic portions of the SNP and PE loops were compared to baseline using
simple linear regression analysis. The angular coefficient of the SNP or PE diastolic
parts were not significantly different from baseline for the placebo or the bosentan
group (placebo: baseline, 0.67 ± 0.21mmHg/mm2; SNP, 0.11 ± 0.13mmHg/mm2; PE,
0.84 ± 0.16mmHg/mm2; bosentan: baseline, 0.64 ± 0.08mmHg/mm2; SNP, 0.33 ±
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0.15mmHg/mm2; PE, 1.07 ± 0.34mmHg/mm2). Linearity was obtained in the
majority of cases.
5.3.2.3 Effect of acute administration of bosentan
After a stabilisation period following the ESPDR investigation, a bolus of the ETa/b
antagonist bosentan (30 mg-kg"1, i.v.) was infused into placebo animals. Over the
subsequent 40-minute period, a triphasic change in LV pressure was observed. Acute
administration of bosentan resulted in a significant decrease in peak LVSP (117.4 ±
6.2 to 99.4 ± 3.5mmHg, n=6, P<0.05) 10 minutes post-infusion. Subsequently, 16-18
minutes after infusion, the pressure increased (110.1 ± 1.9mmHg), before reducing
again, 30 minutes post-infusion (95.9 ± 4.7mmHg, n=6, P<0.05 compared to pre
infusion). The systolic pressure continued to fall progressively thereafter. MAP was
significantly reduced compared to pre-infusion levels (95.99 ± 4.48 to 61.30 ± 2.23
mmHg, n=6, P<0.001). The PD loops plotted from data captured 32 - 36 minutes
post-infusion were shifted down and to the left, with a similar value for the ESPDR
slope to that obtained with SNP (Figure 5.4).
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Table 5.3. The effect of chronic administration of bosentan, a dual ETa/b antagonist,
on baseline haemodynamic and echocardiographic parameters.
Placebo (n=6) Bosentan (n=6)
Body Weight (g) 508 ± 12 484 ± 17
Heart: body weight ratio (g-kg"1) 2.78 ±0.09 2.68 ±0.10
HR (bpm) 359.9 ± 15.9 351.4 ±15.8
MAP (mmHg) 97.0 ±3.6 94.7 ± 2.7
LVEDP (mmHg) 4.6 ±0.9 5.1 ±1.3
dP/dfmax (mmHg/ms) 4040.3 ± 448.8 4124.3 ±297.4
dP/dfmax/P 70.5 ±5.3 66.4 ±3.2
dP/dfmjn (mmHg/ms) -4304.0 ± 495.8 -4604.7 ± 484.2
dP/dfmin/P -74.3 ±7.6 -72.3 ±5.9
LV diastolic dimension (mm2) 78.1 ±4.2 72.3 ±5.1
LV Ejection Fraction (%) 34.3 ± 1.8 28.9 ±2.0
LV Shortening Fraction (%) 28.6 ±2.3 23.3 ± 1.7
Values are means ± SEM. HR, heart rate; MAP, mean arterial pressure; LVEDP, left
ventricular end-diastolic pressure; dP/d/max, maximal rate of LV pressure rise;
dP/dtmm, maximal rate of LV pressure decline.
Table 5.4. Left ventricular end-systolic pressure-dimension relationship (ESPDR)
values obtained from placebo and bosentan treated rats. The y-intercept and the
correlation coefficient (r) values of the ESPDR straight lines are included.









1.77 7.6 0.99 2.80 -53.4 0.99
3.75 -63.8 0.99 3.61 -66.6 0.97
2.84 -63.5 0.98 2.38 -42.1 0.99
2.56 -51.3 0.78 3.25 -63.7 0.99
3.26 -75.2 0.97 2.51 -67.7 0.91
3.39 -144.6 0.89 2.71 -80.5 0.95
Mean 2.93 -65.1 - 2.88 -62.3 -
SEM 0.29 19.9 - 0.19 5.37 -
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Figure 5.4. Examples of the pressure-dimension loops from individual experiments
(a) placebo or (b) chronic effects of bosentan treatment, under baseline conditions
and during the infusion of sodium nitroprusside (SNP, bottom left loop) or
phenylephrine (PE, top right loop) in control rats. The end-systolic pressure-
dimension relationship (ESPDR) is indicated for each animal. The effect of acute
bosentan administration on the PD loop ofthe placebo animal is also included.
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5.4 Discussion
The purpose of this study was to assess the cardiac contractility of rats in vivo using
the ESPDR index of contractile state. Ventricular contractility was evaluated in rats
12 weeks following CAL surgery and compared with sham-operated animals to
determine the effect of experimental heart failure. In addition, normal rats were given
bosentan or placebo for one week to examine the contribution of endogenous ET-1 to
ventricular contractility.
5.4.1 Pressure-dimension relation in infarcted rat hearts
As previously described, deterioration of haemodynamic parameters are
characteristic of LV dysfunction in the chronically infarcted rat heart (Pfeffer et al.,
1979). In this study, a significant elevation of LVEDP and reduced differential
functions of the LV pressure waveform were observed in rats 12 weeks following
CAL surgery, indicating myocardial dysfunction. These findings were supported by a
significant reduction in LV EL and SL as evidenced by echocardiographic
assessment of LV geometry (Litwin et al., 1994). All groups showed the expected
shift of the PD loops for SNP and PE infusions, indicating that different afterload
states were achieved. The main findings of this investigation were that ESPDR
values were significantly reduced in CAL compared to sham-operated rats, further
substantiating the reduction of ventricular contractility.
Histological assessment of hearts showed that not all CAL rats had developed
transmural scars, indicating variability in the degree of dysfunction sustained.
However, within the CAL group, linear correlation analysis between parameters was
inconsistent, as the rats with larger infarcts did not necessarily display the highest
LVEDP or the lowest EL, SL or ESPDR values. Therefore, an accurate interpretation
of the ESPDR as an index of cardiac contractility in vivo in heart failure was
restricted as rats exhibited varying degrees of LV dysfunction. Using a larger sample
size and imposing a condition which would exclude rats with infarcts under a
specified size, as many studies do (Bauersachs et al., 2000), may provide a more
accurate correlation.
131
Chapter 5 - Results
5.4.2 Effects of chronic administration of bosentan on cardiac
haemodynamics
ET-1 is the most potent vasoconstrictor substance known and contributes to the
increased peripheral resistance in humans and rats with chronic cardiac dysfunction
by inducing peripheral vasoconstriction (Kiowski et al., 1995; Teerlink et al., 1994).
ET-1 has also previously been shown to exert positive inotropic effects in isolated
cardiac tissue preparations (see Chapter 3) but isolated heart and in vivo studies have
failed to provide consistent evidence for the role of ET-1 in regulating myocardial
function. In this study the ETa/b receptor antagonist bosentan was administered to
healthy adult male rats for one week to evaluate the role of endogenous ET in normal
cardiac function. As ET-1 is known for its potent vasoconstrictor properties, it would
be logical to assume that dual receptor blockade would induce dilation. However, in
the current chronic study, treatment did not affect any of the haemodynamic
parameters measured such as MAP, LVSP or dP/dtmax. Similar responses have been
reported in previous studies where sham-operated animals were administered
bosentan for 8 weeks (Fraccarollo et al., 1997) or 11 weeks (Bauersachs et al., 2000)
following surgery. However, bosentan treatment was reported to affect the
parameters of the infarcted animals in both studies (Fraccarollo et al., 1997;
Bauersachs et al., 2000), indicating a role for ET-1 in pathological conditions.
Echocardiographic assessment of the LV showed that there was no difference
between treatment groups for the EF or SF, suggesting that ventricular function had
not been altered by ET receptor blockade. Baseline PD loops were not significantly
different between groups, suggesting that bosentan had not altered the peripheral
resistance to change the afterload. Infusion of SNP and PE produced the expected PD
loop shifts in both placebo and bosentan groups. The condition of linearity was met
for the ESPDR, however, ESPDR values were not significantly different between
groups and neither was the y-intercept value altered, suggesting that contractility was
unchanged between groups. These findings suggest that endogenous ET-1 does not
play a central role in regulating cardiac function in vivo in the healthy rat. Lack of
responses in normal animals, as evidenced by the unaltered contractile parameters, is
possibly due in part to the reduction of nitric oxide via endothelial ETB receptor
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blockade. However, the most likely explanation is that other mechanisms, such as the
renin aldosterone angiotensin system, independent of ET-1 and ET receptors,
become involved and compensate for the influence of ET-1, therefore maintaining
normal haemodynamic pressures to conserve contractile function.
5.4.3 Effects of acute administration of bosentan on cardiac
haemodynamics
Acute administration of bosentan induced a triphasic blood pressure response,
resulting in a significant reduction of systolic and MAP, 30 minutes after infusion.
The initial reduction (10 minutes post-infusion) was due to blockade of the
constrictor ETa/b receptors, lowering peripheral resistance. This was then followed
(16-18 minutes post-infusion) by a rise in pressure, possibly induced by an increase
of plasma ET-1 levels, resulting from inhibition of ETb receptor clearance and
therefore, marked increase in competition for binding sites. The final reduction of
LVSP indicated the ability of the acute administration of antagonist to exert its
effects. Short-term reduction of MAP in response to acute administration of bosentan
has previously been demonstrated in sham-operated rats using telemetry (Teerlink et
al., 1994). Two weeks after surgery, CAL and sham-operated rats with telemetry
implants were administered a dose of either placebo or bosentan (100 mg-kg"1) and
haemodynamics responses were recorded for 48 hours thereafter. The antagonist
caused a reduction ofMAP in the sham group for several hours after infusion, before
returning to normal levels (Teerlink et al., 1994). The triphasic response observed in
the current study was not reported by Teerlink et al. (1994) because the telemetry
data was averaged hourly, however, the response does support the current
observations of the acute study.
PD loops captured 30 minutes after acute infusion of bosentan were shifted down and
to the left, similar to those achieved by SNP, indicating a reduction of afterload. In
most cases, the end-systolic points of the bosentan PD loops were close to the
straight line of the ESPDR, suggesting that cardiac contractility was not altered by
acute ETa/b receptor blockade. Direct assessment of the ESPDR by infusion of SNP
and PE in the presence of acute bosentan was not possible due to the extended
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duration of the experiment, therefore the cardiac responses to acute bosentan were
not confirmed. However, a recent in vitro study demonstrated that endogenous ET-1
contributes to the Frank-Starling mechanism in isolated perfused hearts from
hypertensive double transgenic rats (harbouring human renin and angiotensinogen
genes) but not normotensive nontransgenic rats (Piuhola et al., 2003). The study
observed that bosentan impaired the Frank-Starling response in the hypertrophied rat
hearts by affecting the systolic performance. Absence of this response in the
normotensive nontransgenic animals agrees with the findings from the current
investigation, implying that endogenous ET-1 only contributes to the maintenance of
cardiac function in pathological conditions and indicating that the acute effects were
due to the influence of ET-1 on the peripheral vasculature.
5.4.4 Effects ofpericardiectomy on cardiac performance
Previous studies have demonstrated that removal of the pericardium in experimental
models results in an increase of the maximal oxygen consumption, the maximal
cardiac output and the maximal stroke volume, without changing the heart rate
(Stray-Gundersen et al., 1986; Hammond et al., 1992). Comparison of the two study
groups revealed that the ESPDR values were significantly greater for the sham-
operated group compared to the placebo or bosentan groups, which were investigated
in healthy animals. The effects of pericardiectomy are the most likely explanation
why the contractility of the sham group was greater than that of healthy animals after
placebo of bosentan treatment. In addition, the effects of pericardiectomy are also
associated with increased LV end-diastolic dimension and an estimated increase in
end-diastolic volume (Hammond et al., 1992), which may explain why significant
differences were not observed between the CAL and sham-operated groups of the
current study.
5.4.5 Basal ET-1 activity in the normal heart
Positron emission tomography (PET) is a sensitive technique that has the power to
quantify receptor-bound radioligands in vivo. In a recent study, the distribution of a
radiolabeled dual ETa/b antagonist (nC-L-753,037) was studied for its in vivo
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kinetics, biodistribution and ET receptor binding characteristics in mice (Aleksic et
al., 2001). Results from the kinetic studies showed highest tracer uptake 5 minutes
after injection in the liver (25%), moderate uptake levels in the kidneys (18.7%) and
lungs (15.2%) and lowest levels in the heart (5.6%). However, the initial high levels
in the liver, lungs and kidneys were followed by rapid washout over the next 10
minutes and a very slow clearance during the study period (2 hours after injection).
In contrast, the level of radioactivity in the heart remained constant during the
observation period, indicating that cardiac ET receptors exhibit unique binding
characteristic in vivo. Johnstrom et al. (2002) reported a different pattern of binding
characteristics in the rat using radiolabelled ET-1 (18F-ET-1), where high levels of
uptake were found in the lungs and kidney and moderate levels of uptake in the liver.
In contrast with the Aleksic et al. (2001) study, distribution of binding was not
reported in the heart (Johnstrom et al., 2002), suggesting that binding was either
below detection level or that the tracer was unable to bind to cardiac receptors.
Considering the pharmacology and the other literature (Piuhola et al., 2003), it is
possible that high levels of ET-1 are not achieved in the normal heart and this
concurs with the current findings, which suggest that endogenous ET-1 does not have
a central role in regulating the function of the healthy myocardium.
5.4.6 Study limitations
Echocardiography has emerged as a useful noninvasive tool for the investigation of
cardiovascular research in humans, rats and mice and has previously been shown to
reliably evaluate LV dimensions in the intact heart (Litwin et al., 1994; Williams et
al., 1998; Chen et al., 1997; Urheim et al., 2002). However, the evaluation of
ventricular dimensions critically depends on image quality to correctly define the
endocardial borders and it is accepted that echocardiographic images are harder to
obtain in animals undergoing cardiac catheterisation due to incomplete border
detection, particularly around the mitral-annular plane. This was one of the reasons
why a number of the animals were excluded from the present study.
Automated digital echocardiography quantification (DEQ) has been carried out on
cardiac patients and compared with simultaneous data from a conductance catheter to
135
Chapter 5 - Results
evaluate the accuracy of the technique (Chen et al., 1997). The study concluded that
generally the two methods correlated well when the data was used to construct
steady-state PV-loops but that stable DEQ images were more difficult to define
during extreme loading transients. This is possibly due to viscoelastic myocardial
accommodations as previous studies have identified that marked pressure
(LVSP>200mmHg) or volume (LVEDP>25mmHg) overloads are out-with the
physiological limits and result in deviations of LV PV relations in dogs (Le-Winter et
al., 1979; Way et al., 1986). However, assessment of ESPDR behaviour during
moderate afterload elevations in isolated (Maughan et al., 1984) or in situ (Spratt et
al., 1987; Bregagnollo et al., 2000) canine hearts, have concluded that the linearity of
this contractility index does not significantly change during moderate pressure
elevations. In the current study, variations in cardiac load did not reach the values
reported (Le-Winter et al., 1979) and therefore were not considered capable of
triggering significant changes in the PD relations.
One of the major concerns associated with using an infusion method to alter afterload
is the risk of cardiac volume loading, which is known to affect ventricular
compliance. Previous studies have shown an increased gradient of the diastolic
portion of the curve during volume loading with saline (Urheim et al. 2002). In the
current study, diastolic inclinations were not significantly different between
conditions, indicating that volume loading by i.v. infusion was not significantly
evident in the SNP or PE protocols. This suggests that minimal changes in blood
volume were accommodated and did not influence intrinsic cardiac inotropism to
modify the ESPDR values. These findings indicate that the infusion method was
suitable for the purposes of this study and confirm, within reasonable limits of error,
that the contractility index provided a reliable measurement of ventricular
contractility.
In conclusion, it has been demonstrated that echocardiographic assessment of the
ESPDR during alteration of cardiac afterload is a reliable method of measuring
cardiac contractility in vivo in the rat. Furthermore, reduced cardiac function of CAL
rats as evidenced by elevated LVEDP, reduced EF, SF and differential waveforms of
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LV pressure, were substantiated by the significant reduction of the ESPDR. In
addition, in accordance with recent data, it has been shown that endogenous ET-1
does not appear to play a central role in cardiac contractility.
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Differential gene expression across the LV wall
in failing human hearts
Chapter 6 - Results
6.1 Introduction
Plasma levels of the vasoactive peptide endothelin-1 (ET-1) are found to be
increased in patients with heart failure, irrespective of aetiology (McMurray et al.,
1992) and correlate with prognosis and disease progression (Pacher et al., 1996).
These observations suggest a pathophysiological role for the ET system in chronic
heart failure. However, only scarce information is available on the activity and
modifications of the cardiac ET-1 system in heart failure. Results from previous
investigations have been inconsistent, possibly due to the type or severity of heart
failure studied, the combination of treatments prior to surgery, or the portion of tissue
investigated. ET-1 binding studies carried out by Ponicke et al. (1998) confirmed the
co-existence of ETA and ETb receptors in both failing and non-failing human left
ventricular (LV) myocardium and showed that the density of the ETA receptor had
the tendency to be increased in failing compared to non-failing human myocardial
tissue. Similarly, Pieske et al. (1999) indicated an increase of ETA receptors in LV
tissue from end-stage failing hearts (dilated cardiomyopathy, DCM), with no change
in ETb receptor density. In contrast, Zolk et al. (1999) reported no significant
difference of ETA receptor mRNA or ET-1 mRNA in DCM tissue compared to non-
failing LV tissue. However, the study did observe a significant decrease of ETB
receptor mRNA in DCM samples compared to non-failing, possibly explaining the
elevated plasma ET-1 levels via reduced clearance.
The fundamental principles underlying ventricular mechanics in both physiological
and pathological states requires an understanding of the relationship between the
stresses and deformations acting on the muscle comprising the wall. In the human
heart, wall stress is highest in the endocardial layer, decreasing towards the
epicardium and this is partly attributed to the varying elastic stiffness of the wall
material (Yin 1981). In addition, in diseases characterised by abnormal loading of the
heart, normalisation of wall stress is thought to be the feedback signal that governs
the rate and extent of ventricular hypertrophy. To date, transmural expression of the
ET system in heart failure has not been assessed and as discussed above, no clear or
consistent pattern of ET system expression in heart failure has emerged. Therefore,
investigating different LV portions of hearts exhibiting different types of heart failure
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may lead to clarification of the pathological alterations and may reveal whether ET
system expression relates to wall stress.
Part of the force responsible for restoring resting length after contraction is provided
by the elastic properties of titin (Helmes et al., 1996). Titin, (also known as
connectin), is the third most abundant sarcomeric filament system and is an integral
part of the myofibril (see section 1.1.2). It is the largest protein known to date (3-
4MDa) and is composed of over 27,000 amino acids (Labeit & Kolmerer, 1995).
Single titin molecules extend across half the sarcomere, with their amino- and
carboxy-termini crossing the Z-line and M-line respectively. The polypeptide is
extensively modular and appears as a rod with beaded substructure, this is because it
is mainly composed of fibronectin type 3 (FN3) and immunoglobulin (Ig) repeats,
which fold into globular domains (Labeit et al., 1992). The molecular segment
confined to the I-band is a specialised segment that contains multiple Ig-like domains
and a unique sequence rich in proline, glutamate, valine and lysine residues termed
the PEVK segment (.Figure 1.1). These domains reversibly unfold and can be viewed
as 2 springs connected in series. The I-band of titin is functionally elastic and is
responsible for passive tension generation upon stretch of non-activated striated
muscle (Erickson, 1997; Linke & Granzier, 1998). In contrast, the titin segment that
spans the A-band is functionally inelastic under physiological conditions. This is due
to its strong lateral association with the myosin filaments (Itoh et al., 1988; Labeit et
al., 1992; Soteriou et al., 1993).
Different mobilities of skeletal and cardiac titins on SDS-gels have identified that
titin is expressed in different isoforms in various tissues. These occur as a result of a
series of alternative splicing events of I-band titin in different muscle (Labeit &
Kolmerer, 1995). Differentially expressed Ig-repeats and PEVK domains in skeletal
muscle titin produce a segment termed the N2A region, whereas cardiac muscle titin
coexpresses two distinct sequenced variants, N2A and N2B, at sarcomere level
(Labeit & Kolmerer, 1995; Linke et al., 1996) (Figure 1.1). Labeit et al. (1997)
previously suggested that expression of different tandem I-g segment lengths in
various muscle types might be important for setting the physiological slack length,
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whereas differential splicing of the PEVK-rich sequences may control the
characteristic stiffness of relaxed muscle tissue. Indeed, N2B titin is shorter and has
stiffer elastic properties than N2BA titin. The N2B region contains several Ig
domains and sequence insertions unique to this isoform, while in comparison, N2BA
titin, which contains both N2B and N2A elements, is larger and more compliant. It
contains a much longer PEVK segment than N2B titin (Freiburg et al., 2000) and
contains an additional tandem Ig segment. Investigation of sarcomere length-force
relations has identified that the stiffness of the myocardium is linked to the ratio of
these titin domains and recent studies have also demonstrated that the ratio of cardiac
isoforms differs between species (Cazorla et al., 2000). In addition, Cazorla et al.
(2000) also indicated that the expression ratio differed between the different layers of
the porcine LV wall. Therefore, normal cardiac function and integrity of the
myofibril is influenced by the extensibility of titin molecules via isoform expression.
Previous studies have demonstrated that major cardiomyocyte cytoskeletal proteins
including titin, p-tubulin and desmin are differently regulated in cardiac hypertrophy
(Collins et al., 1996). Immunohistochemistry studies initially reported that titin was
reduced and frequently disorganised in diseased human cardiac tissue (Hein et al.,
1994). Morano et al. (1994) also concluded that titin was reduced in the failing
human myocardium but identified the expression of an additional protein band of
lower molecular weight, now recognised as N2B titin. Therefore, it appears likely
that instead of titin loss there is a switch in the isoform ratio, altered towards the
stiffer element in pathological conditions. Abnormalities of titin expression in heart
failure may be especially important because titin significantly influences sarcomeric
elastic behaviour and is also necessary as a template for the organisation of newly
synthesised myosin and actin filaments. To date, expression of titin isoforms has not
been investigated across the LV wall. Transmural assessment may therefore establish
whether the isoforms correlate to increased endocardial wall stress in failing human
hearts.
Gelsolin is a cardiodependent actin filament severing protein that can control many
aspects of actin organisation, such as severing the fast growing end of each actin
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filament and nucleating actin assembly (Yin, 1987). The importance of gelsolin
regulation has previously been studied in heart failure, where it is likely that
increased gelsolin expression may contribute to the perturbation of the thin filament
organisation and altered calcium channel regulation (Lader et al., 1999). However, it
has not previously been investigated in relation to transmural wall stress.
In the normal adult heart, brain natriuretic peptide (BNP) is expressed at low levels
in both the atrium and ventricles. However, in the diseased state it is highly
upregulated and plasma BNP levels have been shown to correlate with LV
dysfunction (Muders et al., 1997; McDonagh et al., 1998). In addition, mRNA
expression of this gene is often used as an index for ventricular dysfunction in CHF.
Atrial natriuretic peptide (ANP) is also a well-established marker for the early
diagnosis of LV dysfunction. It is primarily produced by atrial cardiac myocytes and
is also upregulated by chronic haemodynamic overload. In this study BNP was
chosen as it is more sensitive to stretch than ANP and different amounts of stretch
reflect the degree of ventricular overload and stress (Mantymaa et al., 1993). In
addition, BNP was incorporated into this study as a reference gene because a
previous investigation demonstrated a transmural difference in mRNA expression,
where it was highly upregulated, predominately in the endocardium of the failing
human ventricle (Prestle et al., 1999).
It is now known that the expression of multiple classes of genes are altered in human
heart failure, some of which provide compensatory mechanisms to sustain cardiac
function and some which contribute to the development of heart failure (Yang et al.,
2000). However, few studies have investigated the transmural expression of these
genes. The aim of this study was to investigate whether there was a difference in
gene expression of the ET system and cytoskeletal proteins across the wall of human
failing LV myocardium and to identify if these alterations related to transmural
differences in wall stress.
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6.2 Methods
Myocardial tissue was obtained from the Scottish Cardiac Transplant unit between
October 1997 and February 1998. Left ventricular (LV) epicardial (epi) and
endocardial (endo) samples of explanted hearts were used from 6 patients with end-
stage heart failure undergoing cardiac transplantation. Endocardial samples were
obtained from trabeculated regions of muscle lying within the ventricular cavity.
Epicardial samples were dissected from a region of the ventricular wall immediately
under the visceral pericardial fat. Samples were immediately frozen in liquid
nitrogen and stored at -70°C until use. Age, aetiology, haemodynamic data and
medication are listed in Table 6.1.
Total mRNA isolation and synthesis of first strand cDNA were carried out as
described in section 2.3. Gene specific primers were designed as previously
discussed for BNP, prepro ET-1 (ppET-1), the ETa receptor, the ETB receptor and
gelsolin (section 2.3.5.2). Titin N2BA and N2B each contain unique sequences
within the I band region (Freiburg et al., 2000) and primers were specifically
designed to amplify products within these sequences for the respective isoforms
(section 2.3.5.2). Primers for GAPDH were also designed to serve as an external
control.
Template cDNA was amplified using polymerase chain reaction (PCR) (see section
2.3.5.4) and myocardial mRNA levels of BNP, ppET-1, ETA receptor, ETb receptor,
gelsolin, titin N2BA and titin N2B were quantified by densitometry and expressed as
a ratio to GAPDH (section 2.3.6). Two-fold serial dilutions of cDNA template were
prepared and amplified by PCR to verify the changes observed in ratios of gene-of-
interest:GAPDH (section 2.3.5.5).
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Table 6.1. Clinical and haemodynamic data ofpatients with heartfailure







Subject 1 M 59 HCM 28 14 46/25 na Ca, Di, Fr, As,
Be
Subject 2 M 56 IHD 26 12 40/23 2.3 Li, Bu, Wa, Di
Subject 3 M 49 IHD 30 4 52/31 na Di, Wa, Li, Am,
Bu, Lo, Is
Subject 4 M 46 IDCM 38 11 55/36 na Li, Bu, Wa, Di,
Be
Subject 5 M 39 ConHD 27 12 33/21 1.68 Ra, Fr, Di
Subject 6 M 53 IDCM 28 15 50/30 1.1 Ca, Di, Be, Fr,
As
HCM indicates hypertrophic cardiomyopathy; IHD, ischaemic heart disease; IDCM,
idiopathic dilated cardiomyopathy; ConHD, congenital heart disease; PCWP,
pulmonary capillary wedge pressure (mmHg); EF, ejection fraction; PAP, pulmonary
artery pressure (mmHg); CO, cardiac output (L-min1); Ca, captopril; Di, digoxin, Fr,
frusemide; As, aspirin; Be, bendrofluazide; Li, Lisinopril; Bu, bumetanide; Wa,
warfarin; Am, amiodarone; Lo, omeprazole; Is, isosorbide mononitrate; Ra, ramipril;
na, not available.
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6.3 Results
Transmural gene expression of the ET system, cytoskeletal proteins and the
hypertrophic marker BNP were evaluated in failing human LV myocardium using a
semi-quantitative RT-PCR method. Figure 6.1 shows scanned agarose gels of the
genes-of-interest, BNP, ppET-1, the ETA receptor, the ETb receptor, gelsolin, N2A
titin and N2B titin. mRNA levels of the constitutively expressed enzyme GAPDH
were also examined to quantify the gene-of-interest: GAPDH ratio.
It can be seen in Figure 6.1 that the abundance of GAPDH is relatively uniform
irrespective of aetiology or whether the band represents an epi or endocardial sample.
Expression of GAPDH mRNA following amplification of serial dilutions of template
also provided similar densitometric results between groups (Figure 6.2), confirming
that this semi-quantitative RT-PCR method was reliable.
In contrast to GAPDH mRNA expression, the gel illustrating cardiac BNP mRNA
tended to have brighter bands most consistently for endocardial samples (Figure 6.1).
This observation was confirmed by examination of the BNP: GAPDH ratio from
end-stage heart failure tissue (Figure 6.3), however, different aetiologies displayed
different degrees of expression (Figure 6.4). BNP mRNA levels across the wall were
not significantly different in tissues from subject 1 (HCM), however all other
subjects demonstrated BNP mRNA to be most abundant in the endocardium.
Subjects 4 and 6, the IDCM pathology, exhibited a large endocardial expression of
BNP mRNA (~4-fold greater) with respect to the epicardial expression (Figure 6.4)
This was also evidenced by the serial dilution curves for this aetiology (Figure 6.5).
ppET-1 mRNA: GAPDH mRNA ratio exhibited a similar distribution to that of the
BNP: GAPDH ratio, where the majority of cases showed that ppET-1: GAPDH ratio
was most abundant in the endocardial tissue samples of hearts from patients with
end-stage heart failure (Figures 6.3 and 6.4).
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ppET-1 290bp ETA receptor 431 bp
ETb receptor 627bp Gelsolin 329bp
Figure 6.1. Representative agarose gels showing transmural mRNA levels of
GAPDH, BNP, ppET-1, ETa receptor, ETb receptor, gelsolin, N2A titin andN2B titin
in epicardium (epi) and endocardium (endo) of the left ventricular free wall from 6
end-stagefailing hearts.
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Figure 6.2. The densitometric values of transmural mRNA expression of the
ubiquitous housekeeping gene GAPDH following 2-fold serial dilution of cDNA
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Figure 6.3. The ratio of genes-of-interest:GAPDH mRNA in epi- and endocardial
samples from explanted end-stage heart failure human myocardium (n=6),
f P=0.06, f P=0.07, * P=0.05.
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Figure 6.4. The transmural difference ofmRNA expression levels ofBNP, ppET-1,
the ETa receptor, the ETb receptor, gelsolin and the titin N2A and N2B isoforms,
normalisedper GAPDH mRNA level in epi- and endocardial samples of the LVwall
of6 patients (a-f) with end-stagefailing heartfailure ofdifferent aetiologies.
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Figure 6.5. Densitometric transmural expression of brain natriuretic peptide (BNP)
mRNA following 2-fold serial dilution ofcDNA template from hearts ofpatients with
idiopathic dilated cardiomyopathy (IDCM) (n=2).
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ETa receptor mRNA expression as a ratio to GAPDH mRNA was more varied
although it tended to be higher in the endocardial samples of LV myocardium from
patients with end-stage heart failure (Figures 6.3). This was clear in subjects 1
(HCM), 3 (IHD), 4 (IDCM) and 5 (ConHD) (Figure 6.4), however, in subjects 2
(IHD) and 6 (IDCM), the ETa: GAPDH mRNA ratio was greater in the epicardium
and this was also identified in the serial dilution curves (Figure 6.6). These patients
did not display the same aetiology but were of a similar age and had similar
haemodynamics (Table 6.1). The ETb receptor: GAPDH mRNA ratio also had the
tendency to be higher in the endocardial layer, rather than the epicardial layer but no
major pattern emerged (.Figures 6.3 and 6.4).
The gelsolin: GAPDH mRNA ratio was consistently more abundant in the
endocardial sample of each subject compared to the epicardial sample (Figure 6.4).
This difference was also reflected in the serial dilution of the template cDNA (Figure
6.7). Both titin N2A: GAPDH and titin N2B: GAPDH mRNA ratios follow a similar
distribution pattern. Most subjects exhibited a greater titin: GAPDH ratio in the
endocardial samples, while subjects 2 (IHD) and 6 (IDCM) were the exception,
expressing abundance in the epicardium (Figure 6.4). The two different expression
patterns of the titin isofoms did not reflect the aetiology of the subjects but did match
that of the ETa: GAPDH mRNA pattern (Figure 6.4). Serial dilution curves also
confirmed the tendency towards abundance in these samples (Figure 6.8).
Figure 6.9 shows summary diagrams of the two different patterns of the ETa
receptor, titin N2A and N2B: GAPDH mRNA expression ratios. Subjects 1, 3, 4 and
5 expressed a greater ratio in the endocardial samples while subjects 2 and 6
expressed ETA, titin N2A and titin N2B: GAPDH mRNA to be greater in the
epicardium of hearts from patients with end-stage heart failure. These findings were
not related to aetiology.
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Figure 6.6. The densitometric values of transmural mRNA expression of the ETa
receptor following 2-fold serial dilution of the cDNA template from patients with
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Figure 6.7. Densitometric values of transmural gelsolin mRNA expression following
2-fold serial dilution of the template cDNA from patients with end-stage heartfailure
(n=6).
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Figure 6.8. The densitometric values of transmural mRNA expression of (a) titin N2A
(n=4) and (b) titin N2B (n=2), showing the different patterns ofexpression following
2-fold serial dilution of the cDNA template from patients with end-stage heartfailure
ofvarious aetiologies.
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Figure 6.9. The two different transmuralpatterns ofdistribution of the ETa receptor,
titin N2A and titin N2B: GAPDH mRNA ratio found in LVmyocardial samples from
patients with end-stage heart failure, (a) pattern 1, where the gene ratio is elevated
in the endocardial section (n=4) fP=0.05, *P<0.05 and (b) pattern 2, where the
genes tend to be more abundant in the endocardium (n=2).
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6.4 Discussion
The purpose of this study was to investigate whether the expression of eight different
genes differed across the LV wall of hearts from patients with end-stage heart failure
and to establish whether the alterations related to ventricular wall stress.
Previous studies have identified that in a transmural cross-section, cardiac wall stress
is highest in the endocardial layer (Mirsky, 1973; Yin, 1981). In the normal heart,
under normal loading conditions, ventricular expression of natriuretic peptides is
low. However, in heart failure, a disproportionate increase of ventricular radius
relative to wall thickness, results in increased ventricular wall stress and this is
considered to be a major determinant for ventricular secretion of natriuretic peptides
(Kinnunen et al., 1993; Ruskoaho et al., 1997). In the current study, a distinct
transmural difference of BNP: GAPDH mRNA ratio existed across the LV wall.
Semi-quantitative RT-PCR evaluation of mRNA expression levels showed that the
hypertrophic marker was more abundant in the endocardial layer of hearts from
patients with end-stage heart failure. These findings are consistent with Prestle et al.
(1999), who demonstrated that BNP mRNA was highly upregulated, predominantly
in the endocardium compared to the epicardium of failing human LV myocardium.
As previously discussed, studies have indicated a role for ET-1 in the
pathophysiology of heart failure (McMurray et al., 1992; Pacher et al., 1996).
Elevated production of ET-1 is thought to contribute to systemic and pulmonary
vasoconstriction, as well as to cardiac hypertrophy, fibrosis and remodelling
(Cooper, 1997; Mulder et al., 1997). Elevation of ppET-1 mRNA has previously
been demonstrated in human heart failure, however, it does appear to be related to
aetiology. Zolk et al. (1999) failed to detect a change in ppET-1 mRNA expression
in hearts from patients with end-stage chronic heart failure (CHF) due to DCM
compared to non-failing. In contrast, Serneri et al. (1999) demonstrated that patients
with adequate hypertrophy compared to inadequate hypertrophy showed higher
values of cardiac formation of ET-1 and Big ET-1 as well as increased ppET-1
mRNA levels. Furthermore, this selective stimulus for ET-1 activation was also
observed by Serneri et al. (2000), where ppET-1 mRNA levels were found to be
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significantly increased in the myocardium and isolated myocytes from ischaemic
cardiomyopathy (ICM) compared to DCM hearts. However, although ischaemia has
been reported to induce ET-1 formation (Tpnnessen et al., 1995; Ito et al., 1996),
there is an ischaemic component present in the heart of DCM patients (Parodi et al.,
1993; Beltrami et al., 1995), suggesting that pressure overload is a major mechanism
of cardiac ET-1 system activation in ICM (Serneri et al., 2000). In the current study,
the expression ratio of ppET-1: GAPDH mRNA was not compared to normal human
LV myocardium, as none was available. However, expression was more pronounced
in the endocardial layer of human failing LV, suggesting that like BNP, regulation of
ppET-1 is determined by ventricular wall stress. In addition, expression of ppET-1
may also have been influenced by BNP (see section 1.2.3).
Previous studies of the cardiac ET-1 system in heart failure have only evaluated the
differences between failing and non-failing tissues. In the current study, transmural
mRNA levels of ETa and ETb receptor mRNA were examined to establish whether
receptor expression was related to the altered wall stresses known to occur in heart
failure. The current study identified that expression of the ETa receptor across the
LV wall of hearts from patients with end-stage heart failure displayed two different
patterns. Distribution in 4 of the 6 hearts studied exhibited a greater abundance of
ETa: GAPDH mRNA ratio in the endocardial sections as opposed to the epicardium,
which were not related to aetiology. However, this pattern did coincide with the
distribution of the titin isoforms. Expression of the ETB receptor: GAPDH mRNA
ratio in the current study did not follow any particular pattern although it had the
tendency to be higher in the endocardial layer, rather than the epicardial layer. It is
known that the ETB receptor is less abundant than the ETa receptor in the human LV
(Ponicke et al., 1998), therefore, it is not surprising that it is less sensitive to change
across the wall. BNP: GAPDH mRNA expression tended to have a greater difference
across the wall in pattern 2 compared to pattern 1, however, sample size would have
to been increased for these observations to be statistically significant. Gelsolin:
GAPDH mRNA expression was also elevated in the endocardium but was to a
similar extent in both distribution patterns.
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ET-1 receptor subtypes have been investigated in myocardial homogenates of hearts
from patients with end-stage DCM (Ponicke et al., 1998; Pieske et al., 1999; Zolk et
al., 1999) or ICM (Ponicke et al., 1998) with conflicting results. Serneri et al. (2000)
compared the two types, DCM and ICM directly and found that although plasma
levels of ET-1 were elevated in both types of heart failure, consistent differences in
the expression pattern of the cardiac ET-1 receptors existed between LV samples of
end-stage failing hearts from ICM or DCM patients (Serneri et al., 2000). Cardiac
ET-1 formation, mRNA levels for ppET-1 and the ETA and ETB receptors were
increased in both the myocardium and isolated myocytes of ICM compared to DCM
hearts. ET-1 binding studies also indicated that both ETA and ETB receptors were
increased in ICM but not DCM LV and this selective upregulation of the ET-1
system components in ICM patients appears to be functionally important in the
maintenance of cardiac function (Serneri et al., 2000). In the current study transmural
samples were evaluated without the reference of non-failing myocardium. However,
the lack of a distinct pattern of ET receptor expression across the wall relating to
aetiology suggests that changes are subjective to other influences such as severity or
degree of hypertrophy. Additionally, Asano et al. (2002) recently demonstrated that
both ETa and ETB receptor mRNA were increased in DCM and ICM failing human
hearts, while ETB receptor mRNA was only increased in ICM. The study also
suggested that based on the lack of correlation with ET-1 tissue levels, it was
unlikely that the failure-related changes in mRNA and protein levels of the ETA and
ETB receptors resulted from homogenous regulation by agonist exposure (Asano et
al., 2002).
As with most of the genes investigated in this study, the expression of the actin
filament severing protein, gelsolin has been evaluated in human heart failure but has
not been assessed transmurally. Yang et al. (2000), using high-density
oligonucleotide arrays, previously identified that gelsolin mRNA levels were
upregulated (2-3 fold) in LV tissue from patients with end-stage heart failure. These
changes correlated with similar changes observed in cardiomyopathic hearts from 2
different lines of transgenic mice exhibiting cardiac hypertrophy (racl-expressing
mice) or heart failure phenotypes (tropomodulin-overexpressing mice) (Yang et al.,
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2000) and in coronary artery ligated compared to sham-operated rats (Stanton et al.,
2000). In the current study, the gelsolin: GAPDH mRNA ratio was consistently
upregulated in the endocardial sample of hearts from patients with end-stage heart
failure. Considering that over expression of gelsolin leads to disorganisation of the
thin actin filaments (Lader et al., 1999) and thereby functional impairment, the
altered transmural expression is consistent with the transmural changes in LV wall
stress that occur in heart failure.
In addition to gelsolin, a gene responsible for cell structure and motility, Yang et al.
(2000) and Stanton et al. (2000) demonstrated that multiple classes of genes were
altered in heart failure, such as cytoskeletal and myofibrillar genes, genes involved in
metabolism and genes encoding stress proteins. Furthermore, Tan et al. (2002) have
since demonstrated that certain gene clusters found within heart failure groups,
associate with specific aetiologies, suggesting that heart failure of different
aetiologies may involve different genetic determinants for their development.
However, in the present study, transmural expression did not appear to relate to the
aetiology of heart failure.
The elastic behaviour of the sarcomeric protein titin is responsible for the generation
of the restoring forces in cardiomyocytes. Studies have previously shown that the
myocardium co-expresses two distinct titin isoforms, N2A and N2B transcripts and
that the N2B isoform is the stiffer of the two (Labeit & Kolmerer, 1995). The
expression ratio of these has been found to vary greatly between species, between the
atria and ventricles and within different locations of the pig and dog hearts (Cazorla
et al., 2000; Bell et al., 2000; Trombitas et al., 2001) and is a means of modulating
cardiac stiffness. Cell-cell stiffness variation within species is related to strain
equalisation of muscle fibres in the different layers of the wall. Consistent with this,
transmural expression of the titin isoforms in the current study of hearts from patient
with end-stage heart failure demonstrated an increased N2B: GAPDH mRNA ratio in
the endocardium of 4 of the 6 hearts studied. In addition, the expression ratio of
N2A: GAPDH mRNA also followed this distribution pattern, as did the ETA receptor
(discussed above) but was not related to aetiology. However, knowing that the
159
Chapter 6 - Results
different isoforms influence the compliance of the cardiac muscle, these results
indicate that the stiffness of the endocardial layer in pattern one was much greater
than in the epicardium, correlating with elevations of endocardial wall stress as
evidenced by elevated the endocardial BNP: GAPDH mRNA ratio.
Previous studies of titin isoforms in heart failure have demonstrated that titin N2B is
upregulated in the LV wall of dogs with tachycardia-induced DCM (Wu et al.,
2002). In contrast, Neagoe et al. (2002) reported that the titin N2BA: N2B ratio was
altered in the LV of patients with coronary artery disease (CAD), compared to
nonischaemic human LV samples. The relative N2BA titin content was greater in the
CAD hearts than the normal hearts and was associated with lower myofibrillar
passive tension. The reduction of N2B titin also had a profound effect on mechanical
heart function as evidenced by abnormally high left ventricular end-diastolic pressure
(Neagoe et al., 2002). In addition, Collins et al. (1996) previously showed that titin
transcripts were increased in compensated LV pressure overload hypertrophy but
declined after the transition to decompensated congestive HF. Similarly, Warren et
al. (2003) demonstrated that expression of titin N2B was increased, while titin N2BA
decreased in response to pressure overload in hypertensive rats. Interestingly, recent
studies have identified that mutations within the cardiac-specific N2B region of the
titin gene were associated with CHF due to familial DCM (Itoh-Satoh et al., 2002;
Gerull et al., 2002). Together, these studies suggest that different regulatory
mechanisms control the entry to either the N2B or N2BA splice pathways, thereby
controlling the extensibility and perhaps adding to ventricular mechanical stress in
heart failure. It has also been suggested that the switch of titin isoforms in heart
failure could impair the ability of the heart to use the Frank-Starling mechanism
(Sutko et al., 2001), however, in the present study, the N2B distribution pattern did
not appear to correlate with cardiac output or any of the other haemodynamic
parameters measured.
In summary, investigation of transmural gene expression in the current study
demonstrated that most genes were more abundant in the endocardial sections of
hearts from patients with end-stage heart failure. As expected, the BNP: GAPDH
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mRNA ratio was consistently greater in the endocardial layer, compared to the
epicardium, as were the expression ratios for ppET-1 and gelsolin: GAPDH. This
distribution is most likely attributed to and/or partly responsible for the difference in
ventricular wall stress, which is known to occur across the LV wall of failing hearts.
However, the components of the ET-1 system did not show consistent transmural
expression as the expression of the ET-1 receptors differed across the wall. In most
subjects, the ETB receptor was most abundant in the endocardium, although no
particular pattern emerged, possibly because the ETB receptor is generally less
abundant in cardiac muscle. In contrast, the ETa receptor: GAPDH mRNA ratio was
greater in the endocardium of 4 of the 6 hearts studied. This differential expression
followed that of the titin isoforms, N2B and N2A, however, the two distribution
patterns were unrelated to aetiology. Expression of the N2B isoform is know to be
associated with increased stiffness and like the ETa receptor, is possibly influenced
by pressure overload, suggesting that the end-stage failing hearts in pattern 1
exhibited adequate hypertrophy to upregulate the genes in these locations. Some of
this variation in transmural gene expression may be due to the different background
diagnoses in the patients with one having hypertrophic cardiomyopathy and another
congenital heart disease. Increased sample size and comparison with non-failing epi
and endocardial tissue would help to clarify the distribution of these genes in various
forms of end-stage heart disease, while in situ hybridisation studies would
specifically identify the location of the titin isoforms. GAPDH mRNA levels were
not significantly different across the wall and have previously been shown not to
change in response to heart failure (Yang et al., 2000), therefore, its use as an
external control was viable, as was the semi-quantitative RT-PCR method which was
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Endothelin-1 (ET-1) has been implicated as playing an important physiological role
in cardiovascular regulation and a putative pathophysiological role in a range of
diseases. Increased plasma levels and tissue expression of the peptide has been
reported in patients with heart failure and correlates well with indices of severity
such as pulmonary artery pressure and reduced cardiac index (Pacher et al., 1993).
At the onset of this thesis, there was a distinct lack of clarity regarding the function
of cardiac ET receptor subtypes in failing and non-failing myocardium. Studies have
suggested that the ETa receptor is solely responsible for mediating the inotropic
responses to ET-1 in isolated cardiomyocytes but function in tissue and organ
preparations have been conflicting. Antagonist studies have also been unable to
clarify the receptor subtype(s) responsible for cardiac contraction. In addition,
studies in our laboratory have revealed a selective upregulation of the ETB receptor
subtype 5-12 weeks post coronary artery ligation (CAL) (Sherry, 2000), the
significance of which was unknown. Therefore, the purpose of this study was to
better define the expression and function of ET-1 receptors in failing and non-failing
rat myocardium in vivo and in vitro. In addition, ventricular mechanics are altered in
pathological states and in diseases characterised by abnormal loading of the heart,
normalisation of wall stress appears to govern the rate and extent of hypertrophy.
Transmural expression of the genes marking hypertrophy, cytoskeletal genes and
components of ET system were examined in relation to elevated left ventricular (LV)
wall stress.
In this current PhD investigation, the initial papillary muscle studies indicated, as
expected, that contractile function was impaired in rat failing myocardium. However,
inotropic responses to the administration of exogenous ET-1 were variable. A slight
biphasic response was observed in the sham but not CAL group suggesting that the
function of the endothelial ETB receptor was impaired. LV expression of the ETB
receptor was not significantly altered in the CAL rats 15 weeks post myocardial
infarction (MI) compared to the sham-operated rats. This may have been due to a
combination of reduced endocardial endothelial ETB expression and an increased
cardiomyocyte ETB expression, as previous studies in our laboratory have
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demonstrated selective ETB upregulation. The variable contractile responses to
exogenous ET-1 were attributed in part to the release of endogenous ET-1 by
mechanical stretch. Therefore a follow up study was designed using selective and
dual ET-1 receptor antagonists so that the roles of the receptor subtypes might be
better defined in heart failure.
The antagonist approach was tested using right ventricular papillary muscles from
normal rats, with the intention of following up in CAL rats, to assess the contribution
of endogenous ET-1 to basal myocardial contractility. The findings from this
antagonist study indicated that both ET receptors contributed to the inotropic
response in normal rat myocardium and that ET-1 was released by mechanical
stretch of the papillary muscle. In addition, responses to exogenous calcium were
altered following incubation with ET-1 receptor antagonists, suggesting that calcium
handling may be an important site of ET-1 action. However, significance levels were
not quite reached, therefore the protocol was repeated in a second set of control rats
to increase sample size. The second antagonist study was conducted 6 months after
the initial investigation but the results were not as expected. In contrast to the
previous results, ET-1 receptor antagonists did not influence inotropic responses of
papillary muscles in study 2. This outcome was confusing, a possible explanation for
these findings was that the antagonist was perhaps unable to penetrate the tissue for
some reason, or unable to block all receptors. In order to find some sort of answer,
mRNA expression of the ET system and the hypertrophic marker, atrial natriuretic
peptide (ANP) were investigated. The results indicated that there was a difference in
gene expression between the two studies, which were carried out 6 months apart.
Seasonal differences in gene expression are not uncommon and could have been
responsible for the different responses observed between the two studies. Therefore,
due to the inconsistent responses achieved using this preparation, it was decided not
to continue with an antagonist study in CAL rats as it was not guaranteed to provide
a satisfactory conclusion.
In vivo assessment of cardiac contractility by echocardiography enabled the study of
real time cardiac function without any tissue manipulation or complications such as
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stretch released ET-1. In the CAL versus sham study, the results quite clearly showed
the effect of LV dysfunction on the end-systolic pressure-dimension relationship,
confirming the observed reduction of ejection fraction, shortening fraction and
elevation of the LV end-diastolic pressure. In order to better determine the influence
of endogenous ET-1 on cardiac contractility in normal animals, a protocol was
designed whereby bosentan, a dual ETA/ETB receptor antagonist was administered
chronically for 1 week. When compared to a placebo group, no significant
haemodynamic or contractile influence was observed, suggesting that endogenous
ET-1 did not play a central role in cardiac contractility. However, it is likely that as
the animals were healthy, other factors may have compensated for the loss of ET-1
mediated tone.
In contrast, acute administration of bosentan significantly reduced the contractility of
the heart, shifting the pressure-dimension loop of the cardiac cycle down and to the
left. This may have been a direct effect via cardiac ET-1 receptors or may have been
due to reduced peripheral resistance, thereby reducing the afterload/preload to act via
the Frank-Starling mechanism, or most likely a combination of both. It would be
interesting to repeat this bosentan study using CAL and sham-operated rats to
investigate whether intervention with dual ETA/ETB receptor blockade at different
time points (acute, chronic or delayed chronic) affected the contractility of the
myocardium as studies of LV pressure suggest that it could.
Long-term treatment with mixed ETA/ETB receptor antagonists has previously been
shown to improve survival and has beneficial effects on the haemodynamics of rats
with chronic heart failure (CHF) (Mulder et al., 1997; Sakai et al., 2000). In addition,
Clozel et al. (2002) recently reported that acute administration of tezosentan, another
dual ETa/ETb receptor antagonist, 1 or 24 hours post MI was found to improve long-
term survival of CHF rats by causing a decrease of pulmonary oedema and
preventing cardiac hypertrophy. However, not all studies have demonstrated such
positive outcomes. Use of the mixed ETA/ETB receptor antagonist LU420627
resulted in reduced survival, increased LV dilatation and cardiac dysfunction whether
the treatment was started early or late after MI, indicating unfavourable actions of the
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drug independent of timing of treatment after MI (Nguyen et al., 2001). In addition,
another recent study reported the adverse effects of early intervention with
SB209670, a dual ETa/ETb receptor antagonist, when treatment was initiated 48
hours after MI in rats (0ie et al., 2002).
Prompted by the early positive results from studies in animal models of heart failure
and from acute studies in patients, it was logical to expect that chronic blockade of
ET receptors might be of benefit to patients with CHF. However, since commencing
this PhD investigation, the clinical trials of ET receptor antagonists in heart failure
have mainly been negative. Early studies with bosentan were disappointing due to
the excess of adverse effects encountered and some small clinical trials were even
terminated early. Treatment with bosentan has been associated with the early
development of worsening heart failure, perhaps due to the high dose of drug used
(Cowburn & Cleland, 2001; van Veldhuisen & Poole-Wilson, 2001). In addition, a
further concern is the excess of abnormal liver function tests which have been found
in bosentan-treated groups (van Veldhuisen & Poole-Wilson, 2001). Two larger
studies using lower doses of bosentan have also produced disappointing results.
ENABLE 1 and ENABLE 2 (Endothelin Antagonist Bosentan for Lowering Cardiac
Events) studies found that long-term treatment with the dual receptor antagonist did
not alter mortality or hospitalisation of patients with severe heart failure. It seemed
that fluid retention was a major contributory factor to this outcome, even despite an
increased use of diuretics. The negative results of the ENABLE studies have added
to doubts over the potential benefits of non-selective ET-1 receptor blockade in heart
failure. However, further dose-response studies may still determine an optimal
dosing strategy for specific aetiologies. In addition, administration of bosentan has in
acute studies been shown to improve the haemodynamic parameters in CHF patients
(Sutsch et al., 1998). Furthermore, Torre-Amione et al. (2001) demonstrated that
acute administration of tezosentan in patients with moderate to severe heart failure
led to an improved haemodynamic profile and was safe and well tolerated. Therefore
it may be the case that timing is important. Bosentan is currently used successfully in
the treatment of pulmonary arterial hypertension although its use requires close
monitoring due to its potential of causing liver dysfunction and its teratogenic effects
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(as reviewed by Cheng, 2003). Clozel et al. (personal communication) have also
indicated that administration of bosentan in acute heart failure is of benefit and it is
likely that the ET antagonist may have an application here.
The complexity of the ET system and its diverse roles in multiple disease states
ensures that it will continue to be targeted for drug development. Therefore selective
ETa receptor antagonism may provide certain benefits. In a recent study, Luscher et
al., (2002) (HEAT; Heart Failure ETA Receptor Blockade Trial) demonstrated that 3
weeks treatment with darusentan, selective ETA receptor antagonist, improved the
cardiac index of patients with CHF. However, again it was highlighted that dosage
was important as higher doses were associated with a trend to more adverse events.
Long-term randomised clinical trials of selective antagonists have still to be
conducted and compared to dual ETA/ETB receptor blockade to establish whether
selective ETA blockade is beneficial over dual ET receptor blockade in human CHF.
A myriad of genes undergo altered expression during the development of heart
failure (Yang et al., 2000; Stanton et al., 2000). In this PhD investigation expression
of genes associated with hypertrophy, cytoskeletal proteins and components of the
ET system were investigated across the LV wall of explanted hearts from patients
with end-stage heart failure of various aetiologies to establish if they were related to
wall stress. As expected the hypertrophic marker was more abundant in the
endocardium, the layer associated with increased wall stress. In addition, gelsolin, a
regulator of cytoskeletal organisation also displayed greater expression in the
endocardium as did the ET-1 precursor prepro-ET-1. The ET receptors did not follow
any particular pattern in relation to aetiology but the ETA receptor did display the
same expression pattern as titin, the giant molecule which contributes to the elasticity
of the myocardium. Most types of heart failure contain hypertrophic myocardium
however, the extent and distribution will depend on local wall stress therefore
various regions might contain more hypertrophic markers than others. Variability of
gene expression across the wall may therefore depend on the area from which the epi
and endocardial samples were taken and may not necessarily reflect the distribution
of expression of genes in the whole myocardium. To follow up these findings it
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would be interesting to carry out immunohistochemical analysis on sections of the
tissues, looking at the titin isoforms and the ET system to see how they are
distributed within the different layers of different aetiologies and how they associated
to varying levels stiffness. In addition if more samples were available and some from
non-failing human tissue, the comparison may lead to a better understanding of the
ET system in different types of heart failure and the changes which occur within the
wall organisation.
Finally, as previously discussed (see section 1.2.5), generation of knock-out mice has
demonstrated the importance of the ET system in development. Although many of
the phenotypes are lethal, generation of new conditional or specific knock-outs, such
as the cardiac specific ETb receptor knock-out currently under characterisation in our
laboratory, may provide further insight into the complexity of the ET system in the
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